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Abstract 
 
The developed world is currently in the grip of an obesity epidemic. As a result, there 
is much ongoing research into the development of an effective anti-obesity agent.  
Peptide YY (PYY) is a 36 amino acid gastro-intestinal hormone released post-
prandially by L-cells in the gastro-intestinal tract in proportion to the calorie content 
of a meal. The predominant form of the hormone found in circulation is the truncated 
PYY(3-36). Administration of PYY(3-36) at physiological doses to humans has been 
shown to reduce food intake. However, due to enzymatic degradation these effects are 
short lived, reducing the hormone’s utility as an anti-obesity pharmaceutical agent. A 
series of analogues of PYY(3-36) were designed either with amino acid substitutions 
in specific parts of the peptide sequence and/or with chemical modifications to the 
native sequence with the aim of increasing resistance to enzymatic activity whilst 
retaining or even enhancing the peptide’s bioactivity. The analogues were tested for 
resistance to degradation by different proteolytic enzymes in comparison to natural 
PYY(3-36). Their affinity to the Y2 receptor, for which PYY(3-36) is a natural 
agonist was then investigated. Finally, the effects of peripheral administration of 
selected analogues on food intake in overnight fasted mice were investigated.  These 
studies suggest that PYY(3-36) analogues may be a useful approach for the treatment 
of obesity, but further development work is required.  
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Cpm Counts per minute 
Cys                               Cysteine 
Dap                               α, β-diaminopropionic acid 
DCC                              N,N'-Dicyclohexylcarbodiimide 
DIC                               N,N'-Diisopropylcarbodiimide 
DIPEA                          N, N’-diisopropylethylamine 
DMEM  Dulbecco’s modified eagle medium 
DMF                            Dimethylformamide 
DMSO                         Dimethylsulphoxide 
DPP-IV   Dipeptidyl peptidase IV 
GI  Gastrointestinal   
Gly                               Glycine 
Gln                               Glutamine 
GLP-1 Glucagon-like peptide 1 
Glu                               Glutamic acid 
GPCR G protein coupled receptor 
HATU                        2-(1H-7-Azabenzotriazol-1-yl)--1,1,3,3-tetramethyluronium hexafluorophosphate 
HEPES                          4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
His                                Histidine 
HOAt                            1-Hydroxy-7-azabenzotriazole 
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HOBt                            1-Hydroxybenzotriazole 
HPLC  High-performance liquid chromatography 
ICV Intracerebroventricular  
Ile                                 Isoleucine 
IP Intraperitoneal 
IV Intravenous 
Leu                               Leucine 
MALDI MS                 Matrix assisted laser desorption ionisation mass spectrometry 
Me                                Methyl 
Mtt                               4-methyl trityl 
NMP                            N-methyl pyrrolidone 
NPY Neuropeptide Y 
OAll  Allyl ester 
OPip                            2-phenylisopropyl ester 
Pbf                               2,2,4,6,7-pentamethyldihydrobenzofurane 
PBS                              Phosphate Buffer Solution 
PEG Polyethylene glycol 
Phe                               Phenylalanine 
POMC Proopiomelanocortin 
PP  Pancreatic polypeptide 
Pro                                Proline 
PVN Paraventricular nucleus 
PYY  Peptide YY 
SC Subcutaneous  
Ser                                Serine 
tBu                                Tertiary butyl 
TBTU                           2-(1H-Benzotriazole-1-yl)-1,1,3,3-tetramethyluronium tetrafluoroborate 
TEAP                           Triethylammonium phosphate 
TFA Trifluoroacetic acid 
Thr                               Threonine 
Trp                               Tryptophan 
Trt                                Trityl 
Tyr                               Tyrosine 
UV  Ultraviolet  
Val                                Valine 
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1.1 Obesity 
 
Obesity is a major world health problem. An individual is classed as overweight if 
their Body Mass Index (BMI) is greater than 25.0 and obese if their BMI is greater 
than 30. The World Health Organisation (WHO) projects that by 2015, 2.3 billion 
adults will be overweight and 700 million will be obese worldwide (World Health 
Organization, 2009). Historically thought of as a disease affecting only Western 
countries, in particular the United States of America, there is clear evidence of obesity 
levels increasing across the globe, including in some of the world’s poorest countries. 
Weight gain occurs when energy intake exceeds energy expenditure. The thrifty gene 
hypothesis, first posited in the 1960’s by James Neel, proposed that humans are 
preconditioned to put on weight to protect against starvation (Watve and Yajnik, 
2007). Whilst this would have been advantageous in an environment of limited 
resources when an individual may not have known where their next meal was coming 
from, in the modern developed world in which food is abundant, the hypothesis 
suggests it has resulted in excess consumption becoming the norm. The fostering of a 
“fast food” culture in many modern societies compounds this problem. The 
convenience and relative cheapness of these high calorific foods promote excessive 
energy intake. Coupled with the reduced energy expenditure observed in societies 
with low levels of physical work and mechanised transport, this has easily led to 
widespread weight gain and obesity. 
People who are overweight or obese are at a greater risk of suffering from serious 
medical conditions such as diabetes, cardiovascular disease, strokes and some 
cancers. Many patients suffer from a combination of different disorders and are often 
described as having metabolic syndrome. According to the WHO a person is said to 
have metabolic syndrome if they have type 2 diabetes, impaired glucose tolerance or 
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are insulin resistant plus they also meet at least two of the following criteria; they 
have hypertension, elevated plasma triglyceride levels, reduced high density 
cholesterol concentration, microalbuminuria or a BMI greater than 30 (Groop, 2000). 
Obesity can also have serious psychological effects, with subjects often suffering 
from depression and low self esteem. 
The obesity epidemic is thus placing a strain on healthcare systems across the world. 
In the UK it was estimated that the annual cost to the NHS in England alone of 
treating obesity and its associated disorders was £4.2 billion in 2007 and could 
potentially reach £9.7 billion by 2050 (Swanton, 2008). Additionally it is estimated 
that 18 million sick days are lost annually to UK businesses as a result of obesity 
related problems (Foresight, 2006). 
There would thus be significant health and economic benefits to the successful 
prevention or treatment of obesity. For many years, health professionals and 
governments have expounded the benefits of a healthier lifestyle incorporating 
increased exercise and improved diet. To date, this educational strategy has proven 
unsuccessful; obesity rates have continued to rise. Identifying novel therapeutics to 
reduce food intake and limit weight gain is thus a major focus for academic and 
industrial research. 
 
1.2 Treatments for obesity 
 
1.2.1 Bariatric Surgery 
Gastro-intestinal surgery, in the form of gastric banding or gastric and intestinal 
bypass successfully treats obesity. Gastric banding is the less invasive option and 
involves the placement of a constrictive band around the top portion of the stomach. 
This creates a small pouch in the upper region of the stomach which can only hold a 
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small amount of food. Patients thus feel ‘full’ having eaten only small portions of 
food. NHS guidelines only recommend gastric banding for those patients with a BMI 
in excess of 40 or with a BMI between 35 and 40 who also have a co-morbidity that 
poses a serious health risk, such as diabetes (National Institute for Health and Clinical 
Excellence, 2006). Studies have shown that patients with a BMI of 30 – 35 fitted with 
a gastric band experienced more prolonged weight loss than patients with comparable 
BMI values who underwent non-surgical therapies (O’Brien et al., 2006). Subsequent 
investigations also showed effective weight loss following gastric band surgery in 
patients with a BMI greater than 50, the so called super obese. Four years after 
surgery, an average excess weight loss of 60% was reported (Fielding, 2003). 
However, to remain effective a gastric band requires post operative readjustment at 
regular intervals to maintain optimal restriction of food intake (O’Brien et al., 2006).   
Gastric bypass surgery is a more invasive and therefore riskier procedure. There are a 
number of different forms of this surgery with the most commonly performed in the 
USA being the Roux-en-Y Gastric Bypass (Saliba et al., 2009). It is estimated that 
120 thousand people underwent this particular operation in the USA in 2007 (Couzin, 
2008). The procedure has two elements to it. Firstly, a small gastric pouch is created 
at the top of the stomach that restricts the patient’s capacity for food. Secondly, a so 
called Roux limb is created which connects this pouch directly with the jejunum, thus 
bypassing a considerable section of the small intestine (Saliba et al., 2009). Average 
weight loss following Roux-en-Y Gastric Bypass has been reported to be 66% of a 
patient’s excess weight (Balsiger et al., 2000). Initially it was thought that this 
profound weight loss was due to the combination of reduced gastric volume coupled 
with reduction in nutrient and calorie absorption by the intestine. However, the 
recorded weight loss following gastric bypass surgery exceeded that for gastric 
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banding, which suggests that restriction of volume was not the primary cause of the 
weight loss (Morínigo et al., 2006). It was also discovered that the gut adapts 
following surgery so as to protect against malabsorption of nutrients (le Roux and 
Bloom, 2005). Studies have since shown that the levels of some gut derived hormones 
are altered following gastric bypass surgery. Ghrelin is a known orexigenic peptide 
that is produced in the stomach. Circulating levels are increased by fasting and drop 
following food intake (Chandarana et al., 2011). Several studies reported that gastric 
bypass patients have lower circulating levels of ghrelin than patients who had 
achieved the equivalent weight loss by diet alone. However, other studies have shown 
either no change in ghrelin levels or, in some cases, an increase (Saliba et al., 2009). 
The effect of gastric bypass surgery on circulating ghrelin levels remains 
inconclusive, with some suggesting that the discrepancies between studies may be due 
to the different surgical techniques employed (Saliba et al., 2009). Ghrelin is a so 
called “hunger hormone” which increases food intake following peripheral 
administration in animals and man (Cummings and Shannon, 2003). The theoretical 
reduced circulating levels of ghrelin may therefore contribute to the reduced appetite 
of these patients. In contrast, Peptide YY (PYY) is an anorexigenic peptide released 
postprandially by L-cells in the distal gut (le Roux and Bloom, 2005). Circulating 
levels of PYY are higher in gastric bypass patients compared with subjects of 
comparable weight (le Roux and Bloom, 2005). PYY is released from 
enteroendocrine L cells in the gut and is processed to form PYY(3-36), the major 
circulating form (Chandarana et al., 2011). Peripheral administration of PYY(3-36) 
inhibits appetite in animals and man (Morínigo et al., 2006). The elevated PYY levels 
observed following gastric bypass are thus likely to enhance the feeling of satiety in 
these patients and so lead to reduced food intake.   
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Growing evidence demonstrates that gastric bypass surgery can also have profound 
benefits for patients who suffer from type 2 diabetes, and that this effect may be at 
least partly independent of its effects on body weight (Hayes et al., 2011). Studies 
have reported remission levels of 76.8% of type 2 diabetes in post-operative subjects. 
The number increases to 85.4% when those patients who showed improvement in 
their diabetes are included (Buchwald et al., 2007). The improvements in glucose 
homeostasis are observed within a week of the operation in many cases, often before 
there has been significant weight loss (Hayes et al., 2011).  Glucagon-like peptide-1 
(GLP-1) is another hormone released post-prandially by the L-cell. The active forms 
of GLP-1 inhibit appetite and promote insulin release when peripherally administered 
in animals and man (Saliba et al., 2009). Circulating GLP-1 levels are also increased 
following gastric bypass (Vidal et al., 2009). As GLP-1 is an incretin, it is 
hypothesised that this may be the mechanism by which bypass surgery increases 
insulin secretion and facilitates the remission of diabetes. 
Despite the well reported benefits of these surgical procedures, drawbacks remain. 
Patients must follow a difficult post-operative regime. Typically, patients can only 
consume fluids for at least one week after the operation. They then move onto purees 
for another four weeks before slowly progressing onto more solid food types (British 
Obesity Surgery Patient Organisation, 2011a). 
There also exists a small risk of mortality following surgery. A systematic review of 
bariatric surgery mortality rates published in 2007 reported a total mortality rate of 
0.28% in the first 30 days following surgery and 0.35% in the first 2 years (Buchwald 
et al., 2004). There are a number of other post-operative complications, including 
vomiting, diarrhoea, anastomotic complications, hernia and infection.  
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There is also a significant cost implication to these surgeries. In the UK the cost per 
operation has been estimated at £5000 - £7000 for gastric banding and £8000 - 
£14000 for gastric bypass (British Obesity Surgery Patient Organisation, 2011b). 
These costs restrict the number of operations that can be performed under the NHS 
and prove prohibitive to many people seeking private treatment. Other resources are 
also limited; there are insufficient operating theatres or qualified surgeons to 
realistically treat all of the obese patients who would qualify for surgery. However, 
there is a need to take into account the long term health economics, particularly the 
costs of not performing these surgeries and having to fund the treatment of obesity 
related disorders.   
 
1.2.2  Pharmaceutical therapies 
Using a drug to treat obesity would be much simpler and would avoid the 
inconvenience, costs and risks of surgery. Such a product would have huge market 
potential, and much effort has therefore focused on the development of an anti-obesity 
pharmacotherapy. Despite this effort, only a relatively small number of therapies have 
made it onto the market and none have acquired blockbuster status. 
There is currently only one prescription anti-obesity medication approved for use in 
the UK(National Institute for Health and Clinical Excellence, 2006). Orlistat was 
launched in 1998 by Roche under the trade name Xenical, with worldwide sales in 
2005 totalling $450million (Melnikova and Wages, 2006). Orlistat works by 
inhibiting pancreatic lipase, and thus the breakdown and absorption by the gut of 
approximately 30% of dietary fats (Lean and Mullan, 2007). It has been demonstrated 
to produce an additional weight loss of approximately 3% when compared with 
patients attempting weight loss through changes to their diet (Cooke and Bloom, 
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2006). Orlistat can improve glycaemic control in type-2 diabetics and also reduce the 
risk of overweight and obese individuals with impaired glucose tolerance developing 
type-2 diabetes (Lean and Mullan, 2007). However there are several unwanted side 
effects associated with the use of Orlistat, including faecal urgency and oily stools 
(Drew et al., 2007). There is also the potential for the unwanted reduction in 
absorption of the fat soluble vitamins A, D and E (Drew et al., 2007; Cooke and  
Bloom, 2006). Approval was granted by the U.S. Food and Drug Administration 
(FDA) in 2007 and the European Medicines Agency (EMA) in 2009 for the over the 
counter sale of Alli, a low dosage form of Orlistat produced by GlaxoSmithKline 
(Steffen et al., 2010). 
Until relatively recently other obesity drugs were licensed for use in the UK and the 
rest of the EU. Rimonabant acts as an antagonist of the cannabinoid-1 receptor (CB1), 
which was identified and cloned during investigations into the effects of cannabis 
usage (Foster-Schubert and Cummings, 2006). One of the well reported side effects of 
cannabis use is an increase in appetite.  Identification of ligands for this receptor led 
to the development of several antagonists, of which Rimonabant was the lead 
compound (Foster-Schubert and Cummings, 2006). Major trials with Rimonabant 
were carried out in both Europe and the USA (Pi-Sunyer et al., 2006). In all, modest 
yet significant weight losses were recorded in comparison with placebo groups. In 
2006 the use of Rimonabant for the treatment of obesity was approved in Europe 
despite concerns that patients might develop psychological problems (Cooke and 
Bloom, 2006; Lean and Mullan, 2007). However, because of these concerns the drug 
was never approved for use in the USA, and in 2008 the EMA suspended its use due 
to the risk of users developing serious psychiatric problems and suicidal impulses 
(European Medicines Agency, 2008). 
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Sibutramine was approved by the FDA in 1997 and the EMA in 1999, and recorded 
sales of $230million in 2005 (Melnikova and Wages, 2006). Sibutramine is a 
serotonin and noradrenalin reuptake inhibitor that enhances post-prandial satiety and 
attenuates the fall in metabolic rate that occurs with weight loss (Smith and Goulder, 
2001). It is structurally linked to amphetamines which were once widely used as 
weight loss agents before being banned in the 1970’s because of the associated side 
effects, which include hypertension, cardiac valvulopathy and the potential for 
dependence (Astrup, 2010; Cooke and Bloom, 2006). Sibutramine elicited weight loss 
of around 5% more than in a placebo group (Finer, 2002). Sibutramine usage also 
helped maintain weight loss compared with subjects assigned to a placebo. Over a two 
year period, placebo patients regained nearly 80% of the initial weight loss despite 
adhering to an improved diet and exercise regime, whereas those subjects who 
continued to take Sibutramine retained 85% of their weight loss (Finer, 2002). 
Sibutramine was initially reported to lack the severe side-effects of amphetamines, but 
does increase heart rate and hypertension (Cooke and Bloom, 2006). These side 
effects were hypothesised to lead to adverse cardiovascular effects, and in 2009, data 
from the Sibutramine Cardiovascular Outcome Trial (SCOUT) showed an increased 
risk of non-fatal cardiovascular episodes from Sibutramine usage when compared to 
placebo groups (Haehling et al., 2007). As a result, in 2010 both the FDA and the 
EMA recommended it be withdrawn from the market (European Medicines Agency, 
2010; U.S. Food and Drug Administration, 2010). 
Despite the limited success thus far of anti-obesity drugs there continues to be 
extensive research in this field. Such is the complex nature of the human energy 
homeostasis system that there exist these many different pathways for scientists to 
investigate and target. There are many drugs in the pipeline, at various stages of the 
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drug development process. A major difficulty is that the signalling molecules that 
regulate appetite often have other physiological roles, making the specific targeting of 
food intake extremely challenging, and increasing the risk of side effects.  
Another difficulty is that body weight regulation is a homeostatic process that has 
evolved to preserve nutritional status under conditions of limited food availability. 
Even if a particular anorectic pathway can be successfully and specifically targeted to 
reduce food intake and body weight, compensatory changes in other appetite-
regulating pathways may limit the efficacy of this approach. This may explain the 
modest weight loss reported with previously developed therapies.  
It is thus important to understand the physiological mechanisms regulating food 
intake and body weight in order to develop anti-obesity agents. 
The neuronal and hormonal systems involved in the regulation of energy homeostasis 
work through both long and short term control mechanisms, regulating food intake 
and energy expenditure in response to, for example, adipose tissue mass or acute 
nutritional status, respectively. 
 
 
1.3 Long term regulation of energy homeostasis 
 
1.3.1 Insulin 
Insulin is produced by the ß-cells of the Islets of Langerhans in the pancreas. It is 
released in response to an increase in blood glucose levels following food intake 
(Taubes, 2009). Insulin is an anabolic signal.  Insulin stimulates the uptake of glucose 
by muscle and liver cells where it is then stored as glycogen for use by the body as a 
source of energy for periods of sudden and strenuous activity (Berg, et al., 2002). 
Insulin also prevents the use of fat tissue as an energy source by inhibiting the release 
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of the hormone glucagon. A 29 amino acid peptide hormone, glucagon is released into 
circulation following a decrease in blood glucose levels and stimulates hepatic 
glucose release via two different mechanisms (Jiang and Zhang, 2003). The first is 
glycogenolysis which is the process by which glycogen is broken down into glucose. 
The second mechanism is gluconeogenesis whereby glucose is generated from non-
carbohydrate sources. Other roles for glucagon within the body include the regulation 
of plasma lipid levels and food intake (Habegger et al., 2010). 
There are several disorders linked to abnormalities of the body’s insulin system. The 
most widely recognised is diabetes mellitus, the name given to any condition 
characterized by hyperglycaemia (World Health Organization, 1999). The two most 
common forms of the disease are type 1 and type 2 diabetes mellitus. Type 1 diabetics 
are unable to produce sufficient insulin due to autoimmune destruction of their 
pancreatic ß-cells (World Health Organization, 1999). They are required to regularly 
check their blood glucose levels and administer exogenous insulin accordingly. 
Failure to do so adequately can lead to high levels of blood sugar which over the long 
term can cause organ damage and death (van Belle et al., 2011). Conversely, 
overdosing with insulin can cause blood glucose levels to fall, putting the patient at 
risk of hypoglycaemic coma. The cause of type 1 diabetes is still unknown but several 
risk factors have been identified (van Belle et al., 2011). There is currently no cure for 
the condition, though many different avenues including ß-cell transplantation, vaccine 
development and the inhibition of the actions of glucagon are being investigated as 
potential treatments (van Belle et al., 2011).       
Type 2 diabetes is the most prevalent form of diabetes and is characterised by insulin 
resistance (Taubes, 2009). Sufferers are still able to produce their own insulin but the 
body becomes relatively unresponsive to its actions
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diabetes is also unknown, but it is strongly associated with obesity (Taubes, 2009). It 
has been suggested that their insulin resistance is caused by overloading or 
inflammation of the body’s fat cells leading to a breakdown in the mechanisms which 
mediate the actions of insulin (Taubes, 2009). Type 2 diabetics are encouraged to 
make lifestyle changes to help manage the condition. It has been shown that regular 
exercise and dietary improvements increases insulin sensitivity and so help lower 
blood glucose. If these changes are made early enough they reduce the incidence of 
at-risk patients going on to develop type 2 diabetes. In 2011, a group from Newcastle 
University reported the results of a study in which a small group of type 2 diabetics 
were placed on a restricted (600 kcal/day) diet for 8 weeks. At the end of this period 
the patients were found to have normalised beta cell function and insulin sensitivity, 
thus giving rise to the hope that type 2 diabetes could be a potentially reversible 
condition for many sufferers (Lim et al., 2011).  
As type 2 diabetics are still able to produce insulin there is a greater potential to 
develop effective treatments than with type 1 diabetes.  
Those treatments currently on the market can be classified into three classes according 
to their action. The first are insulin secretagogues which stimulate release of insulin 
by the pancreas. Sulfonylureas were the first such compounds used to treat diabetes, 
although they have now been superseded by second generation compounds. Common 
side effects from these treatments include weight gain and hypoglycaemia (Rendell, 
2004). Some of the newest diabetes treatments on the market and in clinical trials are 
drugs based on natural incretins (hormones within the body that promote insulin 
release). One such endogenous incretin is Glucagon-like peptide-1 (GLP-1) 
(discussed in more detail in sections 1.2.1 and 1.5.3), and two drugs based on its 
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structure, Exenatide and Liraglutide, have been approved for use in the treatment of 
type 2 diabetes (Nachnani et al., 2010; Parks and Rosebraugh, 2010).  
The second class of anti-diabetic drugs are insulin sensitizers which increase the 
sensitivity of peripheral tissue to the effects of insulin (Lu et al., 2011). One example 
is Metformin, one of the biggest selling drugs in the field and the first line drug of 
choice for overweight and obese patients as weight gain is not an associated side 
effect of its use (Rendell, 2004). Avandia, another insulin sensitizer and one of the 
Thiazolidinedione group of compounds was also heavily prescribed for diabetes 
treatment until it was recommended for removal from the European market in 2010 
amid concerns over cardiovascular risks.  
The final class of anti-diabetic treatment has no direct effect on insulin levels or 
action but instead slows the rate of glucose absorption into the bloodstream. Examples 
of this type of treatment are Miglitol and Acarbose (Van de Laar et al., 2005). They 
have the effect of artificially lowering blood sugar levels, enabling endogenous 
insulin to have an affect even if the body has begun to develop a resistance to it. 
However as levels of insulin resistance increase, this type of drug becomes less 
useful. Reported side effects of their use include flatulence, diarrhoea and stomach 
pains (Van de Laar et al., 2005).  
In addition to these drugs, many type 2 diabetics are prescribed insulin itself as a 
treatment for their diabetes, often in combination with other treatments (Swinnen et 
al., 2009). Although these patients have insulin resistance, administering exogenous 
insulin at supra-physiological levels can activate their insulin-responsive signalling 
pathways, at least to some limited degree (Swinnen et al., 2009).  
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1.3.2 Leptin 
 
Leptin was identified following studies on two strains of mutant mice that were 
extremely obese (Friedman, 2009). The mutant genes were labelled as ob and db and 
the similarities in phenotypes between the two strains suggested that the genes were 
involved in the same physiological process. Further studies led to the proposal that the 
ob gene encoded an as yet unknown substance that reduced food intake whilst the db 
gene encoded its receptor (Friedman, 2009). 
Cloning of the mutant gene led to identification of the ob gene and the discovery that 
it was expressed by adipose tissue. The gene was predicted to encode a 167 amino 
acid protein which later became known as leptin (Friedman and Halaas, 1998). This 
was subsequently found to circulate in the plasma of a number of mammals, including 
humans. Circulating leptin levels increase with adipose tissue mass and decrease 
when adipose tissue is lost (Oswal and Yeo, 2010). The leptin receptor is expressed in 
regions of the hypothalamus known to be involved in energy homeostasis (Scott et al., 
2011). Central or peripheral leptin administration reduces food intake and body 
weight in both wild type and ob/ob mice (Friedman, 2009). Leptin was thus 
hypothesised to act as an adipose tissue derived hormone that operated in a negative 
feedback loop to help maintain levels of adipose tissue by influencing the neuronal 
mechanisms that control food intake and energy consumption (Oswal and Yeo, 2010). 
As adipose tissue mass increases, leptin levels rise, causing a reduction in food intake 
to help reduce adiposity.  
This led to the hope that leptin had therapeutic utility in the treatment of obesity 
(Friedman, 2009). However, it was subsequently discovered that most obese humans 
already had high circulating levels of plasma leptin and were relatively leptin 
insensitive, meaning that supra-physiological doses of leptin were required to reduce 
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food intake (Heymsfield, et al., 1999). These findings suggested that obese humans 
were resistant to the effects of leptin and led some to hypothesise that the 
development of this resistance was a primary cause of obesity (Friedman and Halaas, 
1998). This theory has been challenged, with others proposing that leptin resistance is 
a consequence, rather than the cause, of obesity (Arch et al., 1998). The mechanism 
behind leptin resistance is not fully understood. As fat tissue increases rapidly with 
sustained over-eating so the levels of plasma leptin increase in response. This has 
been suggested to lead to the saturation of the leptin responsive circuits in the 
hypothalamus, causing an unknown disturbance in the leptin pathway that leads to a 
reduced effect. This then results in a compensatory increase in leptin secretion which 
drives a cycle of chronic weight gain (Oswal and Yeo, 2010). It has been shown in 
rats that chronic leptin infusion eventually causes leptin resistance. It has also been 
proposed that leptin resistance is caused by a breakdown in the transport of leptin into 
the hypothalamus via the blood brain barrier (Oswal and Yeo, 2010). This followed 
studies that showed that diet induced obese mice developed resistance to peripherally 
administered leptin but retained sensitivity to centrally administered leptin. Further 
studies have suggested that these defects in the leptin transport mechanism are a 
consequence of obesity rather than a cause. 
As leptin is secreted by adipose tissue and has been shown to reduce food intake it 
was widely believed that its physiological role was that of a satiety signal. However, 
subsequent studies and the discovery of leptin resistance mean that it is now thought 
of as a starvation signal, with its main purpose to retain sufficient fat stores in 
readiness for periods of inadequate food supply (Oswal and Yeo, 2010). This would 
be a vital in an evolutionary context for organisms that live in an insecure nutritional 
environment but for the many humans living in a world where high calorie food is 
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readily available, it is less important, and may actually play a role in driving the 
development of obesity. 
Although the majority of obese humans have high circulating levels of leptin, a small 
number do not. These humans have leptin signalling defects similar to those in the 
ob/ob mouse, and display a similar phenotype. It has been shown that in these 
individuals, leptin treatment has a beneficial effect on body weight (Friedman, 2009). 
There exist in humans other conditions associated with low levels of plasma leptin 
and which have been shown to be receptive to leptin treatment. Lipodystrophy is 
characterised by complete or partial absence of normal adipose tissue depots. It can be 
caused by mutations of the genes that regulate adipose tissue development or by 
alterations in the immune system, as is the case with some HIV patients. This results 
in lipids being deposited in other organs, particularly the liver, and the subsequent 
development of insulin resistance. As leptin is secreted by adipose tissue, 
lipodystrophic patients have extremely low leptin levels.  It has been found that leptin 
treatment prevents lipid deposition in the liver and corrects insulin resistance in these 
patients (Friedman, 2009). 
Loss of leptin signalling in animals or man results in infertility. It is thought that 
leptin acts as a signal to the reproductive axis that sufficient energy stores are 
available to support reproduction; low leptin levels signal that it is likely a period of 
limited nutritional availability, and hence reproduction should be delayed. 
Hypothalamic amenorrhea is a condition characterised by suspension of the female 
menstrual cycle. It can result from weight loss, typically caused by periods of extreme 
exercise or an eating disorder. The resulting energy deficit leads to disruption in the 
secretion of gonadotropin-releasing hormone and it is hypothesised that this 
disruption is caused by a decrease in circulating leptin levels. In accord with this, 
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recombinant leptin administration to patients with hypothalamic amenorrhea 
improved reproductive function in just a few months, even in subjects who had not 
menstruated for several years (Welt, et al., 2004). 
Although the phenomenon of leptin resistance prevents the development of solely 
leptin based therapies for the treatment of obesity, development work has continued 
on leptin combinatorial treatments. Perhaps the most promising of these was until 
recently the combination of amylin with leptin. Amylin is a 37 amino acid peptide 
hormone that is secreted with insulin from the pancreatic ß-cells, and which helps to 
regulate glucose and energy homeostasis (Roth et al., 2008). Studies into the effects of 
peripheral administration of the amylin analogue pramlintide (produced by Amylin 
Pharmaceuticals) in obese subjects found it caused average weight loss of 8% over a 
24 week period. In the same study a similar result was achieved with those people 
receiving metreleptin (an analogue of human leptin) treatment. However, when the 
two therapies were combined a significantly greater average weight loss of 12.7% was 
recorded, without weight loss plateauing before the end of the study (Roth et al., 
2008). The exclusivity of this enhancing effect on leptin was tested by combining 
leptin with other known anorexigenic peptides PYY and GLP-1. The weight loss 
recorded with these combination therapies was not as great as observed with the 
amylin/leptin treatment. It has therefore been suggested by Amylin Pharmaceuticals 
that amylin enhances central leptin signalling that is usually diminished in the obese 
state (Turek, et al., 2010). However, clinical trials on the combination of pramlintide 
and metreleptin have very recently been abandoned at phase 2.  
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1.4 The central nervous system centres controlling energy homeostasis 
 
Both long and short term signals of the body’s nutritional state are integrated by the 
Central Nervous System (CNS). Most regions of the brain and the neurons within 
them in the CNS are protected from exposure to endogenous signals and potentially 
toxic exogenous substances by the blood brain barrier (BBB) (Norsted et al., 2008). 
The BBB is a specialised vascular structure that prevents diffusion of all but the 
smallest lipophilic molecules into the CNS (Price et al., 2008). Larger hydrophilic 
molecules such as peptides and proteins usually require selective transport 
mechanisms (Norsted et al., 2008). However, there exist regions of the CNS where 
the BBB is incomplete. These regions are referred to as circumventricular organs 
(CVO), and allow the brain to directly sample peripherally circulating signals (Price 
et al., 2008). 
The hypothalamus and the brainstem are the two main regions of the brain responsible 
for the regulation of energy homeostasis, and both contain circumventricular organs – 
the median eminence and the area postrema respectively – allowing the sampling of 
circulating signals of the nutritional state (Price et al., 2008).   
 
1.4.1 The hypothalamus 
The hypothalamus is centrally located near the base of the brain below the thalamus. 
In humans the hypothalamus is about the size of an almond and is extensively 
connected to the pituitary gland (Cone et al., 2001). It functions as a link between the 
nervous and endocrine systems and plays a role in a number of metabolic processes. It 
has long been recognised as being involved in the control of appetite (Arora and 
Anubhuti, 2006). Initial studies concluded that the lateral hypothalamic area was the 
“hunger centre” and the ventromedial hypothalamus was a “satiety centre” (Suzuki et 
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al., 2010). It has since been discovered that a number of different hypothalamic nuclei 
and neuronal circuits are involved in appetite regulation (Figure 1.1). 
 
1.4.2 The arcuate nucleus 
The arcuate nucleus is located at the base of the hypothalamus and is critical to the 
regulation of energy homeostasis (Cone et al., 2001; Berthoud and Morrison, 2008).  
It contains two distinct populations of neurons which are responsive to the hormone 
leptin, which, as described above, acts as a peripheral signal of adipose tissue mass. 
Within the ventromedial section of the nucleus are located a population of neurons 
that express the orexigenic peptides neuropeptide Y (NPY) and agouti-related peptide 
(AgRP). Another neuronal population in the ventrolateral section of the nucleus 
express the protein pro-opiomelanocortin (POMC), a precursor of the anorectic 
neuropeptide alpha- melanocyte-stimulating hormone (α-MSH) (Suzuki et al., 2010).  
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Figure 1.1 A schematic diagram showing the nuclei and regions of the brainstem 
involved in energy homeostasis. 
A simplified representation of how different areas of the brain are linked for the regulation of appetite. 
Abbreviations: PVN, paraventricular nucleus; VMH, ventromedial nucleus of hypothalamus; LHA, 
lateral hypothalamic area; DMH, dorsomedial hypothalamic nucleus; AP, area postrema; NTS, nucleus 
of tractus solitarius; DMV, dorsal motor nucleus of vagus. 
 
1.4.3 NPY   
NPY is a 36 residue peptide and a member of the PP fold family of peptides which 
also includes Pancreatic Polypeptide (PP) and Peptide YY (PYY). All three PP fold 
peptides have a C-terminal amide moiety and conserved proline residues in positions 
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2, 5 and 8 which help to maintain their characteristic PP fold, hairpin like structure 
(Nygaard et al., 2006). They mediate their effects via a family of G-protein coupled 
receptors called the Y receptors. Thus far, five separate Y receptors have been 
identified; Y1, Y2, Y4, Y5 and Y6 (Wraith et al., 2000). The existence of a Y3 receptor 
has been proposed based upon binding studies but it has yet to be successfully cloned 
(Lee and Miller, 1998). With the exception of Y6, found only in rat and rabbit tissue, 
the Y receptors are expressed in various human tissues (Wraith et al., 2000). The PP 
fold peptides each have different affinities for various Y receptors. NPY has high 
affinities for all of the Y receptors with the exception of the Y4 receptor (Wraith et al., 
2000).  
Central administration of NPY into rats potently and powerfully increases food intake, 
and chronic administration causes prolonged hyperphagia and the development of 
obesity (Arora and Anubhuti, 2006). Hypothalamic NPY gene expression is higher in 
the leptin deficient ob/ob mice than in wild type controls, suggesting that leptin 
inhibits NPY expression (Erickson et al., 1996). In accord with this, NPY knockout 
ob/ob mice are less obese than ob/ob mice due to reduced food intake and increased 
energy expenditure (Erickson et al., 1996). 
NPY knockout mice display no profound changes in feeding behaviour or body 
weight. It was originally thought that AgRP signalling might compensate for the lack 
of NPY in this model.  
NPY is thought to mediate its orexigenic effects via the Y1 and Y5 receptors (Turnbull 
et al., 2002). However, studies with selective Y1 and Y5 receptor agonists and 
antagonists have thus far given contrasting results. The Y5 receptor was believed to 
the most important facilitator of NPY induced feeding. Central administration of the 
NPY analogue [Ala31, Aib32]NPY, a Y5 agonist, significantly increases food intake in 
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rats (Cabrele et al., 2000). However a number of studies with non-peptidic Y5 
antagonists have shown no significant reduction in food intake (Turnbull et al., 2002; 
Della-Zuana et al., 2004). Further to this, Y5 receptor knock out mice display normal 
feeding and growth patterns, and counter-intuitively develop mild late-onset obesity. 
The importance of the Y1 receptor in the orexigenic action of NPY was confirmed by 
the observation that Y1 knockout mice consumed less food than wild type controls, 
following central administration of NPY (Kanatani et al., 2000).    
NPY is also implicated in a number of other physiological functions, including 
anxiety, memory, vasoconstriction and the regulation of alcohol consumption (Arora 
and Anubhuti, 2006). 
 
1.4.4 AgRP 
AgRP is a 132 amino acid peptide that was discovered in 1997 and quickly identified 
as a mediator of energy homeostasis. Like NPY, AgRP expression is inhibited by 
leptin. However, unlike NPY, which is widely expressed in the brain and peripheral 
tissues, AgRP expression is much more limited; within the brain, AgRP is only 
synthesised within the arcuate nucleus (Arora and Anubhuti, 2006). 
Chronic central administration of AgRP in rats increases daily food intake and 
adipose tissue mass, and causes a decrease in energy expenditure independent of 
effects on food intake (Small et al., 2001). 
Mice bred to over-express AgRP are hyperphagic and exhibit severe obesity (Ilnytska 
and Argyropoulos, 2008). However, like NPY knockout mice, AgRP knockout mice 
display no profound changes in feeding behaviour or body weight (Ilnytska and 
Argyropoulos, 2008). NPY/AgRP double knockouts also lack a profound energy 
homeostasis phenotype, suggesting that these signals are not required to compensate 
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for the loss of one another. However, post-embryonic ablation of AgRP neurons in 
mice has been shown to reduce food intake (Bewick et al., 2005). This suggests that 
although developmental processes can compensate for the loss of NPY and AgRP 
early in life, this neuronal population is vital in the physiological regulation of energy 
homeostasis in adult animals. However, it does not reveal the relative importance of 
the signalling factors expressed by these neurons. 
AgRP works as a potent and selective antagonist of the melanocortin-3-receptor 
(MC3R) and melanocortin-4-receptor (MC4R), which inhibits the binding of the 
anorexigenic POMC product α-MSH to these receptors (Rossi et al., 1998). Recent 
evidence also suggests AgRP can act as an inverse agonist in another melanocortin-
independent pathway (Arora and Anubhuti, 2006).  
 
1.4.5 POMC 
POMC is a functionally inert precursor protein that undergoes tissue specific 
translation to yield a number of different biologically active molecules (Pritchard et 
al., 2002). The POMC derived peptides, which include adrenocorticotropin (ACTH), 
ß-endorphin and α-, ß- and γ-melanocyte stimulating hormones (MSH), have a wide 
range of functions within the body that are largely mediated through melanocortin 
receptors (MCR) (Coll et al., 2005). Of the five identified MCR’s, only the MC3R 
and MC4R are thought to be involved in energy homeostasis (Pritchard et al., 2002). 
MC4R is densely expressed in those regions of the hypothalamus known to control 
appetite. Mice deficient in MC4R are obese due to hyperphagia, as are mice bred to 
over express AgRP, the natural antagonist of MC4R (Pritchard et al., 2002). 
Mutations of the POMC gene in both humans and mice result in a phenotype of 
hyperphagia and obesity, and also cause glucocorticoid deficiency and altered 
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pigmentation due to the role of POMC products in the hypothalamo-pituitary-adrenal 
axis and in skin and hair colouration (Coll et al., 2005). Fasting down regulates, and 
over feeding increases hypothalamic POMC expression in rodents. This effect is 
believed to be partially mediated by leptin, as POMC levels are significantly 
decreased in ob/ob and db/db mice, and increased by leptin administration (Pritchard 
et al., 2002).  
These results support involvement of the melanocortin system, and most importantly 
the MC4R in appetite regulation. In humans it has been found that mutations in 
MC4R are the most common monogenetic cause of human obesity, being found in up 
to 4% of adults with severe childhood-onset obesity (Hsiung et al., 2005).  
Of the POMC translational products, α-MSH is thought to be the primary ligand for 
MC4R. Intracerebroventricular administration of α-MSH decreases food intake in 
rodents (Hsiung et al., 2005). This inhibitory effect is blocked by the administration of 
AgRP, further emphasising the dynamic relationship between AgRP and POMC 
neurons in the hypothalamus (Arora and Anubhuti, 2006). 
Aside from α-MSH, desacetyl-α-MSH and ß-MSH have been shown to bind to MC4R 
suggesting a role for these and possibly other POMC derived peptides in energy 
homeostasis (Hsiung et al., 2005). 
 
1.4.6 Other hypothalamic regions 
In addition to the arcuate nucleus, a number of other hypothalamic regions play an 
important role in energy homeostasis.  The paraventricular nucleus (PVN) is a site of 
convergence of number of different neuronal projections including NPY/AgRP and 
POMC neurons from the arcuate nucleus. The PVN integrates nutritional signals with 
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the regulation of the thyroid and hypothalamic-pituitary-adrenal axes (Arora and 
Anubhuti, 2006).  
The dorsomedial hypothalamic nucleus (DMH) is thought to act as an integration 
centre for information sent from other hypothalamic nuclei due to its extensive 
network of neuronal connections (Arora and Anubhuti, 2006). 
The ventromedial nucleus of hypothalamus (VMH) is also a major site via which 
leptin mediates its effects. Ablation of the VMH results in hyperphagia, and it is 
considered to be an important satiety centre (Arora and Anubhuti, 2006). 
The lateral hypothalamic area (LHA) contains glucose sensitive neurons that respond 
to states of hypoglycaemia by inducing hyperphagia. It also expresses the orexigenic 
neuropeptides orexin and melanin-concentrating hormone (MCH). Ablation of the 
LHA results in hypophagia, and it is therefore considered a feeding centre (Arora and 
Anubhuti, 2006). 
 
1.4.7 The brainstem 
The brainstem is the region of the brain that connects the cerebrum to the spinal cord 
and is linked extensively to the hypothalamus (Neary, et al., 2004). The vagus nerve, 
the longest of the cranial nerves, extends from the brainstem to the neck, chest and 
abdomen. The brainstem receives gut-derived neural and hormonal signals via this 
nerve, which plays an important role in controlling individual meal size. Rats that 
have their connections between the brain stem and the forebrain severed are unable to 
compensate for decreases in meal frequency (Neary, et al., 2004).  
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1.4.8 The nucleus tractus solitarius (NTS) 
The NTS is the site of extensive neuronal connections between the brainstem and the 
hypothalamus. The NTS has been found to contain dense populations of the Y 
receptors Y1 and Y5 (Arora and Anubhuti, 2006). NPY is expressed by neurons within 
the NTS and in rats its levels rise before and fall following a meal (Yoshihara, et al., 
1996). There is also evidence of a melanocortin pathway within the NTS that is 
independent of that found in the arcuate nucleus. These neurons express POMC and 
extend into the VMH and spinal cord (Ellacott and Cone, 2004). The leptin receptor 
Ob-R was found to be expressed within the NTS, suggesting it is a target for leptin, 
and plays a role in its appetite-inhibiting effects. 
 
1.4.9 The area postrema (AP) 
The AP is a sensory circumventricular organ which allows for direct sampling of the 
circulation. Neurons within the AP express a number of different receptors for 
peptides and hormones involved in energy homeostasis. These include the Y1, Y2 and 
Y4 receptors, the receptor for the orexigenic gastric hormone ghrelin and for the 
anorexigenic gut hormones GLP-1 and cholecystokinin (Price et al., 2008).  
 
1.4.10 The dorsal motor nucleus of vagus (DMV) 
The DMV is largely made up of vagal preganglionic neurons that project onto 
postganglionic neurons in the gastrointestinal tract. These consist of both excitatory 
and inhibitory pathways and exert an influence on gastric motility, gastric secretion, 
pancreatic secretion and liver gluconeogenesis (Cruz et al., 2007; Niedringhaus et al., 
2008).  
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1.5 Gut hormones 
The gastro-intestinal tract is the largest endocrine organ in the body and is responsible 
for the secretion of over 20 regulatory hormones. The physiological role of the gut is 
to digest and absorb nutrients.  These regulatory hormones act in concert with the 
CNS to optimize this process. Many of these hormones have well characterised roles 
in the regulation of gut motility and secretion, and are known to act upon, for 
example, smooth muscle and the peripheral nervous system. Whereas leptin and 
insulin serve as long term regulators of the body’s nutritional state, many of the gut 
derived hormones respond acutely to individual meals, and therefore act as short term 
regulators, conveying feelings of hunger or satiety (Figure 1.2). 
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Figure 1.2 A schematic diagram showing how the different gut derived hormones 
influence energy homeostasis via the CNS. 
Abbreviations: NPY, neuropeptide Y; AgRP, agouti-related peptide; POMC, pro-opiomelanocortin; 
PP, pancreatic polypeptide; PYY, peptide YY; GLP-1, glucagon-like peptide-1; OXM, oxyntomodulin; 
CCK, cholecystokinin.  
 
1.5.1 Ghrelin 
Ghrelin was originally isolated from rat stomach as the endogenous ligand for the 
growth hormone secretagogue receptor (GHS-R) (Kojima et al., 1999). It is a 28 
amino acid peptide with a unique acylation of the Serine3 residue with an octanoyl 
group and which is highly conserved across species; rat and human forms differ by 
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just two amino acids (Chollet et al., 2009; Wren, et al., 2001). The stomach is the 
primary site of ghrelin secretion but other areas of the gastro-intestinal tract also 
contain ghrelin secreting cells. Acylation of the Serine3 residue occurs post 
translationally and is driven by the enzyme ghrelin-O-acyltransferase (GOAT) 
(Barnett et al., 2010). Acyl and desacyl ghrelin are both found in the circulation but 
the octanoyl group is required for binding to the GHS-R and may also facilitate 
ghrelin transfer across the blood brain barrier. Although initially discovered as a 
stimulator of growth hormone release, the role of ghrelin in the regulation of feeding 
soon became apparent (Chollet et al., 2009).  
Circulating ghrelin levels were found to be raised during periods of fasting and 
decreased post-prandially, suggesting a role for ghrelin as an initiator of feeding 
(Chaudhri et al., 2006). Acute central or peripheral administration of ghrelin increased 
food intake in rodents. Chronic administration of ghrelin to rats was shown to 
significantly increase food intake and to lead to obesity (Wren, et al., 2001). 
Intravenous administration of ghrelin in humans was subsequently shown to increase 
the amount of food consumed in a free choice buffet (Wren, et al., 2001). Studies with 
ghrelin and GHS-R knockout mice have challenged the importance of ghrelin in the 
maintenance of energy homeostasis. Both strains of mice were found to display 
similar phenotypes to wild type mice as regards food intake, body size and growth 
rate. However, later studies have suggested that the loss of ghrelin signalling is 
associated with resistance to diet induced obesity; whether these results are due to the 
strain or age of the mice is unclear (Murphy and Bloom, 2006). It may be that in the 
absence of ghrelin, compensatory pathways develop to maintain the process of meal 
initiation and energy homeostasis. 
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Ghrelin mediates its orexigenic effects by activating NPY/AgRP neurons within the 
arcuate nucleus, in opposition to leptin which inhibits these neurons. While ghrelin 
and leptin modulate food intake via shared pathways, there appears to be no feedback 
by which they regulate the levels of one another (Klok et al., 2007).  Ghrelin may 
activate NPY/AgRP neurons directly, but there is also evidence that it may work via 
vagal pathways.  
Ghrelin levels are low in the obese and rise following weight loss, suggesting they 
may be regulated to limit weight gain in the obese state (Chaudhri et al., 2006).  
Ghrelin may rise with weight loss to preserve fat levels and thus to increase survival 
chances during periods of famine. 
Since its discovery, the ghrelin system has been the subject of extensive research as a 
possible therapy for obesity. Synthetic GHS-R antagonists have been developed 
which reduce food intake in both lean and obese mice (Chollet et al., 2009). However, 
so far clinical trials of GHS-R antagonists have proven unsuccessful in the treatment 
of obesity. As ghrelin is the only hormone known to contain an octanoyl group, 
inhibition of the GOAT enzyme has emerged as another potential therapeutic avenue. 
Chronic peripheral administration of a GOAT antagonist to mice reduced circulating 
ghrelin levels and blunted the high fat diet induced weight gain observed in control 
animals (Barnett et al., 2010).  Conversely, ghrelin and other GHS-R agonists may 
prove beneficial in the treatment of disorders characterised by anorexia, such as 
kidney disease, HIV and some cancers. Ghrelin increased food intake in cancer 
patients with appetite loss and malnourished dialysis patients (Neary, et al., 2004; 
Wynne, et al., 2005a).  
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1.5.2 Cholecystokinin (CCK) 
Cholescystokinin (CCK) was the first gut hormone implicated in the control of 
appetite. As early as 1973 it was reported that exogenous administration of CCK to 
rats inhibited food intake (Moran, 2000). This has since been proven in other species, 
including humans (Wynne et al., 2004). There are a number of biologically active 
forms of CCK found in circulation, but all share the common C-terminal heptapeptide 
which contains a sulphated Tyrosine residue (Crawley and Corwin, 1994). CCK is 
produced by I-cells in the small intestine and released post-prandially, stimulating the 
release of digestive enzymes and bile, increasing intestinal motility and inhibiting 
gastric emptying (Chaudhri et al., 2006).  
CCK mediates its effects via two distinct G-protein coupled receptors; CCK-1 and 
CCK-2 (Wynne et al., 2004). Both receptors are expressed in multiple sites within the 
brain and gut, but it is the receptors expressed on the afferent vagus nerve that are 
critical to the effects of CCK on feeding (Chaudhri et al., 2006).  Antagonist 
experiments confirmed that these effects are mediated through the CCK-1 receptor. 
Administration of a CCK-1 receptor antagonist to rats results in a dose dependent 
increase in food intake, suggesting a physiological role for CCK-1 receptor signalling 
in food intake (Lo et al., 2010). In contrast, a CCK-2 receptor antagonist had no effect 
on food intake (Lo et al., 2010). Otsuka Long Evans Tokushima Fatty (OLETF) rats 
lack CCK-1 receptors and are hyperphagic and obese (Murphy and Bloom, 2006). 
However, CCK-1 receptor knockout mice display normal daily food intake, 
suggesting that CCK may not be crucial for controlling appetite in some species, or 
that the activation of developmental pathways can compensate for its loss (Moran and 
Kinzig, 2004). It is a matter of debate whether CCK mediates its effect on food intake 
through endocrine, paracrine and/or neurocrine actions (Wynne et al., 2004). This 
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follows reports that the physiological levels of circulating CCK are insufficient to 
activate the necessary vagal circuits.   
The effects of CCK are short lived; when administered just 30 minutes prior to 
feeding, no anorectic effect was observed (Arora and Anubhuti, 2006). Continuous 
administration of CCK to rodents inhibited food intake for 24 hours, after which this 
effect ceased (Murphy and Bloom, 2006). Intermittent pre-prandial injections did 
reduce subsequent meal size but were compensated for by an increase in meal 
frequency (Murphy and Bloom, 2006). This suggests that CCK may not be a useful 
target for drugs to alter long term energy homeostasis.  
 
1.5.3 Glucagon-like peptide-1 (GLP-1) 
Preproglucagon is a large precursor protein produced in pancreatic α cells, the L-cells 
of the small intestine and within the CNS (Stanley et al., 2004). It undergoes tissue 
specific enzymatic cleavage to yield a number of biologically active peptides, some of 
which are implicated in the regulation of appetite. GLP-1 is generated by 
preproglucagon processing in the small intestine, and is released into the circulation 
after a meal (Wynne et al., 2004). A number of different forms are present in the 
circulation, with the most predominant being GLP-1 (7-36) amide (Murphy and 
Bloom, 2006). GLP-1 is highly conserved across different species, suggesting an 
important physiological role. The primary role of GLP-1 within the body is as an 
incretin; and central and peripheral administration of GLP-1 potently increases insulin 
secretion (Murphy and Bloom, 2006). In addition to its incretin effects, GLP-1 has 
also been shown to inhibit glucagon release, gastric emptying, gastrointestinal fat 
absorption and appetite (Arora and Anubhuti, 2006). 
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GLP-1 exerts these effects through the GLP-1 receptor (GLP-1R). This is a G-protein 
coupled receptor found in the gut and CNS (Knudsen et al., 2007).  
Administration of GLP-1 (7-36) amide intracerebroventricularly or directly into the 
PVN inhibits food intake in rats. Chronic intracerebroventricular administration 
reduces weight gain in rats (Flint et al., 1998). In humans, intravenous administration 
of GLP-1 (7-36) amide reduces food intake in both lean and obese volunteers (Flint et 
al., 1998).  
It has also been reported that obese humans have lower circulating levels of GLP-1 
and that weight loss subsequently increases GLP-1 levels. This suggests that a 
reduction in GLP-1 secretion could promote obesity. However, other studies have 
disputed these findings (Chaudhri et al., 2006). 
The discovery that obese humans were sensitive to the effects of exogenously 
administered GLP-1 led to hope that a GLP-1 based therapy could be developed for 
the treatment of metabolic disorders such as obesity and type-2 diabetes. However, 
GLP-1 (7-36) amide has a relatively short circulating half life of approximately two 
minutes (Chaudhri et al., 2006). This is predominantly due to the action of the enzyme 
dipeptidyl peptidase IV (DPP-IV), which cleaves the first two N-terminal amino acids 
from GLP-1 (7-36) amide; the resulting peptide, GLP-1 (9-36) amide, has been found 
to act as an antagonist, rather than an agonist for the GLP-1R (Stanley et al., 2004). 
The circulating half-life of GLP-1 is extended to 10 minutes in DPP-IV deficient rats 
(Chaudhri et al., 2006). 
The development of GLP-1 based therapies has thus far followed two main avenues; 
the development of DPP-IV resistant analogues, and the use of DPP-IV inhibitors. 
The venom of the Gila monster lizard contains a number of biologically active 
peptides. One of these peptides, exendin-4, has 53% sequence homology with GLP-1 
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(7-36) amide and is a potent GLP-1R agonist (Göke et al., 1993). It is also resistant to 
degradation by DPP-IV due to the nature of its N-terminal dipeptide sequence. 
Because of its potent incretin effects, exendin-4 or exenatide was developed as a 
therapy to improve glycaemic control in type-2 diabetics. Marketed as Byetta, 
exenatide is licensed for use in the USA and Europe as an injectable treatment for 
type-2 diabetes (Nachnani et al., 2010). Alongside the beneficial effects on glycaemic 
control, treatment with exenatide also elicits decreased food intake and moderate 
weight loss. However, recent studies in rats have suggested that there may be an 
increased risk of developing pancreatitis associated with exenatide treatment 
(Nachnani et al., 2010).   
Liraglutide is a synthetic analogue of GLP-1 incorporating a palmitoyl functional 
group that aids binding of the peptide to albumin in the circulation. The resulting 
albumin-peptide conjugate is resistant to degradation by DPP-IV, and has a 
circulating half life of up to 13 hours (Cummings et al., 2010). Liraglutide, marketed 
as Victoza, was licensed for use in Europe in 2009 and USA in 2010 as a once daily 
injectable treatment for type-2 diabetes (Parks and Rosebraugh, 2010). As with 
exenatide, patients taking Victoza experienced moderate weight loss and a reduction 
in hyperglycaemia (Cummings et al., 2010). Concerns have been raised over the 
safety of liraglutide. An FDA review in 2010 highlighted the risk of developing 
cancer of the thyroid C-cells, after studies in rats and mice showed an increase in 
occurrence of benign adenomas and malignant carcinomas following prolonged 
exposure to liraglutide (Parks and Rosebraugh, 2010). Concern was also raised over 
the risk of developing pancreatitis as it has a similar mechanism of action to 
exenatide.  
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Other GLP-1 analogues are in clinical development, including Taspoglutide which 
has amino-isobutyric acid (Aib) substitutions in two amino acid positions prone to 
enzymatic cleavage. The bulky side chain of Aib confers steric hindrance to these 
positions, making the molecule resistant to enzymatic degradation whilst also 
stabilizing the peptide’s conformation to improve receptor binding. Taspoglutide has 
a plasma half life of 9 hours in rats (Sebokova et al., 2010). When taken in 
combination with Metformin, Taspoglutide improves both glycaemic control and 
body weight in type 2 diabetics that were not being adequately controlled by 
treatment with Metformin alone (Nauck et al., 2009).  
A number of different DPP-IV inhibitors are either in clinical development, or have 
been approved for release and are currently on the market for the treatment of type-2 
diabetes. Sitagliptin and vildagliptin are the most established of those currently 
available (White, 2008). Although they produce the desired effects on glycaemic 
control, neither significantly reduces body weight (Murphy and Bloom, 2007). This 
may be because inhibition of DPP-IV causes only a modest increase in circulating 
GLP-1 levels. DPP-IV is implicated in the enzymatic degradation of a number of 
other biologically active peptides, which may be related to the reported side effects of 
DPP-IV inhibitors, which include nasopharyngitis, headaches and dizziness (White, 
2008). The gut hormone PYY is cleaved to its anorectic form, PYY(3-36), by DPP-
IV, so DPP-IV inhibitors may increase levels of one anorectic hormone only to reduce 
the levels of another, limiting effects on appetite and body weight (Mentlein, 1999).  
In the light of the difficulties facing the development of peptide based therapeutics, 
non-peptidic GLP-1R agonists have become an attractive concept. Several different 
lead compounds have been developed, including ‘compound 2’ and ‘Boc5’. These 
compounds are said to be allosteric ligands which bind to GLP-1R at sites distinct 
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from the binding site of the natural ligand (Koole et al., 2010). Allosteric ligands may 
act as an agonist themselves and/or enhance the natural ligand’s affinity for the 
receptor. However, there have been no clinical trials of these molecules reported to 
date.  
 
1.5.4 Oxyntomodulin (OXM) 
Oxyntomodulin (OXM) is another post-translational product of preproglucagon and is 
released by the L-cells of the distal small intestine following food intake in proportion 
to the calorie content of the meal (Wynne et al., 2006). It is 37 amino acids long and 
contains the entire 29 amino acid sequence of glucagon with the remaining 8 amino 
acids extending the C-terminal end. This change in structure reduces the affinity of 
the molecule for the glucagon receptor and increases its affinity for the GLP-1R. 
Intracerebroventricular, direct PVN or peripheral administration of OXM reduces 
food intake in rats, and peripheral administration reduces food intake in rats and mice 
(Chaudhri et al., 2006). Chronic peripheral administration of OXM in rats 
significantly reduced body weight gain compared to saline controls and to pair fed 
saline controls (Dakin et al., 2004). As the calorie intake of the pair fed and 
oxyntomodulin groups were very similar, this experiment suggests in addition to 
reducing food intake, OXM also increases energy expenditure. 
Pre-prandial intravenous administration of OXM into healthy humans significantly 
decreased food intake by 19% at a buffet meal (Cohen et al., 2003). Repeated pre-
prandial sub-cutaneous injection of OXM three times a day over 4 weeks to 
overweight and obese subjects was shown to produce an average weight loss of 2.4% 
of body weight, compared to 0.5% in a saline treated control group (Wynne, et al., 
2005b). In a separate study, OXM was shown to increase energy expenditure in obese 
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humans, further enhancing its potential as an anti-obesity therapeutic (Wynne et al., 
2006). In particular its more limited incretin effect compared to GLP-1 makes it a 
potential treatment for those obese subjects without type-2 diabetes. 
However, the mechanisms by which OXM facilitates its anorectic effects are not yet 
fully understood. OXM has been shown to bind to both the GLP-1 and glucagon 
receptors, but with less affinity than the natural ligands. However, the anorectic effect 
of OXM is comparable to that of GLP-1, which suggests that it may in part act 
through a separate pathway (Stanley et al., 2004). Alternatively, the pharmokinetics or 
tissue availability of OXM may increase its anorectic activity out of proportion to its 
receptor affinity.  Administration of the known GLP-1R antagonist exendin (9-39) 
directly into the arcuate nucleus reduced the anorectic effect of peripherally 
administered OXM but not GLP-1 (Murphy and Bloom, 2006). These results suggest 
that although the GLP-1R is present in the arcuate nucleus, there may also exist an as 
yet unidentified OXM specific receptor that is also antagonised by exendin (9-39). 
However, OXM does not reduce food intake in GLP-1R knockout mice (Chaudhri et 
al., 2006). It may be that the presence of specific receptor-associated proteins are 
required to mediate the differential effects of GLP-1 and OXM via the GLP-1R, 
perhaps similarly to the effect of receptor-activity-modifying proteins on the 
adrenomedullin/calcitonin gene-related peptide receptor. Downstream of the receptor 
involved, OXM may work in part by suppressing ghrelin secretion. OXM infusion 
reduced pre-prandial levels of ghrelin in rats following an overnight fast, and OXM 
reduces circulating ghrelin levels in rats via the hypothalamus (Patterson et al., 2009). 
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1.5.5 Pancreatic polypeptide (PP) 
Pancreatic Polypeptide (PP) is a member of the PP fold family of peptides, which also 
includes NPY and PYY. PP is 36 amino acids long and is the least conserved of these 
peptides between species. It is produced predominantly in the endocrine pancreas and 
is released in response to food intake at levels proportional to the calorie content of 
the meal (Batterham, et al., 2003a). It functions by delaying gastric emptying, 
suppressing the release of ghrelin and increasing vagal tone. It is also believed to 
increase energy expenditure, thus helping to promote a state of negative energy 
balance (Chaudhri et al., 2006). 
The role of PP in appetite regulation has been known for over 30 years. In 1977 it was 
discovered that the genetically obese ob/ob mice lacked the pancreatic cells needed to 
produce PP, and that twice daily peripheral administration of bovine PP to these mice 
reduced food intake and body weight gain (Stanley et al., 2004). Later studies with 
normal mice confirmed this potent inhibitory effect and showed that it lasted for 24 
hours after administration (Wynne et al., 2004). Transgenic mice that over express PP 
are lean and display reduced food intake compared with wild type mice (Asakawa et 
al., 2003). 
Intravenous administration of PP reduced ad libitum food intake two hours later by 
22% in healthy human volunteers. This effect was sustained over a 24 hour period 
resulting in a cumulative reduction in daily food intake of 25% (Batterham, et al., 
2003a). 
Prader-Willi syndrome is a genetic disorder characterised by hyperphagia and obesity 
from an early age (Jin, 2011). Sufferers of Prader-Willi syndrome have low basal and 
postprandial levels of PP and intravenous infusion of PP to Prader-Willi patients 
significantly reduces their food intake (Balasubramaniam et al., 2006). It has been 
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reported that non-syndromic obese humans also have reduced circulating levels of PP, 
whilst anorexic subjects have elevated levels, thus suggesting PP may have a causal 
influence on the development of obesity (Chaudhri et al., 2006).  
As a member of the PP fold family, PP binds to the G-protein-coupled Y receptors. It 
has been found to have greatest affinity for the Y4 receptor (Balasubramaniam et al., 
2006). Due to the nature of the N-terminal region of the PP sequence, it is unable to 
cross the blood brain barrier. However, the Y4 receptor is highly expressed in the area 
postrema of the brainstem, a circumventricular organ, and it is thus believed that PP 
facilitates its anorectic effect via the Y4 receptors in this region (Kojima et al., 2007).  
PP has been shown to have conflicting effects on food intake depending upon the 
route of administration. Central administration of PP in rats increased food intake and 
stimulated gastric emptying. These inimical effects may be due to different sites of 
receptor activation, or may reflect pharmacological levels of PP binding to the Y5 
receptor. Studies showed the orexigenic effect of central PP was blunted in Y5 knock 
out mice, but not by Y5 antisense oligonucleotides, leaving the issue unresolved 
(Wynne et al., 2004).    
 
1.5.6 Peptide YY (PYY) 
PYY is also a member of the PP fold family of peptides and is named for the presence 
of tyrosine (Y) residues at both terminals of its amino acid sequence. PYY is 
synthesised by intestinal L-cells and is widely expressed throughout the 
gastrointestinal tract, although it is most densely expressed in the distal gut 
(Batterham and Bloom, 2003). Following food intake, PYY is released into the 
circulation in proportion to the calorie content of the meal (Batterham and Bloom, 
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2003). It delays gastric emptying and inhibits gallbladder and pancreatic enzyme 
secretion. 
Once it is released into the circulation, PYY undergoes rapid enzymatic cleavage by 
DPP-IV to yield the predominant circulating form, PYY(3-36) (Batterham and 
Bloom, 2003). Unlike GLP-1, PYY(3-36) retains biological activity after this 
enzymatic degradation. As a member of the PP fold family, PYY binds to the Y 
receptors. PYY(1-36) has been shown to have greatest affinity for the Y1 and Y5 
receptors but PYY(3-36) is a selective agonist for the Y2 receptor (Batterham and 
Bloom, 2003). 
It was reported in 2002 that intraperitoneal administration of PYY(3-36) acutely 
reduced food intake in rats, and that intermittent seven day administration reduced 
cumulative food intake and reduced weight gain in rats (Batterham et al., 2002). A 
number of independent research groups originally failed to reproduce these results, 
with some actually recording an increase in food intake (Chaudhri et al., 2006). 
However, subsequently a number of these researchers have found PYY(3-36) to have 
an anorectic effect. It has been suggested that these discrepancies may be due to the 
effects of stress masking the anorectic effects of PYY(3-36) (Abbott et al., 2006). 
PYY knockout mice are hyperphagic and develop obesity, suggesting a physiological 
role for PYY in appetite (Boey et al., 2006).  
In humans it was reported that intravenous administration of PYY(3-36) to healthy 
volunteers, 2 hours prior to being given access to a buffet lunch, reduced food intake 
by 36% compared with saline controls. Food intake was recorded for 24 hours after 
infusion and the PYY(3-36) group showed a 34% decrease in total daily food intake 
(Batterham et al., 2002). The Y2 receptor mediates the effects of PYY(3-36) on food 
intake; Y2 knockout mice are immune to the anorectic effects of peripheral PYY(3-
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36) administration (Batterham and Bloom, 2003). It is proposed that PYY(3-36) 
facilitates its anorectic effect by freely crossing the blood brain barrier into the arcuate 
nucleus and binding to the Y2 receptors which are highly expressed there. Direct 
injection of PYY(3-36) into the arcuate nucleus reduces food intake in rats ( 
Batterham et al., 2002). The arcuate Y2 receptors act as presynaptic inhibitors which 
suppress NPY/AgRP neurons, which in turn disinhibits POMC neurons and increases 
their activity (le Roux and Bloom, 2005). However, PYY(3-36) reduces food intake in 
POMC and MC4 receptor deficient mice, suggesting the melanocortin system is not 
necessary for the actions of PYY(3-36) (Chaudhri et al., 2006).  There is also 
evidence that PYY(3-36) may act through vagal signalling pathways to reduce food 
intake. Like PP, PYY has also been shown to have opposing effects on food intake 
depending upon the route of administration. When administered 
intracerebroventricularly, PYY(3-36) increases food intake in mice. It has been 
suggested that this orexigenic effect is the result of pharmacological levels of PYY(3-
36) binding to Y1 and Y5 receptors, for which PYY(3-36) retains a degree of affinity. 
Both Y1 and Y5 receptors are thought to mediate the orexigenic effects of NPY 
(Wynne et al., 2004). 
PYY(3-36) may represent a potential therapeutic agent for the treatment of obesity. 
Obese humans have been reported to have lower fasting levels of PYY than lean 
humans, suggesting that reduced levels of PYY may be a causal factor for obesity. 
However, this finding has been challenged by a number of other researchers. Obese 
humans retain sensitivity to the effects of exogenously administered PYY(3-36). At a 
buffet lunch, 2 hours after receiving an intravenous infusion of PYY(3-36), the obese 
group had a 30% decrease in food intake, compared with 31% decrease in the lean 
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group. The fact that obesity did not appear to be characterised by PYY resistance 
suggests that PYY has utility as an anti-obesity medication (Batterham, et al., 2003b).  
However, there are difficulties in using PYY(3-36) as a drug to reduce appetite and 
body weight. The circulating half life of PYY(3-36) is very short, thus to be used as 
an effective drug, PYY(3-36) would need to be administered on a regular basis or in 
high doses. However, it has been reported that administration of supra-physiological 
doses of PYY(3-36) causes nausea suggesting it only has a narrow therapeutic 
window (Murphy and Bloom, 2006). There is also the possibility of patients 
developing tachyphylaxis to its effects.  
A number of hormones have been shown to elicit anorectic effects. Co-administration 
of these hormones may result in an additive or even synergistic inhibitory effect on 
food intake. By combining different hormones, it may also be possible to reduce the 
doses of individual hormones and thus potentially reduce related side effects. 
Consequently, a number of groups have investigated the effects of co-administering 
PYY with other known anorexigenic hormones. The effect on food intake of co-
administration of PYY(3-36) and GLP-1(7-36) amide was tested in both rodents and 
humans (Neary et al., 2005). It was reported that dual PYY(3-36) and GLP-1(7-36) 
amide treatment resulted in an enhanced inhibitory effect on food intake when 
compared to the effect of single peptide infusion in humans and in lean and obese 
mice. Similarly co-administration of PYY(3-36) with the long acting GLP-1R agonist 
exendin-4 had an increased anorectic effect compared with the individual treatments. 
The reduction in food intake for the combination treatment was greater than the 
effects of the two single treatments added together, suggesting that PYY(3-36) and 
GLP-1(7-36) amide may operate in a synergistic manner (Neary et al., 2005). 
Although PYY and GLP-1 are co-secreted by the L-cells of the small intestine, they 
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then act through independent mechanisms. The pathways mediating this synergistic 
effect are as yet unclear. 
It was then hypothesised that that the combination of PYY(3-36) and PP may also 
show enhanced inhibition of food intake, as both act via different Y receptors. 
However, in human studies, volunteers treated with both PP and PYY(3-36) 
consumed more food than those receiving PP alone (Neary et al., 2008). In mice the 
combination treatment led to a statistically insignificant decrease in food intake 
compared to the single treatments (Neary et al., 2008).  
It has been reported by Amylin Pharmaceuticals that the combination therapy of 
amylin and PYY(3-36) resulted in a synergistic reduction in food intake compared 
with treatment with either peptide alone (Roth et al., 2007). This has been proposed to 
be due to amylin induced signalling in the area postrema positively influencing 
upstream PYY(3-36) signalling in the arcuate nucleus. 
The effects of PYY(3-36) on food intake are short lived. Fasting, or a reduction in 
body weight causes a drop in the circulating levels of leptin which elicits a subsequent 
increase in appetite, which may oppose any longer acting effects of PYY(3-36). It was 
thus suggested that co-administration of leptin might extend the anorectic effects of 
PYY (3-36) (Unniappan and Kieffer, 2008). This combination did prolong the 
anorectic effects of PYY(3-36) in ad libitum fed rats, but not in 24 hour fasted rats, 
suggesting that decreased circulating leptin is not the only factor behind the short 
lived effects of PYY(3-36).  
Another possible approach to producing a successful PYY(3-36) based therapeutic 
would be to increase its selectivity for the anorectic Y2 receptor over other Y 
receptors. The C-terminal tyrosine residue of PYY is thought to be essential for 
binding as an alanine scan of PYY(3-36) found that (Ala36)PYY(3-36) had a complete 
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loss of affinity for the Y2 receptor (Pedersen et al., 2009). A number of PYY(3-36) 
analogues have been produced with altered aromatic side chain functionalities of the 
tyrosine36 residue. Analogues with the hydroxyl group replaced by an amino or 
halogen functionality, retained affinity for the Y2 receptor but had greatly increased 
selectivity for the Y2 over the Y1 receptor (Pedersen et al., 2009).  
Pegylation is the process by which a polyethylene glycol (PEG) group is attached to a 
peptide, usually in an attempt to improve its potency as a drug within the body. The 
large size of the PEG group hinders enzymatic degradation and slows renal clearance 
(Elinav et al., 2009). The chemical nature of the PEG group greatly increases 
solubility and stabilises the drug over a greater pH and temperature range. PEG 
displays minimal toxicity and is expelled from the body intact either through the 
kidneys or in faeces, depending upon the size of the PEG unit. PEG is therefore 
approved by the FDA for use as a vehicle or base for pharmaceuticals, cosmetics and 
foods (Harris and Chess, 2003). 
A number of studies have been conducted on pegylated PYY and Y2 agonists. 
PYY(24-36)-L31 has been shown to be a selective Y2 agonist. Studies were 
performed on a series of C and N-terminal pegylated cysteine analogues of PYY(24-
36)-L31 (DeCarr et al., 2007). It was found that any C-terminal pegylation was 
detrimental to receptor binding, but that all N-terminal pegylations decreased Y2 
affinity by less than a factor of 10. In the subsequent feeding studies, PEG20-
PYY(24-36)-L31 was shown to induce a greater reduction in food intake than native 
PYY(3-36) in mice (DeCarr et al., 2007). Another group developed a pegylated form 
of PYY(3-36) in which the PEG moiety was attached to the N-terminal of PYY(3-36) 
via an FMS linker that would be spontaneously and slowly hydrolysed under 
physiological conditions to yield the free peptide (Shechter et al., 2005). The group 
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had previously shown that irreversibly bound PEG40-PYY(3-36) was biologically 
inactive. Feeding studies in mice with the reversibly bound PEG40-PYY(3-36) found 
it had a circulating half life of 24 hours and that it resulted in a reduction in food 
intake comparable to that seen with continuous infusion of PYY(3-36), the effects of 
which only last for a few days (Shechter et al., 2005). These results support the 
concept of pegylation as a means of improving PYY based drug delivery.  
To improve the utility of peptide based drugs, it may be necessary to change the route 
of entry into the body. One alternative to intravenous or subcutaneous injection is to 
administer the peptide orally so that it can be absorbed into the circulation in the small 
intestine thus mimicking its physiological release (Beglinger et al., 2008). The main 
drawback to this strategy is that peptides do not readily survive the acidic conditions 
and proteolytic enzymes found in the stomach.  Novel drug formulation technology 
(details not supplied) were used to develop a form of PYY(3-36) suitable for oral 
administration. Oral administration of this molecule results in a rapid, dose dependent 
increase in plasma concentrations of PYY(3-36) and a suppression of ghrelin 
secretion (Beglinger et al., 2008). No information was supplied regarding subsequent 
effects on feeding behaviour, but this study demonstrates that a peptide can be 
successfully delivered into the circulation via oral administration. 
Another possible route of entry for peptide drugs is through the nasal mucosa, which 
acts as an absorptive surface for the transfer of peptides into the circulation. Nasal 
administration can also potentially facilitate direct transfer into the CNS. An 
intranasal formulation of PYY(3-36) was used in a 12 week study in obese subjects 
(Gantz et al., 2007). The study showed no significant weight loss at low doses and a 
high drop out rate at high doses caused by intolerance of the adverse events including 
nausea and vomiting. It is possible that the failure to promote weight loss at low doses 
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was the result of PYY(3-36) binding to central Y5 receptors following the theoretical 
transfer of PYY(3-36) directly into the CNS via the nasal mucosa. It may also be that 
the sharp but short-lived rise in circulating PYY(3-36) was insufficient to chronically 
reduce appetite and body weight.  
 
1.6 Gut hormones as obesity therapeutics 
Current anti-obesity therapies are insufficient to stem the obesity epidemic. There is 
thus much academic and industrial research into potential anti-obesity agents. Gut 
hormone systems offer a promising pharmaceutical target. As these hormones are 
released daily, it seems less likely that a patient would develop tachyphylaxis to their 
effects. They may also be less likely to cause side effects. Gut hormones are 
endogenous peripheral factors evolutionarily “designed” to influence central appetite-
control circuits. A drug based on gut hormones would therefore target specific 
neuronal pathways and may therefore be less likely to cause side effects. In contrast, 
agents such as Sibutramine have sympatho-mimetic side-effects because of their non-
specific targeting of neurotransmitter systems.  
Using a small molecule agonist for a gut hormone receptor would have advantages 
over the use of the peptide hormone itself. Such molecules are more likely to be orally 
active and so could be used in tablet form as opposed to requiring injection. However, 
designing small molecules so that they will act as agonists for gut hormone receptors 
is inherently difficult. The receptors often have large interaction sites and the amino 
acids important for receptor binding in the peptide can be dispersed throughout the 
sequence (Murphy and Bloom, 2007). 
It therefore seems logical to modify the hormone molecule itself, rather than trying to 
design a small molecule mimetic. Several modified peptide hormones are in 
widespread clinical use in injectable form e.g. modified forms of vasopressin for 
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diabetes insipidus, and of somatostatin for neuroendocrine tumours. Such modified 
hormones are synthetically produced using chemical techniques.  
 
1.7 Peptide chemistry 
Natural peptides can be extracted from tissue and in the past, many peptides were 
characterised and obtained for experimental and even clinical use in this manner. 
Subsequent developments in peptide chemistry meant that peptides needed for 
experimental work could be made by chemical means; in particular, this was the only 
way of obtaining unnatural sequences. In recent years, the development of 
recombinant DNA technology has provided the option of producing natural peptides 
and proteins of a hundred amino acids or more using biological methods. However, 
chemical synthesis is still the most important and widely used method for producing 
peptides, in particular those without more complex secondary structures. 
Peptide chemistry can be said to date back to the beginning of the 20th Century with 
the synthesis of the first peptide bond by Fisher. For the first half of the century 
peptides were synthesised using classical organic chemistry methods. This strategy is 
now referred to as solution phase peptide synthesis as all of the reagents are held 
within the liquid phase. Coupling reactions are generally performed in an organic 
solvent. Upon completion of the reaction, the desired compound is separated from 
unused reagents and by-products via a series of extractions and phase separations with 
different organic solvents and aqueous solutions. The process is cumbersome, time 
consuming and requires a high level of skill. The synthesis of simple peptides can still 
take many days to complete, whilst longer sequences can take months due to the need 
to perform multiple purification steps on intermediate products. However, solution 
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phase synthesis methods are still applied commercially in the large scale production 
of certain peptides.      
In 1963 the biochemist Bruce Merrifield reported a new method for the synthesis of 
peptides that he named Solid Phase Peptide Synthesis (SPPS) (Merrifield, 1963). His 
approach was to build a peptide chain in a stepwise process whilst it was anchored at 
the carboxyl terminus via a covalent bond to an insoluble solid support. Merrifield 
initially reported the synthesis of a model tetrapeptide (H-Leu-Ala-Gly-Val-OH) 
which was identical to a sample produced using the classical solution method. He 
later reported the successful solid phase synthesis of bradykinin that had full 
biological activity (Merrifield, 1964). Crucially Merrifield reported a production time 
of 8 days and a final yield of 68%. 
Merrifield’s method was initially met with widespread scepticism within the scientific 
community but in time became accepted as the most efficient way to synthesise 
peptides, in particular those with long sequences. 
The method involved the use of an insoluble but porous polymer resin onto which the 
peptide is anchored through the carboxyl group of the C-terminal amino acid. The 
peptide is then built up via the coupling of the subsequent residue to the free α-amino 
group of this amino acid. The α-amino group of the new amino acid is masked with a 
temporary protecting group which is not affected by the conditions of the coupling 
reaction, but which can subsequently be selectively removed to allow addition of the 
next residue in the sequence. 
Any amino acid containing a reactive side chain needs to have an additional 
protecting group present. This needs to be stable not only during the coupling reaction 
but also during the reaction to remove the temporary α-amino protecting group. Once 
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the peptide has been fully assembled, the side chain protecting groups are removed 
and the peptide simultaneously cleaved from the resin (Figure 1.3) 
 
Figure 1.3 The mechanism behind the principle of solid phase peptide synthesis 
(SPPS) 
X = temporary α-amino protecting group; R = amino acid side chain; Y = temporary side chain 
protecting group; n = number of amino acids in the peptide sequence.  
 65 
 
The main advantages of this method are that the peptide can easily be separated from 
all soluble reagents by simple filtration instead of time consuming extractions and 
separations. Washes can be performed quickly and easily, and excesses of reagents 
can be incorporated to speed reactions up, as they can also be easily removed at the 
end of the synthetic process. As the peptide is anchored to the solid support, loss of 
peptide is greatly reduced. Finally, Merrifield was quick to realise the potential for his 
methods to be amendable to automated synthesis (Merrifield, 1963).  
There are some drawbacks to this method. Incomplete couplings and incompletely 
blocked side reactions cause undesired products to accumulate on the resin. These 
affect the purity and yield of the resulting crude peptide, and have to be removed 
using one or more of the available purification methods.    
The basic principles of Merrifield’s method remain at the core of modern day solid 
phase peptide synthesis, but it has evolved over 40 years and now exists in two 
distinct forms. 
 
1.7.1 Boc/Bzl (Merrifield) SPPS 
This version of SPPS is very similar to the original method pioneered by Merrifield 
and works on the principle of increasing acidity for the removal of the α-amino 
protecting group, and for release of the final peptide and removal of the side chain 
protecting groups. The tertiary butoxycarbonyl (Boc) group (Figure 1.4) is used to 
protect the α-amino group of the amino acid residues and is removed by treatment 
with trifluoroacetic acid (TFA). This imparts a positive charge on the exposed α-
amino group and a neutralisation step is therefore required following each 
deprotection. A variety of TFA stable, benzyl based compounds are used to protect 
the reactive amino acid side chain groups. Final peptide release is brought about with 
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the very strong acid, anhydrous hydrogen fluoride (HF). However, HF is highly toxic 
and its use requires skill. Glass is not stable to HF and specialised HF resistant 
equipment is therefore required. Another drawback with Boc SPPS is the effect that 
repeated exposure to harsh acidic conditions has on the resin bound peptide. Certain 
peptide bonds are more sensitive than others to low pH and a number of by products 
are often produced following Boc SPPS of some peptides. In addition, the principle of 
Boc SPPS is reliant on the selectivity of the acidolysis reactions. However, these 
reactions were not always precisely selective, resulting in the accumulation of 
impurities on the resin, or loss of product due to premature cleavage of the peptide-
resin linker. As soon as these limitations were recognised, work began on devising 
alternative methods of SPPS.       
 
 
 
Figure 1.4 The chemical structures of the Boc and Fmoc α-amino protecting 
groups. 
AA = position at which the protecting group attaches to the amino acid. 
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1.7.2 Fmoc/tBu SPPS 
In 1970 Louis Carpino reported the development of a new amino protecting group, 9-
fluorenylmethyloxycarbonyl (Fmoc) that was completely stable to acidic conditions 
but was readily cleaved in mild basic conditions (Carpino and Han, 1972).  His study 
reported the successful synthesis and subsequent deprotection of a number of Fmoc 
protected amino acids and also the synthesis of some Fmoc dipeptides using solution 
phase methods.  
It was not until 1978 that two independent research groups reported the successful 
application of Fmoc protected amino acids in solid phase peptide synthesis 
(Meienhofer et al., 1979; Atherton et al., 1978). Both employed an orthogonal 
protecting strategy whereby reactive amino acid side chain groups were protected 
with tertiary butyl based structures that were acid labile. Removal of the Fmoc group 
was performed using the secondary amine piperidine, a basic substance in the 
presence of which the other protecting groups and the resin linker were completely 
stable.  
Final removal of the peptide from the resin together with the remaining protecting 
groups was facilitated by treatment with TFA. The use of a less harsh acid than that 
used with the Merrifield method meant that the cleavage reaction could be performed 
using standard laboratory glassware. 
In the thirty years that followed, Fmoc SPPS grew in popularity and, aided by a 
decrease in the cost of commercially available Fmoc protected amino acids, is now 
the synthesis method of choice in the majority of peptide laboratories. In 1992 the 
Association of Biomolecular Core Facilities (ABRF) conducted a study in which they 
asked their associate peptide facilities to synthesise the same peptide using their 
individual method of choice and submit a crude sample for analysis (Smith et al., 
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1992). Of the samples submitted exactly half were prepared by Boc SPPS and the 
other half by Fmoc SPPS. Although it was feasible to synthesise the sequence in 
question by either method, on average those facilities conducting Fmoc SPPS 
achieved greater success than those using Boc SPPS. All of the Fmoc crude samples 
contained at least 25% of the desired product, but only 56% of the Boc samples did.   
All of the peptides in the studies described in this thesis are synthesised using the 
Fmoc strategy, and all subsequent peptide chemistry information will thus relate to 
this strategy.  
 
1.7.3 Resins 
Polystyrene based resins cross linked with 1 – 2% divinylbenzene are still the most 
commonly employed solid supports in SPPS. It was on this same structure that 
Merrifield conducted his first successful synthesis of the tetrapeptide H-Leu-Ala-Gly-
Val-OH (Merrifield, 1963). The nature of the polymer matrix is such that 99% of the 
coupling sites on each resin bead lie within the bead and not on the surface (Amblard 
et al., 2006). Therefore to achieve optimum permeability for reagents to access the 
growing peptide chain, as well as accommodating the increasing size of the peptide, 
the resin has to sufficiently swell in the solvents in which reactions are performed. 
Polystyrene based resins display a good degree of swelling in both 
dimethylformamide (DMF) and particularly dichloromethane (DCM), but as the 
common peptide synthesis reagents are more soluble in polar solvents it is DMF that 
has become the primary solvent in Fmoc SPPS. DCM is still utilised in specific 
reactions and also to perform certain wash cycles. Alcohols and aqueous solutions 
have been found to be inadequate for most SPPS procedures as they lack the desired 
resin swelling properties (Amblard et al., 2006). In the presence of alcohols, 
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polystyrene based resins shrink and this property is now utilised as a means of 
adequately washing away unused reagents by alternating a swelling wash with a 
shrinking wash. The most commonly used alcohol for this is iso-propanol. 
In later years, alternative polymer supports were developed. The most commonly used 
was a polystyrene–polyethylene glycol (PEG) hybrid whereby PEG molecules were 
grafted onto the polystyrene matrix. PEG imparts a hydrophilic character to the resin 
support which increases its swelling properties across a wider range of solvents. This, 
together with a decrease in the loading capacity, make PEG based hybrid resins useful 
for the synthesis of long and difficult sequences (Novabiochem, 2010). Disadvantages 
of using these resins include their high cost and the propensity for PEG leaching to 
occur during cleavage owing to the lability of the bond between the PEG and 
polystyrene molecules. Recently, a number of different pure PEG based resins have 
become commercially available that claim to overcome these disadvantages 
(Novabiochem, 2010). 
The peptide is attached to the polymeric support through a linker molecule. The 
nature of the linker determines both the required final cleavage conditions and also 
the functionality of the C-terminal residue. The two most common C-terminal 
functional groups are the free acid (COOH) and amide (CONH2). In 1973 Wang 
devised a TFA labile resin for the production of protected peptides in Boc SPPS 
(Wang, 1973). This polystyrene based resin has a p-alkoxybenzyl alcohol linker and is 
now the standard resin in many peptide laboratories for the production of peptide 
acids in Fmoc SPPS. Other commonly used resins for the production of peptide acids 
are 2-chlorotrityl chloride resin and Super Acid Sensitive Resin (SASRIN). The linker 
group in both only requires a low concentration of TFA to be cleaved, so these resins 
are used for the production of protected peptide acids whereby the peptide is released 
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from the resin, but all amino acid and N-terminal protecting groups are retained. This 
approach is necessary when reactions with the C-terminal carboxylic acid group are 
required.    
The most frequently used resins for producing peptide amides are Rink amide resin, 
Ramage amide resin and 4-Alkoxy-2,6-dimethoxybenzylamine (PAL) resin. Sieber 
developed an acid sensitive, peptide amide yielding resin that can be used for the 
production of protected peptide amides (Figure 1.5) 
For peptide acids and amides there exist a number of commercially available PEG 
based resins that carry these same linkers. These include TentaGel resins supplied by 
Rapp Polymere (Tübingen, Germany) and NovaSyn resins supplied by Novabiochem 
(Nottingham, UK). 
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Figure 1.5 The chemical structures of the most commonly used resin linker 
compounds for the synthesis of peptide acids and amides. 
 
Peptides can be produced with a number of other C-terminal functionalities such as 
alcohols, aldehydes and alkyl esters. There are specialised resins for the production of 
these peptides that are often compatible with standard TFA cleavage methods. 
Alternatively, 2-chlorotrityl chloride and SASRIN resins can be used and specific 
cleavage conditions applied to produce the desired functionality (Mergler, 1999). 
The attachment of the first amino acid to the resin is carried out under a variety of 
conditions dependent upon the nature of the resin. For the production of a peptide 
amide, attachment to the resin of the first residue uses the same conditions as for all 
subsequent amino acid couplings. Thus there is no need to perform a separate resin 
loading reaction and the base resin can be purchased in bulk and used directly in an 
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automated process. When a peptide acid is required, loading of the 2-Chlorotrityl 
resin is a relatively straightforward procedure involving the use of an excess of amino 
acid in solution in the presence of a base and mixing for up to 4 hours. For the 
alkoxybenzyl based resins such as Wang resin, attachment of the first amino acid is a 
more problematic and inconsistent procedure (Chan and White, 2000). It is necessary 
to form an activated species of the amino acid prior to loading. The activation 
procedure utilised serves to increase the risk of epimerization. This is a particularly 
problem with the amino acids histidine (His) and cysteine (Cys). With peptides that 
contain a C-terminal His or Cys residue, many laboratories will choose to use a 2-
Chlorotrityl based resin as the epimerizations levels are much lower than with 
alkoxybenzyl based resins. Due to the specificity of the loading reaction and the 
problems associated with it, many choose not to load the resin themselves and instead 
purchase alkoxybenzyl based resins that are pre-loaded with the relevant Fmoc amino 
acids. 
 
 
1.7.4 Fmoc deprotection 
The most common method for removing the Fmoc group from a resin bound peptide 
is to wash the resin with a solution of 20-50% piperidine in DMF. Piperidine 
deprotonates the fluorene ring of Fmoc, which leads to removal of the molecule from 
the peptide as dibenzofulvene and carbon dioxide. The dibenzofulvene intermediate is 
then scavenged by piperidine to form an adduct that strongly absorbs UV radiation 
(Figure 1.6). 
This property enables the monitoring of Fmoc deprotection reactions by certain 
automated peptide synthesisers which have built in UV monitoring systems. This 
measures the UV absorbance of a sample of the deprotection solution during the 
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deprotection reaction. If the UV absorbance reading is above a preset level, the 
assumption is made that this is due to the presence in the solution of the 
dibenzofulvene-piperidine adduct, and thus the deprotection reaction is not yet 
complete. The reaction is then repeated until the UV absorbance reading falls below 
the preset level and the deprotection is considered complete. In comparison, those 
conducting manual syntheses, or who do not have access to such synthesisers, at least 
two consecutive washes, of between 2 and 30 minutes, are performed as standard to 
ensure effective deprotection.  
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Figure 1.6 The reaction mechanism of Fmoc group removal by piperidine. 
 
There are a variety of chemical tests that can be conducted on a sample of resin to 
help the chemist determine whether the Fmoc deprotection reaction has been 
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successful. The most commonly used of these is the Kaiser test. This involves 
washing a sample of resin in iso-propanol and then adding three drops each of 
ninhydrin in butan-1-ol, phenol in butan-1-ol and pyridine. The sample is then heated 
to 100°C for 5 minutes; the resin beads turn blue if free α-amino groups are present. 
The colour results from the formation of the chromophore molecule Ruhemann’s 
Purple (Bottom et al., 1978). As the chromophore is formed by the reaction of 
ninhydrin with primary amines, a blue colour is not seen when the amino acid being 
tested is proline. As proline is a secondary amine, an orange/brown colour is usually 
recorded. The resin beads will not change colour in the event of a negative result. This 
same test can also be applied to the monitoring of the subsequent coupling reaction.  
For some long and difficult peptides, piperidine has been shown to be ineffective in 
completely removing the Fmoc group, even when longer deprotection times and 
higher piperidine concentrations are used. In these cases it is often beneficial to use a 
stronger base such as 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) (Figure 1.7), which 
has been shown to improve the synthesis of, for example, amyloid β protein (1-42) 
which is known to be a difficult sequence to synthesise (Tickler et al., 2001). 
In contrast, certain sequences can contain amino acids that are sensitive to piperidine 
and as such require the use of a milder base such as n-methylpiperidine (Figure 1.7). 
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Figure 1.7 Chemical structures of alternative basic substances to piperidine for 
the removal of Fmoc groups. 
 
There are a number of different side reactions that can occur during Fmoc 
deprotection. Certain C-terminal dipeptide sequences are susceptible to base catalysed 
diketopiperazine formation (Chan and White, 2000). In this process the N-terminal 
amino group of the penultimate amino acid cleaves the resin ester linkage, releasing a 
cyclic dipeptide and leading to a loss of yield. The reaction is more likely to occur 
when the dipeptide contains proline (Pro) and glycine (Gly) residues and the resin is 
alkoxybenzyl based. It is therefore recommended that trityl based resins are used for 
C-terminal proline and glycine peptides, as the bulkier trityl group hinders 
diketopiperazine formation. Alternatively, the second and third amino acids can be 
coupled together as a dipeptide.  
In basic conditions aspartic acid (Asp) residues are prone to aspartimide formation. 
This is a sequence dependent reaction, with certain Asp-xxx sequences more prone 
than others. The problem occurs when the α nitrogen of the xxx residue reacts with 
the protected Asp side chain group in a base catalysed reaction. This forms the cyclic 
aspartimide compound and leads to subsequent loss of the aspartic acid protecting 
group. Aspartimides readily undergo ring opening reactions that subsequently produce 
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a number of different products, most commonly the α and β aspartyl isomers and, in 
the presence of piperidine, the α and β piperidide adducts (Mergler, et al., 2003b) 
(Figure 1.8). The most likely xxx residues to facilitate aspartimide formation are 
glycine, aspartic acid, asparagine and serine (Mergler, et al., 2003a). The use of strong 
bases such as DBU exacerbate aspartimide formation, as does prolonged exposure to 
basic conditions, meaning that longer sequences are more susceptible to higher levels 
of aspartimide derived impurities. 
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Figure 1.8 The reaction mechanisms behind aspartimide formation and the 
subsequent conversion to aspartyl and piperidide impurities. 
Abbreviation: Asp, aspartic acid. 
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There are a number of different strategies to overcome aspartimide formation. One is 
to use an alternative aspartic acid side chain protecting group other than the standard 
t-butyl ester (OtBu) group. Studies have demonstrated that employing the bulkier 3-
methylpent-3yl ester (OMpe) protecting group greatly reduced aspartimide formation 
when compared with t-butyl (Mergler, et al., 2003a) (Figure 1.9). The only drawback 
to this is the relatively high cost of this Fmoc derivative compared to the standard 
derivative.   
 
 
 
Figure 1.9 The chemical structures of two aspartic acid protecting groups  
 
As stated above, Asp–Gly sequences are particularly prone to aspartimide formation, 
but using the dipeptide building block Fmoc-Asp(OtBu)-(Dmb)Gly-OH greatly 
reduces aspartimide formation in Asp-Gly containing sequences. It contains the 
group, 2,4-dimethoxybenzyl (Dmb) on the α-amino group of the glycine residue 
(Figure 1.10). Its presence hinders aspartimide formation due to its bulky nature; it is 
stable to Fmoc deprotection and amino acid coupling conditions and is completely 
removed during TFA cleavage. Again, the cost of purchasing this derivative is high, 
thus preventing its routine use by all in the field. 
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Figure 1.10 The chemical structure of a dipeptide for use in the reduction of 
aspartimide formation in Asp-Gly containing sequences 
Abbreviations: Fmoc, 9-fluorenylmethyloxycarbonyl; Asp, aspartic acid; Dmb, 2,4-dimethoxybenzyl; 
Gly, glycine. 
 
Finally, specific additives in the deprotection solution can also help to suppress 
aspartimide formation. The addition of 1-hydroxybenzotriazole (HOBt) has been 
reported to be particularly effective in this role. 
 
1.7.5 Coupling 
A solid phase peptide coupling reaction involves the reaction of the resin bound α-
amino group with the carboxylic acid of the next Fmoc protected amino acid in the 
sequence. A molar excess of amino acid, relative to the scale of the synthesis, can be 
used to drive the reaction to completion, as any unused reagent is subsequently 
washed away.  In classic organic chemistry, it has long been established that amide 
bond formation requires activation of the carboxylic acid group to drive the reaction. 
However, the commonly used activating methods in organic chemistry are deemed 
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too harsh for peptide synthesis, due to the generation of over activated intermediate 
products that can facilitate multiple side reactions (Chan and White, 2000). A number 
of milder activation strategies have thus been devised specifically for use in peptide 
synthesis. In the initial SPPS of his tetrapeptide, Merrifield employed N, N’-
dicyclohexylcarbodiimide (DCC) as an activating agent, forming the symmetric 
anhydride of the protected amino acid (Merrifield, 1963). This method of activation is 
still widely used today, but has its limitations. Two molar equivalents of the protected 
amino acid and one equivalent of DCC are needed to generate one equivalent of the 
symmetric anhydride (Pennington and Dunn, 1994). It is best to form the anhydride 
20-30 minutes prior to it being added to the peptide bound resin, which increases the 
synthesis time per amino acid cycle. Activation proceeds more rapidly in the apolar 
solvent DCM as opposed to the polar solvent DMF. However, some reagents are 
insoluble in DCM, meaning that a compromise has to be reached whereby a certain 
concentration of DMF is present in the activation reaction. A by product of the 
activation process is dicyclohexylurea, and although this is inert during the coupling 
reaction, it is also insoluble. This usually requires that the reaction mixture be filtered 
prior to being added to the resin (Pennington and Dunn, 1994). This problem can be 
overcome by the use of other carbodiimides such as diisopropylcarbodiimide (DIC), 
which produces a completely soluble urea. 
Carbodiimides can also be used in combination with the triazole based compounds 
HOBt and 1-hydroxy-7-azabenzotriazole (HOAt) to activate amino acids. In this 
process the OBt or OAt active ester form of the amino acid is produced. This form of 
activated amino acid has been reported to improve coupling reactions by reducing the 
amount of racemization that occurs (Pennington and Dunn, 1994). Activation 
proceeds smoothly in both DCM and DMF, and as with the symmetrical anhydride 
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method, is best occurring 20-30 minutes prior to addition to the resin. If DIC is the 
carbodiimide species being used then there is no risk of precipitate forming during 
activation. Several automated peptide synthesiser models are thus able to perform 
HOBt/DIC mediated couplings. 
As solid phase peptide synthesis evolved, so a new class of coupling reagents became 
available. The aminium and phosphonium class of coupling reagents were first 
reported in the 1970’s and have now become popular in many peptide laboratories. 
The main advantage with these reagents is that the activation reaction can take place 
in situ with no need for separate pre-activation. This speeds up the coupling cycle, 
with reactions generally complete within 30 minutes of activation. These reagents all 
share some degree of structural homology with HOBt, but also contain either an 
aminium or phosphonium salt which in the presence of a tertiary base such as N,N-
diisopropylethylamine (DIPEA) will convert a protected amino acid to its OXt ester. 
The most commonly used reagents within this class are Benzotriazole-1-yl-oxy-tris-
pyrrolidino-phosphonium hexafluorophosphate (PyBOP), 2-(1H-Benzotriazole-1-yl)-
1,1,3,3-tetramethylaminium hexafluorophosphate (HBTU) and 2-(1H-Benzotriazole-
1-yl)-1,1,3,3-tetramethylaminium tetrafluoroborate (TBTU), all of which generate 
OBt active esters. All are widely available, readily soluble in DMF and stable in 
solution for a number of days, making them compatible with automated synthesisers. 
Reagents that generate the more reactive OAt ester are also available. The most 
effective of these is O-(7-Azabenzotriazol-1-yl)-N,N,N’,N’-tetramethyluronium 
hexafluorophosphate (HATU), but its high cost prevents its widespread use as a 
standard coupling reagent (Albericio, F. and, 1997). Instead, it is utilised for specific 
coupling reactions that are known to be difficult (Figure 1.11). 
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Figure 1.11 The chemical structures of the most commonly used amino acid 
activating agents 
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With the exception of PyBOP, all of these reagents are capable of reacting with amino 
groups, meaning that a potential side reaction during their use is N-terminal 
guanidation of the peptide chain (Gausepohl et al., 1992). To prevent this, a slightly 
lower molar excess of coupling reagent compared with protected amino acid is 
employed. In theory this ensures that all of the coupling reagent will be exhausted 
during the activation process.  
Aminium and phosphonium reagents are reported to increase the propensity for 
certain amino acids to racemize during coupling. The most susceptible residues are 
cysteine and histidine (Chan and White, 2000). In the case of cysteine, many 
recommend the use of carbodiimides for activation as opposed to aminium and 
phosphonium reagents. An alternative option is to include HOBt in the activation 
reaction as this can help to suppress the racemization of susceptible amino acids. 
 
1.7.6 Difficulties in peptide synthesis 
During elongation the peptide chain can form secondary structures such as β sheets, 
or can aggregate with other peptide chains or with the polymer support on which they 
are anchored (Mutter, 1985). These interactions can lead to difficulties in the α-amino 
deprotection and/or coupling reactions. These problems are entirely sequence 
dependent, but are most commonly experienced with sequences containing clusters of 
hydrophobic amino acids. In the most extreme cases, aggregation is such that the resin 
bed is seen to shrink in size, making further couplings very difficult (Chan and White, 
2000).  
A number of different techniques have been developed to help overcome these 
difficulties. The simplest technique is to cap any unreacted amine groups at the end of 
each coupling step with a small reactive group such as acetyl. This will prevent the 
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generation of single amino acid deletion impurities.  Another method is to use a PEG 
based resin instead of the standard polystyrene based support. The benefits of this are 
twofold. Firstly, the presence of the PEG group will increase the swelling properties 
of the resin, thus making the α-amino group readily accessible. Secondly, PEG based 
resins generally have lower loading values than the standard resins, and individual 
peptide chains are therefore spaced further apart and are less prone to intermolecular 
interactions. 
Other techniques that can be employed are to use a more effective activating reagent 
such as HATU and to increase coupling times. In both cases this can also lead to an 
increase in undesirable side reactions occurring.  
In recent years a number of “secondary amino acid surrogates” have been developed 
to improve the synthesis of difficult peptides by suppressing aggregation. Insertion of 
the temporary protecting groups, 2-hydroxy-4-methoxybenzyl (Hmb) and Dmb, onto 
the backbone of the peptide chain helps to disrupt secondary structure formation, due 
to their bulky nature (Novabiochem, 2010). The protecting groups are attached to the 
α-nitrogen of an Fmoc protected amino acid and can be incorporated as a single 
residue or within a dipeptide. In the case of the single residues, coupling times have 
been found to be sluggish. The Hmb/Dmb group is released from the peptide chain 
during the final cleavage reaction, leaving behind the native peptide sequence. 
A peptide sequence rich in proline residues is naturally resistant to aggregation due to 
the rigidity conferred on the peptide chain by the cyclic structure of proline. In 1992, 
Mutter developed pseudoproline dipeptides which are held in a temporary oxazolidine 
“proline like” structure and so can be incorporated into peptide sequences containing 
little or no proline residues to confer the same aggregation disrupting properties 
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(Mutter et al., 1995). The temporary structure then breaks down upon cleavage with 
TFA, returning the peptide to its natural configuration (Figure 1.12).  
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Figure 1.12 The chemical structure and mechanisms behind the use of 
pseudoproline dipeptides 
Abreviations: Ser, serine; Thr, threonine; TFA, trifluoroacetic acid. 
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Pseudoprolines have also been shown to aid in the synthesis of resin bound cyclic 
peptides whereby two residues within the same peptide chain are linked 
(Novabiochem, 2010). The nature of the oxazolidine structure means that the carboxyl 
amino acid of the dipeptide must be either serine or threonine. Pseudoprolines can 
therefore only be used in sequences containing either of these two residues. Although, 
in theory there is no restriction on the identity of the second amino acid within the 
dipeptide, in practice many pseusoprolines are not yet commercially available. 
In 2006 a new class of aggregate disrupting dipeptides were reported. Isoacyl 
dipeptides are similar to pseudoprolines in that serine or threonine residues form a 
dipeptide with another Fmoc protected amino acid held in an alternative, temporary 
structure (Novabiochem, 2010). In this case the Fmoc amino acid is acylated to the 
serine/threonine through its β-hydroxyl side chain. The unused α-amino group of the 
serine/threonine is protected with a Boc group. Replacing the amide bond with an 
ester bond radically alters the confirmation of the peptide chain, creating a 
depsipeptide which helps to disrupt aggregation. Unlike with pseudoprolines, the 
depsipeptide confirmation is stable to TFA cleavage and has been found to be more 
soluble than the native sequence. By retaining the temporary structure post-cleavage, 
the improvement in solubility should in theory aid the purification of the peptide. 
Once purified, the depsipeptide is converted to the native peptide sequence by 
exposure to pH7.4, at which spontaneous conversion occurs (Figure 1.13).  
 
1.7.7 Peptide modifications 
Solid phase peptide synthesis began as a means of efficiently synthesising naturally 
occurring peptide sequences, and subsequently for synthesising analogues of these 
peptides with amino acid substitutions. However the methods employed in SPPS 
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make it amenable to the synthesis of a wide range of chemically modified peptides 
that are unlikely to be found in nature. 
 
Figure 1.13 The chemical structure, and mechanisms behind the use, of isoacyl 
dipeptides 
Abbreviations: Boc, tertiary butyloxycarbonyl; Ser, serine; Thr, threonine; TFA, trifluoroacetic acid. 
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The most straightforward modifications are those that extend the N-terminal of the 
peptide with functional groups not usually associated with peptides. With the peptide 
bound to the resin and all reactive amino acid side chain groups fully protected, the 
exposed α-amino group is the only reaction site available. N-terminal modifications 
can range from simple acetylation, which couples the small acetyl group to the amino 
group which blocks the amino functionality of the peptide. The reaction usually takes 
less than 30 minutes to complete and is fully compatible with automated synthesisers. 
Extension of the N-terminal with larger compounds is also possible using a number of 
long chain fatty acids, such as palmitic and myristic acid, which are routinely coupled 
to peptides for use in biological studies (Lumbierres et al., 2005). 
A wide range of labelling compounds can also be coupled to peptides via the N-
terminal. The most common of these is biotin, which helps the peptide bind to 
streptavidin and avidin for subsequent use in biological assays. Chromogenic labels 
which emit at specific wavelengths are useful tools for those working with peptides in 
enzymology, immunology and histochemistry. In the study of proteolytic enzymes, 
such labels are utilised to help detect sites of enzymatic cleavage. The enzyme 
substrate is “double labelled”, with a fluorophore group in one position of the peptide 
and a quencher molecule in another. Whilst the peptide remains intact the 
fluorescence of the fluorophore is suppressed by the quencher via a process called 
Fluorescence Resonance Energy Transfer (FRET). An enzymatic cleavage which 
separates the two labels will result in a sudden increase in fluorescence. 
Spacer molecules are often employed between label and peptide to prevent steric 
hindrance during coupling of the often bulky label molecule. Common spacers in 
peptide chemistry are the straight chain hydrocarbon, non-standard amino acids β-
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alanine and aminohexanoic acid. Recently, the more hydrophilic compound 8-Amino-
3,6-Dioxa-Octanoic Acid (AEEAc) has become a popular alternative spacer molecule 
as it helps increase the solubility of these labelled peptides.  
When modification of a specific amino acid side chain group rather than the N-
terminal amino group is required, the strategy of orthogonal protecting groups is 
applied. This involves protecting the amino acid to be modified with a functional 
group that can be removed in conditions that also retain the integrity of both the resin 
linker and all of the other protecting groups. This is most frequently applied to lysine 
residues as the side chain functionality is as of a primary amine which can be 
modified in exactly the same way as the N-terminal. There are a number of different 
lysine protecting groups available, each with their own specific deprotection 
conditions (Figure 1.14). An example is 4-methyl-trityl (Mtt), a very acid labile 
protecting group that can be removed by 1-2% TFA, a concentration at which all 
standard protecting groups are theoretically stable. However, deprotection occurs 
slowly and requires repeated washes with the TFA solution. The process can take up 
to an hour to complete and the degree of deprotection cannot be easily quantified.  
Alternatively, 1-(4, 4-dimethyl-2, 6-dioxocyclohex-1-ylidene)ethyl (Dde) is an amine 
protecting group that was introduced in 1993. It is cleaved with 2-5% hydrazine 
hydrate in DMF and the reaction is usually complete in 10 – 15 minutes. As it is 
completely orthogonal to the standard protecting groups, the deprotection reaction can 
be readily followed by High Performance Liquid Chromatography (HPLC) and mass 
spectrometry. It was later reported that Dde was prone to migration to other amino 
groups during piperidine mediated Fmoc deprotection (Novabiochem, 2010). To 
overcome this, the bulkier 1-(4, 4-dimethyl-2, 6-dioxocyclohex-1-ylidene)-3-
methylbutyl (ivDde) protecting group was developed. This was proven to be 
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considerably more stable to piperidine than Dde. The Dde and ivDde derivatives are 
significantly more expensive than the Mtt derivative, and deprotection can only be 
carried out once the peptide has been fully assembled, as the Fmoc group is not stable 
to hydrazine treatment.    
Allyloxycarbonyl (Aloc) is a protecting group that is stable to both TFA and 
piperidine, but can be cleaved by reaction with a palladium(0) catalyst in the presence 
of acetic acid and N-methylmorpholine in DCM. Drawbacks are that the deprotection 
reaction can take up to 2 hours, and the palladium catalyst has a short shelf life once 
exposed to air. However, the derivative is cheaper than both the Mtt and Dde/ivDde 
versions and the mild deprotection conditions ensure the stability of all other 
protecting groups.   
Sometimes modification of a peptide requires exposure of a carboxyl group as 
opposed to an amine. In this instance, selective deprotection of either an aspartic acid 
or glutamic acid residue can be carried out. Both amino acids are commercially 
available with side chain protecting groups that are complementary to the required 
deprotection strategy of the previously mentioned amine protecting groups (Figure 
1.14). Of these, 2-phenylisopropyl ester (OPip) is removed by treatment with 1-2% 
TFA, 4{N-[4, 4-dimethyl-2, 6-dioxo-cyclohexylidene)-3-methylbutyl]-
amino}benzyloxy (ODmab) is removed with 2-5% hydrazine hydrate, and allyl ester 
(OAll) is cleaved by exposure to palladium(0) catalyst.  
A lactam bridge is an intramolecular bond between the amine group of a lysine and 
carboxyl group of an aspartic acid or glutamic acid residue that alters or restrains the 
conformation of the peptide. Such bridges can be formed on the resin by selectively 
deprotecting the two residues to be linked. If both have complimentary protecting 
groups then the deprotection can be performed simultaneously. Successful lactam 
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bridge formation is sequence dependent as it relies upon the two bridge forming 
functional groups being in close proximity on the resin bound peptide. If the two 
groups are too far apart on the resin, there is the risk of either intermolecular lactam 
bridge formation or reaction of the functional groups with the reagents being used to 
facilitate lactam formation.   
 
 
 
Figure1.14 The chemical structures of alternative protecting groups for lysine, 
aspartic acid and glutamic acid Fmoc amino acids  
 
A second class of intramolecular bond commonly formed in peptides are disulphide 
bridges between the thiol side chain groups of cysteine residues. The reaction 
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conditions for disulphide bridge formation are specific to sulphydryl groups, meaning 
that they can be formed on fully deprotected peptides, often during the purification 
stage (Pennington and Dunn, 1994). Disulphide bridge formation is therefore usually 
more straightforward than lactam formation.   
It may be that the carboxyl group required for modification is that at the C-terminal of 
the peptide. In this case it is necessary to remove the peptide from the resin but to 
retain all of the amino acid protecting groups. The peptide must therefore be 
synthesised on an acid sensitive resin such as 2-chlorotrityl chloride or SASRIN. The 
fully protected peptide can then be obtained either by repeated washes with 1-2% 
TFA or with 1 – 4 hour treatment with 1,1,1,3,3,3-Hexafluoro-2-propanol (HFIP) 
(Mergler, 1999). The TFA method requires that each wash is neutralised with pyridine 
to prevent prolonged exposure to TFA. This leads to the formation of pyridinium 
trifluoroacetate which has to be completely removed via extraction or precipitation. 
Conversely some standard protecting groups are sensitive to HFIP and to ensure that 
they are retained during cleavage, the HFIP concentration and reaction times must be 
carefully controlled.      
 
 
1.7.8 Cleavage 
Once the synthesis of the peptide is complete, the next step in the process is to remove 
the peptide from the resin and remove the protecting groups from the amino acids. 
Standard resin linkers such as Wang, Rink and Ramage are all cleaved by treatment 
with TFA at concentrations of 80% or higher. As has been previously mentioned, 
other resin linkers such as 2-chlorotrityl and SASRIN can be cleaved using much 
milder conditions. At the higher TFA concentrations, all standard amino acid 
protecting groups will also be cleaved. Once removed from the amino acid, the 
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protecting group is released into solution as a highly reactive cation that can modify 
other amino acids in the sequence (Pennington and Dunn, 1994). To overcome this, 
scavenger compounds are included in the cleavage solution to remove the reactive 
cation species. A number of different scavengers are routinely used in peptide 
chemistry, with each one effective at removing particular cations. It is therefore 
possible to tailor a cleavage solution for each peptide based upon the amino acids in 
its sequence. However, more commonly chemists utilise a catch all cleavage cocktail 
that can be used for the vast majority of peptides synthesised. The most frequently 
used cocktail is solution K that consists of 82.5% TFA, 5% phenol, 5% H2O, 5% 
thioanisole and 2.5% 1,2-ethanedithiol (EDT). Due to their unpleasant odour some 
users omit both thioanisole and EDT and replace them with the less odorous 
triisopropylsilane (TIS). It is also necessary to remove these two scavengers from the 
cleavage solution if the peptide contains residues that are sensitive to thiol 
compounds. 
The dry peptide resin is suspended in the cleavage solution, usually at a concentration 
of 10 – 25mL per gram of resin, and agitated gently. Some laboratories choose to start 
the cleavage reaction in an ice bath.  
The reaction is left to mix for a minimum of 2 hours, but the actual cleavage time is 
sequence dependent. Certain amino acid deprotection reactions proceed more slowly 
than others, with arginine side chain protection groups the slowest. It may thus be 
necessary to extend the cleavage time for sequences containing multiple arginine 
residues for up to 24 hours (Chan and White, 2000). 
Once the reaction is complete, the resin is filtered away and the peptide that remains 
in an acidic solution can either be directly precipitated or concentrated under vacuum 
before precipitation. Concentrating the solution helps to speed up the subsequent work 
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up. However, cysteine residues are sensitive to the concentration conditions as they 
are prone to reattachment of their protecting group. Precipitation of the peptide is 
commonly facilitated with the addition of cold diethyl or tertiary butyl methyl ether. 
This suspension is usually refrigerated overnight. The peptide is then isolated by 
filtration before being washed with fresh ether to remove any residual TFA and 
scavengers, and then being dried to a powder if possible. 
Several side reactions, other than reaction with the protecting group cations that 
reduces the purity of the resulting crude peptide can occur during the cleavage 
process. If the peptide contains methionine residues, they can undergo acid catalysed 
oxidation to methionine sulphoxide (Chan and White, 2000), although this reaction 
can be reversed with the addition of reducing agents prior to the end of the cleavage 
reaction. 
N-terminal glutamine residues also undergo acid catalysed modification, irreversibly 
forming pyroglutamic acid (Chan and White, 2000). In this case the crude material 
will contain an impurity that is impossible to separate from the target peptide. 
Peptides containing N-terminal glutamine are therefore usually acetylated or 
synthesised with pyroglutamic acid as the final residue.   
 
 
1.7.9 Purification 
For all but the shortest sequences, the quality of the crude peptide material produced 
from cleavage is seldom good enough for its desired end use. The process of purifying 
the peptide is therefore as important as the process of synthesising it. A variety of 
different techniques have traditionally been employed in the purification of peptides 
including ion-exchange chromatography, countercurrent distribution and gel-filtration 
chromatography (Miller and Rivier, 1996). However, the development of HPLC has 
 95 
led to this becoming the standard method of purifying peptides in most laboratories. 
The specific form of HPLC traditionally used is reverse phase HPLC, in which the 
stationary phase is either octyl (C8) or octadecyl (C18) modified silica which is 
tightly packed under pressure into a column of varying diameter and length. The C8 
or C18 group confers a hydrophobic nature on the stationery phase to which the 
peptide binds. To help suppress any hydrophilic characteristics in the peptide and 
hence increase binding, the mobile phase is generally a low pH solution so as to force 
the protonation of any carboxyl groups which also contains anions that act as counter 
ions to any basic amino acids (Miller and Rivier, 1996). The most commonly used 
buffering compound that meets these requirements is trifluoroacetic acid. 
The sample is loaded onto the column in a suitable solution and the HPLC system 
then begins to pump the mobile phase under high pressure through the column. To 
begin with, the mobile phase is usually a fully aqueous solution of the buffer which 
will flush any salts and loading solvent off the column. Unless the peptide is very 
short and/or hydrophilic it should remain bound to the stationary phase in the column. 
The system will then run a gradient whereby the organic content of the mobile phase 
is gradually increased. The most commonly used solvent for peptide purification is 
acetonitrile, although iso-propanol is an alternative option. As the organic 
concentration increases, the peptides within the sample will begin to display greater 
affinity for the mobile phase and so begin to elute from the column. The chemical 
differences between the components of the sample mean that they will likely each 
have different affinities for the two phases at any particular solvent concentration. 
This causes them to elute from the column at different times during the gradient. 
Within the HPLC system is a UV detector that operates at wavelengths of 200-220nm, 
the absorption wavelength range of the peptide bond (Mant et al., 2007). Peptides 
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containing a number of aromatic components, such as protected peptides, can also be 
detected at longer wavelengths such as 254nm.     
Depending upon the size of column and the capacity of the solution pumping system, 
HPLC systems are used for different tasks. At the smallest scale they are used as 
analytic tools to produce a representative chromatogram of the peptide sample. As 
they increase in size, the systems can begin to handle larger amounts of material and 
so are used to purify the peptide. In this case, as each component elutes from the 
column and is detected, the eluent is collected in fractions. Each fraction can then be 
analysed and those containing the desired product can be retained. These fractions can 
then be combined either for lyophilisation or for further processing.    
There are now a wide range of different columns and stationery phase materials 
available to the peptide chemist to enable them to tailor the purification of any 
particular peptide. 
In some peptide laboratories a second chromatography technique called Flash 
Chromatography is used alongside reverse phase HPLC. This is complementary to 
HPLC in that is uses the same buffer solutions and the same stationery phase material. 
The difference is that Flash Chromatography operates at lower pressures and the 
particles of the stationery phase are generally larger than those found in HPLC 
columns. This means that resolution is not as high for Flash Chromatography, but also 
means material that would damage the HPLC reverse phase column can be loaded 
without damage to the Flash Chromatography column. This makes it an excellent tool 
for the initial purification of crude peptide samples, thus preserving the lifetime of the 
more expensive HPLC column. Flash Chromatography gradients are also generally 
shorter than HPLC gradients, which helps to reduce overall solvent consumption and 
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to speed purification. Typical Flash Chromatography gradients are 20 – 30 minutes 
long compared with typical HPLC gradients of over an hour. 
The final analytical tool routinely used in the purification and characterisation of 
peptides is mass spectrometry. There are a number of different types of mass 
spectrometers available depending upon the desired method of sample ionization and 
subsequent mass analysis. The most common types found in peptide laboratories are 
Matrix Assisted Laser Desorption-Ionization (MALDI) and Electrospray Ionization 
(ESI) mass spectrometers (Wysocki et al., 2005). For MALDI mass spectrometry, the 
peptide sample is crystallised onto the sample plate together with a small organic 
matrix compound such as sinapinic acid or α-cyano-4-hydroxycinnamic acid (CHCA) 
(Wysocki et al., 2005). The matrix compound contains an aromatic ring structure that 
absorbs radiation at the wavelength of the laser that is used to ionize the sample 
(Moore, 1997). 
In ESI mass spectrometry, the peptide sample is introduced as a solution which is 
passed through a high voltage needle. The charged solution is then sprayed from the 
tip of the needle through an electrostatic field which evaporates the carrier solvent, 
creating an ionized sample for analysis (Wysocki et al., 2005). 
There are a number of different methods for analysing sample masses. The most 
common method used in tandem with MALDI and ESI, is time of flight (TOF) 
analysis. In TOF analysis, the ions are accelerated along a flight tube of fixed length 
using a small voltage gradient. The flight time of an ion is proportional to its mass-to-
charge ratio (m/z), which allows ions of different masses within the sample to be 
resolved (Wysocki et al., 2005).     
With MALDI mass spectrometry, usually only the singularly charged ion, (M+H) is 
generated, where M is the molecular weight of the peptide being analysed and H is a 
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proton. Meanwhile, ESI generates a range of charged species (M+z/z), making the 
interpretation of the resultant spectra less straightforward.   
 
1.8 Aims 
I intend to utilise some of the described SPPS techniques to produce analogues of the 
gut derived anorectic hormone PYY(3-36) and investigate the effects of these 
analogues both in vitro and in vivo. The aim is to produce a PYY(3-36) analogue that 
has a greater effect in reducing food intake than the endogenous peptide. This can be 
achieved by increasing the stability of the peptide to enzymatic degradation and/or by 
increasing the affinity of the peptide to the Y2 receptor, to which PYY(3-36) is a 
natural agonist. 
Should such an analogue be produced, then it could potentially be developed as an 
anti-obesity therapeutic.  
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2.1 Introduction 
 
As described in Chapter 1, Peptide YY (PYY) is a hormone released by the L-cells of 
the small intestine in response to food intake (le Roux and Bloom, 2005). The major 
circulating form of the peptide is PYY(3-36), formed by the action of the proteolytic 
enzyme dipeptidyl peptidase IV (DPP IV), which cleaves the N-terminal dipeptide, 
Tyr-Pro from the parent sequence (Mentlein, 1999). Administration of PYY(3-36) at 
physiological doses has been shown to reduce food intake in both lean and obese 
humans (Batterham, et al., 2003b). Thus, extensive research has been conducted with 
the aim of harnessing the anorectic effects of PYY(3-36) and using it in an anti-
obesity therapeutic. To date, although several therapies based on PYY(3-36) have 
made it to the clinical trial phase, none have yet made it onto the market (Cooke and 
Bloom, 2006). 
The anorectic effects of PYY(3-36) are short lived. The body naturally processes such 
hormones through enzymatic degradation, allowing the signal that the hormone is 
conveying to be turned off. Compensating for this by administering supra 
physiological doses leads to nausea (Murphy and Bloom, 2006). Therefore, 
chemically modifying the sequence and/or structure of PYY(3-36) to increase its 
efficacy as an anti-obesity agent is an attractive option. Somatostatin analogues, for 
example, have a longer half-life than somatostatin and are regularly used in the 
treatment of acromegaly and neuroendocrine tumours (Pettit and El-Modir, 2011).  To 
succeed in producing PYY(3-36) analogues that have increased efficacy in reducing 
food intake, there are two options. One is to increase the resistance of the peptide to 
the actions of proteolytic enzymes, thus extending the circulating half life of the 
analogue. The second option is to increase the binding affinity to the Y2 receptor. An 
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analogue of PYY(3-36) that fulfilled both of these criteria, could prove to be effective 
in combating the rising obesity epidemic.  Currently, peptide drugs are usually 
administered either intravenously or subcutaneously, but oral administration of a gut 
derived peptide drug would be preferable; it could be absorbed into the circulation 
from the small intestine, thus mimicking its physiological release (Beglinger et al., 
2008). Also, oral administration would be more convenient and palatable to patients 
than administration via injection. Unfortunately, the gastro-intestinal tract efficiently 
breaks down proteins through the actions of a number of different protease enzymes. 
 
2.1.1 Sites of proteolytic enzyme degradation within PYY(3-36) 
The sequence of PYY(3-36) contains a pair of basic amino acids in positions 25 
(arginine) and 26 (histidine) that are conserved across different species. Basic amino 
acids are a common site of degradation by proteolytic enzymes (Stoller and Shields, 
1989). Many small peptide hormones within the body are synthesised as larger 
precursor molecules which undergo post-translational cleavage by enzymes to release 
the active peptide. Within the sequence of the precursor, it is common for the 
hormone sequence to be flanked by pairs of basic amino acids at which processing by 
enzymes take place (Stoller and Shields, 1989). 
 
2.1.2 N-terminal modifications of PYY(3-36) 
Modifications to the N-terminal of PYY(3-36) have been shown to effect its efficacy 
both beneficially and detrimentally, depending upon the nature of the modification. 
Acetylation of the N-terminal of PYY(3-36) has been shown to greatly reduce the 
potency of the peptide, but studies with PEG modified PYY(3-36) have shown 
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promising results (Shechter et al., 2005). It appears that the size of the PEG molecule 
is important to the preservation of activity. 
 
2.1.3 Binding of PYY(3-36) to the Y2 receptor 
As a member of the PP fold family of peptides, PYY(3-36) binds to the NPY Y 
family of G-protein coupled receptors (Wraith et al., 2000). The C-terminal 
pentapeptide of the PP fold peptides is highly conserved between peptides and species 
(Table 2.1) and has been shown to play a crucial role in the binding of these peptides 
to the Y receptors (Beck-Sickinger et al., 1994; Pedersen et al., 2009). 
 
Table 2.1 The C-terminal pentapeptide sequences of the PP fold family of 
peptides. 
Abbreviations; NPY, neuropeptide Y; PP, pancreatic polypeptide; PYY, peptide YY. 
 
Peptide 32 33 34 35 36 C-terminal 
NPY Threonine Arginine Glutamine Arginine Tyrosine NH2 
PP Threonine Arginine Proline Arginine Tyrosine NH2 
PYY Threonine Arginine Glutamine Arginine Tyrosine NH2 
 
The PP fold family peptides have different affinities for the Y receptors. NPY binds 
with greatest affinity to the Y1 and Y5 receptors, PP has greatest affinity with the Y4 
receptor and PYY(3-36) has greatest affinity for the Y2 receptor, through which it 
mediates its anorectic effects (Wraith et al., 2000). The specificity displayed by the PP 
fold peptides for particular Y receptors must be due to the difference in the sequences 
outside of the C-terminal pentapeptide.  
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2.1.4 The hairpin like structure of PYY(3-36) 
1H NMR studies have determined that PYY(3-36) adopts a hairpin like structure in 
aqueous solution (Nygaard et al., 2006). This characteristic shape is caused in part by 
the presence of proline residues in positions 5 and 8, hydrophobic leucine and tyrosine 
residues in positions 17, 20, 24 and 27, and acidic glutamic acid residues in positions 
15 and 16. This all serves to bring the N-terminal and C-terminal regions in close 
proximity to each other (Figure 2.1). Both of these regions were thought to play an 
important role in binding to the Y receptors, but subsequent studies suggest that whilst 
this is true for the Y1 receptor, it is less so for the Y2 receptor (Nygaard et al., 2006).  
 
 
C-terminal
N-terminal
 
Figure 2.1 The “hairpin like” structure of PYY(3-36) as determined by 1H NMR 
studies (Nygaard et al.,2006)  
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2.2 Hypothesis and aims 
 
 
2.2.1 Hypothesis 
Analogues of PYY(3-36) with positional substitutions or structural modifications can 
be successfully produced using solid phase peptide synthesis (SPPS) techniques. 
 
2.2.2 Aims 
1. To produce analogues of PYY(3-36) containing unnatural amino acid 
substitutions in positions 25 and 26 of the sequence. 
2. To produce N-terminal pegylated analogues of PYY(3-36). 
3. To produce analogues of PYY(3-36) containing natural amino acid 
substitutions in the positions 30, 31 and 32 of the sequence. 
4. To produce analogues of PYY(3-36) that contain a cross linkage between the 
amino acids in position 4 and 29 of the sequence. 
 
2.3 Materials and methods 
2.3.1 Position 25 and 26 PYY(3-36) analogues 
2.3.1.1 Peptide design 
 
Unnatural amino acids, that were structural analogues of the endogenous residues, 
were chosen so as to retain the structure of the native peptide as much as possible. In 
doing so, it is hoped that bioactivity is not compromised. For the position 25 
substitutes, unnatural amino acids were selected that share structural and/or functional 
homology with the native arginine residue. The residues selected for position 26 are 
either isomers, or methylated imidazole ring analogues of the native histidine residue 
(Table 2.2 and Figure 2.2).  
Table 2.2 The peptide sequences of ten PYY(3-36) analogues containing substitutions with unnatural amino acids in positions 25 and 26. 
IP codes were assigned to facilitate subsequent biological testing. Residues highlighted in red are those that differ from the endogenous 
sequence. 
 
 
a
 PYY(3-36) human was synthesised at the same time for use as a standard in subsequent studies. 
b This analogue was synthesised at the same time for potential use in a fluorescence receptor binding assay.
  
 
 
Figure 2.2 The chemical structures of the amino acids used in positions 25 and 26 
of PYY(3-36)
 
analogues.  
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2.3.1.2 Peptide synthesis 
 
All peptides were synthesised on a Symphony multiple peptide synthesiser (Protein 
Technologies, Tucson, Arizona, USA) using standard Fmoc/tBu chemistry. The 
amino acids used were Fmoc-Ala-OH, Fmoc-Arg(Pbf)-OH, Fmoc-D-Arg(Pmc)-OH, 
Fmoc-Arg(Me)2-OH (symmetrical), Fmoc-Arg(Me)2-OH (asymmetrical), Fmoc-
Asn(Trt)-OH, Fmoc-Asp(OtBu)-OH, Fmoc-Cit-OH, Fmoc-D-Cit-OH, Fmoc-
Gln(Trt)-OH, Fmoc-Glu(OtBu)-OH, Fmoc-Gly-OH, Fmoc-His(1-Trt)-OH, Fmoc-
His(1-Me)-OH, Fmoc-His(3-Me)-OH, Fmoc-Homoarg(Pmc)-OH, Fmoc-Ile-OH, 
Fmoc-Leu-OH, Fmoc-Lys(Boc)-OH, Fmoc-Pro-OH, Fmoc-Ser(tBu)-OH, Fmoc-
Thr(tBu)-OH, Fmoc-Tyr(tBu)-OH and Fmoc-Val-OH purchased from Bachem AG 
(Bubendorf, Switzerland) and Fmoc-Phe(4-guanidinoPMC)-OH purchased from Iris 
Biotech (Marktredwitz, Germany). The resin used was tricyclic amide linker resin 
(loading of 0.63mmol/g) also purchased from Bachem AG. 
All peptides were synthesised at a scale of 0.05mmol (except for PYY(3-36) at 
0.1mmol and Biotinyl-PYY(3-36) at 0.6mmol) using double couplings for all 
residues. Each amino acid was added sequentially to the growing peptide chain from 
the C to the N terminus applying 2-(1H-Benzotriazole-1-yl)-1,1,3,3-
tetramethylaminium tetrafluoroborate (TBTU), 1-hydroxybenzotriazole (HOBt) (both 
Severn Biotech Ltd, Kidderminster, UK) and N,N-diisopropylethylamine (DIPEA) 
(Apollo Scientific, Stockport, UK) as coupling reagents.  Removal of the Fmoc 
protecting group was carried out with 20% piperidine (Romil, Cambridge, UK) in N-
methyl pyrrolidone (NMP) (M56 Chemicals, Runcorn, UK) followed by sequential 
washes with dimethylformamide (DMF) (Apollo Scientific). All amino acid 
derivatives (8-fold excess), TBTU and HOBt (7.8-fold excess), and DIPEA (16-fold 
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excess) were dissolved in DMF. All solvents used were of peptide synthesis grade 
quality. 
For Biotinyl-PYY(3-36), the biotin moiety was coupled manually due to its poor 
solubility in DMF and the potential for slow coupling. D-(+)-Biotin (Alfa Aesar, 
Lancaster, UK) was dissolved in 1:1 solution of DMF and dimethylsulphoxide (Sigma 
Aldrich, Poole, UK) together with O-(7-Azabenzotriazol-1-yl)-N,N,N’,N’-
tetramethyluronium hexafluorophosphate (HATU) (Novabiochem, Nottingham, UK) 
and DIPEA. The coupling reaction took 2 hours to complete and was monitored by 
Kaiser test. This involved taking a sample of resin from the reaction, washing it with 
iso-propanol, before adding 3 drops each, of the solutions; 42.5M phenol in butan-1-
ol, 0.28M ninhydrin in butan-1-ol and pyridine. The resin was then heated to 100°C 
for 5 minutes, the presence of a blue colour to the solution or any of the resin beads 
indicated that the coupling was incomplete. No change to the colour of the solution or 
beads indicated that the coupling was complete. 
  
2.3.1.3 Preparation of solution K 
 
To prepare 100mL of solution K, 7.5g of Phenol (Alfa Aesar) was dissolved in 5mL 
of water. Thioanisole (5mL) and 1,2-ethanedithiol (2.5mL) (both Alfa Aesar) were 
added and the solution made up to a final volume of 100mL with the addition of 
trifluoroacetic acid (TFA) (Romil). 
 
2.3.1.4 Peptide cleavage 
 
The peptides were cleaved from the resin with simultaneous deprotection using 
solution K (10mL/g of resin) at room temperature for 2½ h.   
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The cleavage mixture was filtered through a porosity 2 sinter funnel into a round 
bottom flask. The resin was washed with TFA, then acetonitrile (Avantor, Deventer, 
Netherlands) and filtered again. The solvent was then removed on a rotary evaporator 
connected to a high vacuum pump. When all the solvent had been evaporated, the 
peptide was precipitated with the addition of ice cold diethyl ether (Avantor). The 
precipitates were stored at 4oC overnight and were collected by filtration through a 
porosity 3 sinter funnel, washed with ice-cold diethyl ether, and allowed to dry at 
room temperature. The crude peptides were dissolved in a mixture of 0.1%TFA in 
60%acetonitrile/water and lyophilized overnight (-50oC, 6 mbar). 
 
2.3.1.5 Characterisation of crude peptides 
 
Peptides were characterised by reverse phase High Performance Liquid 
Chromatography (HPLC) (Gilson, Middleton, Wisconsin, USA) using an analytical 
C-18 column (Vydac 218TP54, 250 x 4.6mm, 5 µm particle size, and 300 Å pore 
size) and a linear AB gradient of 0–100% for B over 40 min at a flow rate of 
1mL/min, where eluent A was 0.1% TFA/water and eluent B was 0.1% TFA in 60% 
acetonitrile/water. Mass was confirmed using a Kompact Probe Matrix Assisted Laser 
Desorption Ionisation Mass Spectrometer (MALDI-MS) (Kratos, Manchester, UK). 
 
2.3.1.6 Purification of peptides 
 
Peptides were purified by reverse phase HPLC (Varian, Oxford, UK) using a C-18 
column (Vydac 218TP101550, 250 x 50 mm, 10-15 µm particle size and 300Ǻ pore 
size). A linear AB gradient program of 0-40% B in 4 min followed by 40-90% B in 70 
min at a flow rate of 120mL/min was applied. Eluent A was 0.1% TFA/water and 
 110 
eluent B was 0.1% TFA in 60% acetonitrile/water. The collected fractions were 
analysed by MALDI MS and analytical reverse phase HPLC. The relevant fractions 
were then pooled together and lyophilized overnight (-50oC, 6 mbar).  
In the case of peptides (Cit)25 PYY(3-36) and Biotinyl-PYY(3-36), a second stage of 
purification was required. This involved the use of a different AB solvent system, 
where eluent A was 0.2% Triethylamine (TEA) and 0.3% Orthophosphoric acid (both 
VWR, Leicestershire, UK) in 10% acetonitrile/water and eluent B was 0.2% TEA and 
0.3% Orthophosphoric acid in 60% acetonitrile/water. The pH of the system was 2.3. 
 
2.3.1.7 Quality Control (QC) 
 
Full QC was performed on all purified peptides by dedicated QC personnel.  Purity 
was determined by reverse phase HPLC (Series 200, Perkin Elmer, Waltham, 
Massachusetts, USA) using a C18 column (Vydac 218TP54, 250 x 4.6mm, 5 µm 
particle size, and 300 Å pore size) and a linear AB gradient of 0–100% for B over 40 
min at a flow rate of 1mL/min. The purity was determined in two separate buffer 
systems. In the first, eluent A was 0.1% TFA/water and eluent B was 0.1% TFA in 
60% acetonitrile/water. For the second system, eluent A was 0.2% TEA and 0.3% 
Orthophosphoric acid in 10% acetonitrile/water and eluent B was 0.2% TEA and 
0.3% Orthophosphoric acid in 60% acetonitrile/water. The molecular weights of the 
peptides were detected by MALDI mass spectrometry (Kratos). Amino acid analysis 
was performed using a Beckman 6300 amino acid analyzer (High Wycombe, UK), 
following hydrolysis overnight in 6M hydrochloric acid (P & R Labpack, St Helens, 
UK).    
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2.3.2 N-terminal pegylated analogues of PYY(3-36) 
 
2.3.2.1 Peptide design 
The following set of analogues were designed to test the effects of adding relatively 
small PEG molecules to the N-terminal of PYY(3-36). The peptide sequences and 
structure of the PEG molecules are shown in Table 2.3 and Figure 2.3. 
Table 2.3 The peptide sequences of three N-terminally pegylated PYY(3-36) analogues 
The numerical codes assigned to the analogues are internal Bachem identification numbers and will be used for identification purposes in 
subsequent biological studies. Residues highlighted in red are those that differ from the endogenous sequence. 
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Figure 2.3 The chemical structures of the PEG molecules to be coupled to the N-terminal of three PYY(3-36) analogues 
 
The internal Bachem identification codes are included to cross reference the PEG molecule with the relevant analogue 
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2.3.2.2 Peptide synthesis 
All peptides were synthesised as per the methods described in section 2.3.1.2. Fmoc-
Leu-OH and Fmoc-Gln(Trt)-OH were purchased from Novabiochem. The resin used 
was tricyclic amide linker resin (loading of 0.66mmol/g) (Bachem AG). 
All peptides were synthesised at a scale of 0.1mmol. Amino acids (4-fold excess), 
TBTU (Bachem AG) and HOBt (3.9-fold excess) and DIPEA (Romil) (8-fold excess) 
were dissolved in DMF (Romil). 
For the N-terminal PEG modifications, AEEAc was introduced as Fmoc-AEEAc-OH 
(Bachem AG) via an automated process on the Symphony synthesiser, as per the other 
amino acids. Final Fmoc group removal was also performed on the synthesiser using a 
solution of 20% piperidine in DMF. The remaining PEG molecules were coupled as 
Fmoc-NH-PEG3-COOH and Fmoc-NH-PEG5-COOH respectively. Both reagents 
were purchased from Novabiochem; the discrepancies in the PEG numbering system 
are due to the different nomenclature protocols at Novabiochem. The PEG molecules 
were manually coupled with TBTU and DIPEA, and monitored by Kaiser test as 
described in section 2.3.1.2 in case of slow coupling times.  In each case, the N-
terminal Fmoc protecting group was then removed with a solution of 20% piperidine 
in DMF, in a reaction monitored by Kaiser test. 
 
2.3.2.3 Peptide cleavage 
Peptides were cleaved as per the methods described in section 2.3.1.4. 
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2.3.2.4 Characterisation of crude peptides 
Crude peptides were characterised as per the methods described in section 2.3.1.5 
using a Voyager DE Matrix Assisted Laser Desorption/Ionisation mass spectrometer 
(MALDI-MS) (Applied Biosystems, Warrington, UK). 
 
2.3.2.5 Purification of peptides   
Peptides were purified as per the methods described in section 2.3.1.6. 
 
 
2.3.3 Position 30, 31 and 32 analogues of PYY(3-36) 
 
2.3.3.1 Peptide design 
 
In human PYY(3-36) the amino acids in positions 30, 31 and 32 are leucine, valine 
and threonine respectively. Natural amino acids with structural similarities to these 
amino acids were chosen to replace them in the analogues. The sequences of these 
analogues are shown in Table 2.4. 
 
 
 
 
 
 
 
 
 
 
 Table 2.4 The peptide sequences of eight analogues of PYY(3-36) with amino substitutions in positions 30, 31 and 32 
IP codes have been assigned for ease of use in subsequent biological studies. Residues highlighted in red are those that differ from the 
endogenous sequence. 
 
 
 
 
 
 2.3.3.2 Peptide synthesis  
All peptides were synthesised as per the methods described in section 2.3.1.2. The 
resin used was tricyclic amide linker resin (loading of 0.61mmol/g)(Bachem AG). 
 
2.3.3.3 Peptide cleavage 
Peptides were cleaved as per the methods described in section 2.3.1.4. 
 
2.3.3.4 Characterisation of crude peptides 
Crude peptides were characterised as per the methods described in section 2.3.1.5. 
 
2.3.3.5 Purification of peptides 
Peptides were purified as per the methods described in section 2.3.1.6. 
 
 
 
2.3.4 Position 4 and 29 cross linked analogues of PYY(3-36) 
 
2.3.4.1 Peptide design 
 
Cross-linkages between amino acid side chains can take different forms, with one of 
the most common being a lactam bridge, usually formed between the basic side chain 
of a lysine residue and the acidic side chain of an aspartic acid or glutamic acid 
residue. The human sequence of PYY contains a lysine residue close to the N-
terminal at position 4 and an asparagine residue close to the C-terminal at position 29. 
As asparagine is the amidated form of aspartic acid, substituting it for an acidic amino 
acid should not drastically alter the structure of the peptide.  
  
Table 2.5 The peptide sequences of five PYY(3-36) analogues containing cross linking bridges between amino acids in positions 4 and 29 
Dap = α,ß-diaminopropionic acid and is an analogue of lysine, containing three less carbons in its side chain functional group. Residues 
highlighted in red are those that differ from the endogenous sequence. Disulphide and lactam bridges are shown as red horizontal lines between 
residues in positions 4 and 29.  
 
 
 
 
 
 
  
The PYY(3-36) analogues described in Table 2.5 were designed to contain cross 
linkages between different amino acid residues at positions 4 and 29. 
To help assess the feasibility of forming a cross linking bridge between positions 4 
and 29, an analogue containing a disulphide bridge between cysteine residues in these 
positions was also synthesised.  
 
2.3.4.2 Peptide synthesis - (Cys4, Cys29)-PYY(3-36) (disulphide bridge) 
 
The peptide was synthesised as per the methods described in section 2.3.2.2. The 
amino acids in positions 4 and 29 were both coupled as Fmoc-Cys(Trt)-OH (Bachem 
AG). The resin used was tricyclic amide linker resin (loading of 0.61mmol/g) and was 
purchased from Bachem AG. 
 
 
2.3.4.3 Peptide cleavage - (Cys4, Cys29)-PYY(3-36) (disulphide bridge) 
The peptide was cleaved as per the methods described in section 2.3.1.4. Due to the 
presence of cysteine residues in the sequence, the filtered peptide solution was 
directly precipitated into diethyl ether.  
 
2.3.4.4 Characterisation of crude peptide - (Cys4, Cys29)-PYY(3-36) (disulphide 
bridge) 
The crude peptide was characterised as per the methods described in section 2.3.1.5. 
In addition, an Ellmans test was performed on a small sample of crude material. This 
involved dissolving the peptide in 200µL of 5,5′-dithiobis(2-nitrobenzoic acid) in 
0.1M disodium hydrogen phosphate (both Sigma Aldrich). A positive result indicates 
the presence of sulphydryl groups in the peptide. 
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2.3.4.5 Disulphide bridge formation - (Cys4, Cys29)-PYY(3-36) (disulphide 
bridge) 
The crude peptide was dissolved in 3mL of TFA and diluted with 30mL of 0.1% 
TFA/acetonitrile/water. This solution was filtered and added to 1.1L of 1.0M Urea 
solution (VWR). The pH of the solution was measured to confirm it was pH7 and a 
sample was then analysed by reverse phase HPLC.  
A 0.01M solution of potassium ferricyanide (K3[Fe(CN)6]) (BDH, Poole, UK) was 
added to the peptide solution in a drop wise manner until the yellow/green colour was 
retained. The solution was again analysed by HPLC and left to mix at room 
temperature for 1 hour. After this time had elapsed, a sample of the solution was 
analysed by HPLC as a co-injection with a sample of the reaction solution at pH7. 
Further K3[Fe(CN)6] solution was added to the reaction and it was left for another 
hour. At this point the reaction was stopped with the addition of 50% acetic acid 
(Romil) and the pH reached 4.  
To this solution, 80mL of acetonitrile was added and the reaction mixture was then 
loaded onto a Companion Combi Flash Chromatography system (Teledyne Isco, 
Lincoln, USA) using a C-18 40g column (Daiso, 50 µm particle size, 200 Å pore 
size). A linear AB gradient program of 10-35% B in 1 min followed by 35-100% B in 
40 min at a flow rate of 40mL/min was applied. Eluent A was 0.1% TFA/water and 
eluent B was 0.1% TFA in 60% acetonitrile/water.    
The collected fractions were identified by MALDI MS and analytical reverse phase 
HPLC. The relevant fractions were then pooled together and lyophilised overnight (-
50oC, 6 mbar).  
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2.3.4.6 Purification of peptide -(Cys4, Cys29)-PYY(3-36) (disulphide bridge)  
The peptide was purified as per the methods described in section 2.3.1.6 using a C-18 
column (Daiso Bio 250 x 21.2mm, 10µm particle size and 200Ǻ pore size). A second 
purification step was carried out using a gradient program of 10-50% in 4 min and 50-
100% in 70 min. 
  
2.3.4.7 Peptide synthesis - (Cyclo(Lys4–Asp29), Asp29)-PYY(3-36)   
The peptide was synthesised as per the methods described in section 2.3.2.2. The 
synthesiser used was a 433A single peptide synthesiser (Applied Biosystems).  The 
residues in positions 4 and 29 were introduced as Fmoc-Lys(Mtt)-OH and Fmoc-
Asp(OPip)-OH respectively (both Bachem AG). The final residue was introduced as 
Boc-Ile-OH.0.5H2O (Novabiochem). The resin used was tricyclic amide linker resin 
(loading of 0.61mmol/g) (Bachem AG). 
Removal of the Fmoc protecting group was carried out with 20% piperidine in N-
methyl pyrrolidone (NMP) (M56 Chemicals) followed by sequential washes with 
NMP. All amino acid derivatives (10-fold excess), TBTU and HOBt (9-fold excess) 
and DIPEA (20-fold excess) were dissolved in NMP. 
Upon completion of the automated synthesis, a sample of resin was cleaved in TFA 
for 2 ½ hours. The solution was filtered, diluted with acetonitrile/water and analysed 
by HPLC and MALDI MS. A second sample of resin was taken and a Kaiser test 
performed as described in section 2.3.1.2 to confirm the presence of all protecting 
groups. 
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2.3.4.8 Cyclisation of resin bound peptide - (Cyclo(Lys4–Asp29), Asp29)-PYY(3-
36)   
 
The amino acids in positions 4 and 29 were selectively deprotected by performing 
repeated washes (9 x 5min) with a solution of 1% TFA/ 5% triisopropylsilane (TIS) 
(Sigma Aldrich) in dichloromethane (DCM) (Avantor). Upon completion of these 
washes a Kaiser test as described in section 2.3.1.2 was performed to confirm removal 
of the protecting groups. 
Lactam bridge formation was achieved by reacting the resin bound peptide with a 
solution of 1 molar equivalent of 1-hydroxy-7-azabenzotriazole (HOAt) (Genscript, 
Piscataway, USA) and 1.5 molar equivalents of diisopropylcarbodiimide (DIC) 
(Sigma Aldrich) in DMF for 15 hours. A Kaiser test was performed and the reaction 
was repeated until complete according to a Kaiser test. 
 
2.3.4.9 Peptide cleavage - (Cyclo(Lys4–Asp29), Asp29)-PYY(3-36) 
The peptide was cleaved as per the methods described in section 2.3.1.4. 
 
2.3.4.10 Characterisation of crude peptide - (Cyclo(Lys4–Asp29), Asp29)-
PYY(3-36) 
The crude peptide was characterised as per the methods described in section 2.3.1.5. 
A second C-18 column was used for characterisation (Daiso Bio, 250 x 4.6mm, 5 µm 
particle size, and 200 Å pore size).  
 
2.3.4.11 Purification of peptide - (Cyclo(Lys4–Asp29), Asp29)-PYY(3-36) 
The peptide was loaded onto a Companion Combi Flash Chromatography system with 
a C-18 40g column (Daiso, 50 µm particle size, 200 Å pore size). A linear AB 
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gradient program of 10-85% B in 22 min at a flow rate of 40mL/min. Eluent A was 
0.1% TFA/water and eluent B was 0.1% TFA in 60% acetonitrile/water. The collected 
fractions were identified by MALDI MS and analytical reverse phase HPLC with a 
Daiso column. The relevant fractions were then pooled together and lyophilised 
overnight (-50oC, 6 mbar). 
 
2.3.4.12 Peptide synthesis - (Cyclo(Lys4–Glu29), Glu29)-PYY(3-36) 
The peptide was synthesised as per the methods described in section 2.3.4.7. Residue 
29 was introduced as Fmoc-Glu(Opip)-OH (Bachem AG). 
 
2.3.4.13 Peptide synthesis - (Cyclo(Dap4–Asp29), Dap4, Asp29)-PYY(3-36) 
The peptide was synthesised as per the methods described in section 2.3.2.2. The 
residues in positions 4 and 29 were introduced as Fmoc-Dap(Mtt)-OH (Novabiochem) 
and Fmoc-Asp(Opip)-OH (Bachem AG) respectively, whilst the final residue was 
introduced as Boc-Ile-OH.0.5H2O (Novabiochem). The resin used was tricyclic amide 
linker resin (loading of 0.55mmol/g) (Bachem AG). The peptide was synthesised at a 
scale of 0.05mmol. 
 
2.3.4.14 Cyclisation of resin bound peptide - (Cyclo(Dap4–Asp29), Dap4, 
Asp29)-PYY(3-36) 
The resin bound peptide was cyclised as per the methods described in section 2.3.4.8 
  
2.3.4.15 Peptide cleavage - (Cyclo(Dap4–Asp29), Dap4, Asp29)-PYY(3-36) 
The peptide was cleaved as per the methods described in section 2.3.1.4. 
 
 124 
2.3.4.16 Characterisation of crude peptide - (Cyclo(Dap4–Asp29), Dap4, 
Asp29)-PYY(3-36) 
The crude peptide was characterised as per the methods described in section 2.3.1.5. 
 
2.3.4.17 Peptide synthesis - (Cyclo(Dap4–Glu29), Dap4, Glu29)-PYY(3-36) 
The peptide was synthesised as per the methods described in section 2.3.4.13. The 
residue in position 29 was introduced as Fmoc-Glu(OPip)-OH (Bachem AG). 
 
2.3.4.18 Peptide synthesis  II - (Cyclo(Lys4–Glu29), Glu29)-PYY(3-36) 
The peptide was synthesised as per the methods described in section 2.3.4.12. The 
resin used was TentaGel R RAM (loading of 0.2mmol/g) (Rapp Polymere (Tübingen, 
Germany). The peptide was synthesised at a scale of 0.05mmol. 
 
2.3.4.19 Cyclisation of resin bound peptide – (Cyclo(Lys4–Glu29), Glu29)-
PYY(3-36) 
The resin bound peptide was cyclised as per the methods described in section 2.3.4.8. 
 
2.3.4.20 Peptide cleavage - (Cyclo(Lys4–Glu29), Glu29)-PYY(3-36) 
The peptide was cleaved as per the methods described in section 2.3.1.4. 
 
2.3.4.21 Characterisation of crude peptide - (Cyclo(Lys4–Glu29), Glu29)-
PYY(3-36) 
The crude peptide was characterised as per the methods described in section 2.3.1.5. 
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2.3.4.22 Peptide synthesis III - (Cyclo(Lys4–Glu29), Glu29)-PYY(3-36) 
The peptide was synthesised as per the methods described in section 2.3.4.13. The 
residues in positions 4 and 29 were introduced as Fmoc-Lys(Mtt)-OH and Fmoc-
Glu(Opip)-OH respectively (Bachem AG). The peptide was synthesised in two 
different reaction channels on the synthesiser. In one of the reaction channels, the 
amino acids in positions 22 and 23 were introduced as the pseudoproline dipeptide 
Fmoc-Ala-Ser(Psi(Me,Me)pro)-OH (Novabiochem). The resin used was TentaGel R 
RAM (loading of 0.19mmol/g) (Rapp Polymere). The peptide was synthesised at a 
scale of 2 x 0.05mmol and upon completion of the automated synthesis the two 
reaction vessels were kept separate 
 
2.3.4.23 Cyclisation of the resin bound peptide - (Cyclo(Lys4–Glu29), Glu29)-
PYY(3-36) 
The resin bound peptide was cyclised as per the methods described in section 2.3.4.8. 
Lactam bridge formation was achieved by reacting the peptide resins with a solution 
of 0.98 molar equivalents of TBTU and 2 molar equivalents of DIPEA for 4 hours.  
 
2.3.4.24 Peptide synthesis IV - (Cyclo(Lys4–Glu29), Glu29)-PYY(3-36) 
The peptide was synthesised as per the methods described in section 2.3.2.2. The 
residues in positions 4 and 29 were introduced as Fmoc-Lys(Aloc)-OH and Fmoc-
Glu(allyl ester)-OH respectively (Bachem AG) whilst the final residue was introduced 
as Boc-Ile-OH (Bachem AG). The resin used was Xanthenyl linker resin (loading of 
0.53mmol/g) (Bachem AG). Also synthesised was the peptide (Glu)29-PYY(3-36) in 
which both Lys4 and Glu29 residues were introduced as the standard Fmoc derivatives. 
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Upon completion, samples of both resins were cleaved in TFA for 2 ½ hours, filtered, 
diluted and analysed by HPLC and MALDI MS as described in section 2.3.1.5. 
 
2.3.4.25 Partial deprotection of resin bound peptide - (Cyclo(Lys4–Glu29), 
Glu29)-PYY(3-36) 
Selective deprotection of the Aloc and allyl ester protecting groups was achieved by 
dissolving 0.4eq of Tetrakis(triphenylphosphine)palladium(0) and 24eq Phenylsilane 
(both Sigma Aldrich) in DCM, adding it to the resin and mixing for 2 hours. The 
reagents were removed by filtration and the resin washed repeatedly with DCM and 
then 0.03M sodium diethyldithiocarbamate trihydrate (Sigma Aldrich) in DMF to 
remove any remaining palladium catalyst. Successful removal of both protecting 
groups was confirmed by Kaiser test as described in section 2.3.1.2, and by cleaving a 
sample of resin in reagent K for 2 ½ hours, filtering and precipitating into diethyl 
ether. The precipitate was immediately isolated, washed with diethyl ether and dried 
under vacuum before being dissolved in 0.1%TFA in acetonitrile/water. This solution 
was analysed by HPLC and MALDI MS as described in section 2.3.1.5. 
 
2.3.4.26 Cleavage of partially protected peptide - (Cyclo(Lys4–Glu29), 
Glu29)-PYY(3-36) 
The partially protected peptide was cleaved by washing the resin with 10mL/g of 2% 
TFA in DCM for 3 minutes. After this time, the resin was filtered and the filtrate 
collected in a flask to which 1.01 molar equivalents (relative to TFA) of ice cold 
DIPEA was added to neutralise. This process was repeated a further six times and the 
filtrates combined. The resin was then washed repeatedly with DCM until the pH of 
the filtrate reached 7. Each DCM wash was neutralised and added to the cleavage 
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filtrate solution. This solution was then extracted three times with water and then 
three times with saturated sodium chloride solution. The organic layer was dried with 
sodium sulphate (BDH) and filtered before being concentrated on a rotary evaporator. 
The resultant residue was precipitated with the addition of ice cold diethyl ether. The 
precipitate was stored at 4oC overnight and was collected by filtration, washed with 
ice-cold diethyl ether, and allowed to dry at room temperature. 
 
2.3.4.27 Characterisation of partially protected peptide - (Cyclo(Lys4–
Glu29), Glu29)-PYY(3-36) 
The partially protected peptide was characterised as per the methods described in 
section 2.3.1.5. Eluent B was 0.1% TFA in 95% acetonitrile/water. Mass was 
confirmed using a Voyager Matrix Assisted Laser Desorption/Ionisation mass 
spectrometer MALDI-MS. 
 
2.3.4.28 Cyclisation of partially protected peptide - (Cyclo(Lys4–Glu29), 
Glu29)-PYY(3-36) 
The partially protected peptide (304mg) was dissolved in 5mL of DMF and diluted to 
25mL with DCM. A solution was made of 10 molar equivalents of HOAt (64mg) and 
20 molar equivalents of DIC (143µL) in 300mL of DCM. The peptide solution was 
added to the HOAt/DIC solution using a Gilson 307 HPLC piston pump at a flow rate 
of 0.03mL/min. Upon completion of the peptide addition, the reaction solution was 
analysed by HPLC and MALDI MS. The DCM was then removed via rotary 
evaporation.  
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2.3.4.29 Cleavage of peptide - (Cyclo(Lys4–Glu29), Glu29)-PYY(3-36) 
Following removal of DCM, the remaining residue was dissolved in solution K 
(100mL) and cleaved as per the methods described in section 2.3.1.4. 
 
2.3.4.30 Characterisation of crude peptide – (Cyclo(Lys4–Glu29), Glu29)-
PYY(3-36) 
The crude peptide was characterised as per the methods described in section 2.3.1.5. 
 
 
 
2.4 Results 
 
2.4.1 Position 25 and 26 PYY(3-36) analogues 
The ten PYY(3-36) analogues with altered residues at position 25 and 26 were all 
successfully produced at purities above 95% by reverse phase HPLC on both TFA and 
triethylammonium phosphate (TEAP) buffer systems. The quantities, purities and 
peptide content (determined by amino acid analysis) of each analogue produced are 
summarised in Table 2.6. 
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Table 2.6 The quantities, purities and peptide content achieved for ten position 
25 and 26 PYY(3-36) analogues 
% Yield = actual yield (mg)/theoretical yield (mg). Theoretical yield = synthesis scale (mmol) x 
molecular weight of peptide. Abbreviations: TFA, trifluororacetic acid; TEAP, triethylammonium 
phosphate. 
 
Analogue Code 
Yield 
(mg) 
Yield 
(%) 
Purity 
(TFA 
system) 
(%) 
Purity 
(TEAP 
system) 
(%) 
Peptide 
content 
(%) 
PYY(3-36) - 83.0 20.5 98.0 96.2 76.9 
(Homoarg)25PYY(3-36)  IP1 40 19.7 97.7 95.1 67.2 
(D-Arg)25PYY(3-36) IP2 40 19.8 96.9 95.2 69.0 
(Arg(Me)2symm)25PYY(3-36)  IP3 33.5 16.4 97.3 95.6 81.9 
(Arg(Me)2asymm)25PYY(3-36)  IP4 18.5 9.1 95.0 96.1 72.2 
(Cit)25PYY(3-36)  IP5 27 13.3 98.4 97.1 75.9 
(D-Cit)25PYY(3-36) IP6 40.6 20.0 96.1 95.7 86.2 
(His(1-Me))26PYY(3-36) IP7 36.4 17.9 97.0 98.0 76.4 
(His(3-Me))26PYY(3-36)  IP8 15.2 7.5 97.6 96.4 82.7 
(D-His)26PYY(3-36)  IP9 33.2 16.4 97.2 97.2 73.4 
(Phe-Gu)25PYY(3-36)  IP10 31.9 15.6 98.9 95.4 83.3 
Biotinyl-PYY(3-36) IP11 189.7 7.4 98.2 95.3 85.0 
  
2.4.2 N-terminal pegylated PYY(3-36) analogues 
The three PYY(3-36) analogues were all successfully produced at purities above 95% 
by reverse phase HPLC in a TFA buffer system. The quantities and purities of each 
analogue produced are summarised in Table 2.7. Due to financial restraints, it was not 
possible to submit these and subsequent analogues for full Quality Control (QC) 
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analysis. Therefore, the same level of analysis as for the previous set of analogues has 
not been acquired. 
 
Table 2.7 The quantities and purities achieved for three N-terminally pegylated 
PYY(3-36) analogues. 
% Yield = actual yield (mg)/theoretical yield (mg). Theoretical yield = synthesis scale (mmol) x 
molecular weight of peptide. Abbreviations: TFA, trifluoroacetic acid. 
 
Analogue Code Yield (mg) Yield (%) 
Purity 
(TFA 
system) 
(%) 
AEEAc-PYY(3-36)  
 
4075004 68.0 16.2 98.1 
Aminoethyl-PEG4-carbonyl-PYY(3-36)  
 
4075005 143.2 33.3 96.7 
Aminoethyl-PEG6-carbonyl-PYY(3-36)  
 
4075006 111.8 25.4 97.63 
 
 
2.4.3 Position 30, 31 and 32 PYY(3-36) analogues 
The eight PYY(3-36) analogues with altered residues in position 30,31 and 32  were 
all successfully produced at purities above 95% by reverse phase HPLC in a TFA 
buffer system. The quantities and purities of each analogue produced are summarised 
in Table 2.8. 
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Table 2.8 The quantities and purities achieved for eight position 30, 31 & 32 
PYY(3-36) analogues. 
% Yield = actual yield (mg)/theoretical yield (mg). Theoretical yield = synthesis scale (mmol) x 
molecular weight of peptide. Abbreviations: TFA, trifluoroacetic acid.  
 
Analogue Code Yield (mg) Yield (%) 
Purity 
(TFA 
system) 
(%) 
(Ala)30PYY(3-36)  
 
IP12 31.4 15.7 96.7 
(Ile)30PYY(3-36)  
 
IP13 43.0 21.2 95.0 
(Val)30PYY(3-36)  
 
IP14 30.2 15.0 98.0 
(Ala)31PYY(3-36)  
 
IP15 26.9 13.4 98.2 
(Ile)31PYY(3-36) 
 
IP16 39.3 19.3 98.0 
(Leu)31PYY(3-36)  
 
IP17 38.0 18.7 97.8 
(Leu)32PYY(3-36)  
 
IP18 38.0 18.7 95.9 
(Ser)32PYY(3-36)  
 
IP19 28.3 14.0 98.3 
 
 
2.4.4 Position 4 and 29 cross linked PYY(3-36) analogues 
 
2.4.4.1 (Cys4, Cys29)PYY(3-36) (disulphide bridge) 
This analogue was successfully produced with a final purity of 91% by reverse phase 
HPLC. The quantities and purities achieved, along with the results of the Ellmans 
tests, at the different stages of oxidation and purification are summarised in Table 2.9. 
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Table 2.9 The quantities, purities and Ellmans test results, achieved at the 
different stages of producing (Cys4, Cys29)PYY(3-36) (disulphide bridge) 
% Yield = actual yield (mg)/theoretical yield (mg). Theoretical yield = synthesis scale (mmol) x 
molecular weight of peptide. 
 
Stage Yield (mg) Yield (%) 
Purity 
(TFA 
system) 
(%) 
Ellmans 
test 
Crude 215 53.6 67.5 + 
After oxidation 51.9 12.9 74.4 _ 
Purification 1 30.4 7.6 91.1 _ 
Purification 2 24 6.0 90.5 _ 
 
2.4.4.2 (Cyclo(Lys4–Asp29), Asp29)-PYY(3-36) 
The synthesis of this peptide was unsuccessful. Following purification of the crude 
peptide via Flash Chromatography, analysis by MALDI MS of the collected fractions 
failed to detect the presence of the target peptide. All of the fractions containing 
peptidic material were combined and lyophilised. The HPLC chromatogram of this 
material is shown in Figure 2.4 
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Figure 2.4 Representative reverse phase HPLC absorption profile of the material 
recovered from the purification of (Cyclo(Lys4–Asp29), Asp29)-PYY(3-36) 
The peptide was dissolved in 0.1% TFA/water/acetonitrile and analysed by reverse phase HPLC using 
an analytical C-18 column (Vydac 218TP54, 250 x 4.6mm, 5 µm particle size, and 300 Å pore size) 
and a linear AB gradient of 0–100% for B over 40 min at a flow rate of 1mL/min, where eluent A was 
0.1% TFA/water and eluent B was 0.1% TFA in 60% acetonitrile/water. Peak detection was by 
spectrophotometry at a wavelength of 210 nm. 
 
 
2.4.4.3 Cyclo(Lys4–Glu29), Glu29)-PYY(3-36) 
The synthesis of this peptide was unsuccessful. Upon completion of the automated 
synthesis, analysis by HPLC and MALDI MS of a cleaved sample of resin showed the 
quality of the linear peptide to be poor, so synthesis was stopped. The HPLC 
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chromatogram is shown in Figure 2.5 and the MALDI mass spectrum is shown in 
Figure 2.6.  
 
Figure 2.5 Representative reverse phase HPLC absorption profile of the peptide 
(Glu)29-PYY(3-36) following automated SPPS 
A sample of peptide resin was cleaved for 2 hours in conc. TFA. The solution was filtered and diluted 
with acetonitrile/water. This solution was analysed by reverse phase HPLC using an analytical C-18 
column (Vydac 218TP54, 250 x 4.6mm, 5 µm particle size, and 300 Å pore size) and a linear AB 
gradient of 0–100% for B over 40 min at a flow rate of 1mL/min, where eluent A was 0.1% TFA/water 
and eluent B was 0.1% TFA in 60% acetonitrile/water. Peak detection was by spectrophotometry at a 
wavelength of 210nm. 
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Figure 2.6 Representative MALDI mass spectrum of the peptide (Glu)29-PYY(3-
36) following automated SPPS 
A sample of peptide resin was cleaved for 2 hours in conc. TFA. The solution was filtered and diluted 
with acetonitrile/water. The solution was analysed by a Kompact Probe MALDI mass spectrometer in 
positive voltage mode. The solution was co-crystallised with α-cyano-4-hydroxycinnamic acid (CHCA) 
matrix compound. The vertical axis represents the relative signal intensity of the molecular ions 
detected and horizontal axis represents mass to charge ratio (M/Z). The expected molecular weight 
could not be detected. 
 
2.4.4.4 (Cyclo(Dap4–Asp29),Dap4, Asp29)-PYY(3-36) 
The synthesis of this peptide was unsuccessful. Analysis by HPLC and MALDI MS 
of the crude peptide, failed to detect the presence of the target peptide. The HPLC 
chromatogram is shown in Figure 2.7. 
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Figure 2.7 Representative reverse phase HPLC absorption profile of the crude 
peptide (Cyclo(Dap4, Asp29), Dap4, Asp29)-PYY(3-36) 
A sample of crude peptide was dissolved in 0.1% TFA/water/acetonitrile and analysed by reverse phase 
HPLC using an analytical C-18 column (Vydac 218TP54, 250 x 4.6mm, 5 µm particle size, and 300 Å 
pore size) and a linear AB gradient of 0–100% for B over 40 min at a flow rate of 1mL/min, where 
eluent A was 0.1% TFA/water and eluent B was 0.1% TFA in 60% acetonitrile/water. Peak detection 
was by spectrophotometry at a wavelength of 210 nm. 
 
 
2.4.4.5 (Cyclo(Dap4–Glu29), Dap4, Glu29)-PYY(3-36) 
The synthesis of this peptide was unsuccessful. Upon completion of the automated 
synthesis, analysis by HPLC of a cleaved sample of resin showed the purity of the 
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linear peptide to be poor, so synthesis was stopped. The HPLC chromatogram is 
shown in Figure 2.8. 
 
Figure 2.8 Representative reverse phase HPLC absorption profile of the peptide 
(Dap4, Glu29)-PYY(3-36) following automated SPPS  
A sample of peptide resin was cleaved for 2 hours in conc. TFA. The solution was filtered and diluted 
with acetonitrile/water. This solution was analysed by reverse phase HPLC using an analytical C-18 
column (Vydac 218TP54, 250 x 4.6mm, 5 µm particle size, and 300 Å pore size) and a linear AB 
gradient of 0–100% for B over 40 min at a flow rate of 1mL/min, where eluent A was 0.1% TFA/water 
and eluent B was 0.1% TFA in 60% acetonitrile/water. Peak detection was by spectrophotometry at a 
wavelength of 210 nm. 
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2.4.4.6 (Cyclo(Lys4–Glu29), Glu29)-PYY(3-36) (Synthesis II) 
The synthesis of this peptide was unsuccessful. Analysis by HPLC and MALDI MS 
of the crude peptide, failed to detect the presence of the target peptide. The HPLC 
chromatogram of the crude peptide is shown in Figure 2.9 and the MALDI mass 
spectrum is shown in Figure 2.10. 
 
Figure 2.9 Representative reverse phase HPLC absorption profile of the crude 
peptide (Cyclo(Lys4-Glu29), Glu29)-PYY(3-36) 
A sample of crude peptide was dissolved in 0.1% TFA/water/acetonitrile and analysed by reverse phase 
HPLC using an analytical C-18 column (Vydac 218TP54, 250 x 4.6mm, 5 µm particle size, and 300 Å 
pore size) and a linear AB gradient of 0–100% for B over 40 min at a flow rate of 1mL/min, where 
eluent A was 0.1% TFA/water and eluent B was 0.1% TFA in 60% acetonitrile/water. Peak detection 
was by spectrophotometry at a wavelength of 210 nm. 
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Expected molecular weight = 4046.54 
 
Figure 2.10 Representative MALDI mass spectrum of the crude peptide 
(Cyclo(Lys4-Glu29), Glu29)-PYY(3-36) 
A sample of crude peptide was dissolved in 0.1% TFA/acetonitrile/water. The solution was analysed by 
a Voyager DE MALDI mass spectrometer in positive voltage mode. The solution was co-crystallised 
with α-cyano-4-hydroxycinnamic acid (CHCA) matrix compound. The vertical axis represents the 
relative signal intensity of the molecular ions detected and horizontal axis represents mass to charge 
ratio (M/Z). The expected molecular weight could not be detected. 
 
 
2.4.4.7 (Cyclo(Lys4–Glu29), Glu29)-PYY(3-36) (Synthesis III) 
The synthesis of this peptide was unsuccessful. Upon completion of the cyclisation 
reactions, analysis by HPLC and MALDI MS of cleaved samples of the two resins 
showed the purity of the crude peptide to be poor. The HPLC chromatograms of both 
samples are shown in Figure 2.11. 
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A 
B 
 
Figure 2.11 Representative reverse phase HPLC absorption profiles of the crude 
peptide (Cyclo(Lys4 – Glu29), Glu29)-PYY(3-36) to compare the effect on purity of 
pseudoproline insertion 
A - peptide synthesised with Ala22-Ser23 introduced simultaneously as the pseudoproline dipeptide 
Fmoc-Ala-Ser(Psi(Me,Me)pro)-OH. 
B - peptide synthesised with Ala22-Ser23 introduced in a stepwise manner as the single, standard Fmoc 
protected derivatives. 
Samples of the crude peptides were dissolved in 0.1% TFA/water/acetonitrile and analysed by reverse 
phase HPLC using an analytical C-18 column (Vydac 218TP54, 250 x 4.6mm, 5 µm particle size, and 
300 Å pore size) and a linear AB gradient of 0–100% for B over 40 min at a flow rate of 1mL/min, 
where eluent A was 0.1% TFA/water and eluent B was 0.1% TFA in 60% acetonitrile/water. Peak 
detection was by spectrophotometry at a wavelength of 210 nm. 
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2.4.4.8 (Cyclo(Lys4–Glu29), Glu29)-PYY(3-36) (Synthesis IV) 
The Aloc and OAll protecting groups were successfully removed from the Lys4 and 
Glu29 residues. This was confirmed by comparing the HPLC chromatograms of 
samples taken before and after the deprotection (Figure 2.12) and observing a 
decrease in retention time, following deprotection. Successful deprotection was 
further characterised by detection of the partially deprotected molecular weight by 
MALDI MS (Figure 2.13) 
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____ (Lys(Aloc)4, Glu(OAll)29-PYY(3-36) 
 
____ (Glu)29-PYY(3-36) 
 
Figure 2.12 Comparison reverse phase HPLC absorption profiles of (Glu)29-
PYY(3-36) samples taken before and after Aloc/OAll removal. 
Samples of the peptide resins were cleaved for 2 hours in conc. TFA. The solutions were filtered and 
diluted with acetonitrile/water and analysed by reverse phase HPLC using an analytical C-18 column 
(Vydac 218TP54, 250 x 4.6mm, 5 µm particle size, and 300 Å pore size) and a linear AB gradient of 
0–100% for B over 40 min at a flow rate of 1mL/min, where eluent A was 0.1% TFA/water and eluent 
B was 0.1% TFA in 60% acetonitrile/water. Peak detection was by spectrophotometry at a wavelength 
of 210 nm. 
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Figure 2.13 Representative MALDI mass spectrum of (Glu)29-PYY(3-36) 
following Aloc/OAll removal. 
A sample of peptide resin was cleaved for 2 hours in conc. TFA. The solution was filtered and diluted 
with acetonitrile/water. The solution was analysed by a Voyager DE MALDI mass spectrometer in 
positive voltage mode. The solution was co-crystallised with α-cyano-4-hydroxycinnamic acid (CHCA) 
matrix compound. The vertical axis represents the relative signal intensity of the molecular ions 
detected and horizontal axis represents mass to charge ratio (M/Z). The expected molecular weight was 
detected. 
 
 
Cleavage of the partially protected peptide yielded 304mg of material. HPLC and 
MALDI MS analysis of this material was inconclusive. The HPLC chromatogram 
contained no peaks and in the MALDI mass spectrum, only those masses 
Expected molecular weight = 4064.56 
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corresponding to the matrix compound, α-cyano-4-hydroxycinnamic acid (CHCA) 
were detected.   
Following lactam formation in solution and subsequent cleavage with solution K, 
408mg of crude material was obtained. It was not possible to identify the molecular 
weight of the target peptide in this crude material following analysis by MALDI MS. 
The HPLC chromatogram of a sample of the crude material is shown in Figure 2.14   
 
_____  TFA A 
 
_____  TFA B 
 
Figure 2.14 Representative reverse phase HPLC absorption profile of the crude 
peptide (Cyclo(Lys4 – Glu29), Glu29)-PYY(3-36) 
A sample of the crude peptide was dissolved in 0.1% TFA/water/acetonitrile and analysed by reverse 
phase HPLC using an analytical C-18 column (Vydac 218TP54, 250 x 4.6mm, 5 µm particle size, and 
300 Å pore size) and a linear AB gradient of 0–100% for B over 40 min at a flow rate of 1mL/min, 
where eluent A was 0.1% TFA/water and eluent B was 0.1% TFA in 60% acetonitrile/water. Peak 
detection was by spectrophotometry at a wavelength of 210 nm. 
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2.5 Discussion 
 
2.5.1 Position 25 and 26 PYY(3-36) analogues  
The ten analogues were produced with final yields that ranged from 7.5% up to 20%. 
All of the analogues achieved final purities in excess of 95% as assessed by HPLC in 
two different buffer systems. The disparity in yields cannot, therefore, be attributed to 
some analogues being produced at a lower purity. The methods used for the synthesis 
and purification of each of the ten analogues were identical, with the exception of 
(Cit)25PYY(3-36) which required a second purification step. The material recovered 
from the first purification step was just less than 95% pure by HPLC on the TEAP 
buffer system (actual purity of 93.88%). The subsequent re-purification of the 
material resulted in a loss of a yield (from 30.7mg to 27mg) and contributed to the 
relatively low final yield of 13.3%. However, there were two analogues that achieved 
final yields of less than 10%, for which only one purification step was required. 
It therefore seems unlikely that the difference in yields seen across the ten analogues 
was not due to any difference in the synthesis or purification methods used, but rather 
reflect the effects that the presence of unnatural amino acids in the sequence, had on 
the synthesis and/or purification. This is supported by comparing the final yield of 
20.5% obtained from the production of the native peptide PYY(3-36), with those 
obtained from the analogues. By comparison, all of the amino acid substitutions had, 
to some degree, a detrimental effect on the final yield. The analogues with the highest 
final yields were (D-Arg)25PYY(3-36), (Homoarg)25PYY(3-36) and (D-Cit)25PYY(3-
36). In the cases of (D-Arg)25PYY(3-36) and (Homoarg)25PYY(3-36), this would be 
expected as the unnatural amino acids D-arginine and homoarginine are the closest in 
structure to the native arginine residue, whilst also retaining the basicity of arginine. 
 146 
This means that they should display the same coupling tendencies as arginine, and 
also confer the same character to the peptide once in solution. 
Citrulline is also structurally similar to arginine but it does not have a reactive side 
chain group owing to the presence of an amide group as opposed to a guanidine. This 
means that the Fmoc derivative contains no side chain protecting group, thus making 
it a smaller molecule which should allow the coupling reaction to proceed at a faster 
rate. The potential improvement in the quality of the crude peptide for (D-
Cit)25PYY(3-36) may be offset by the loss of the basic functionality in the side chain 
group. This confers a more hydrophobic nature to the peptide overall, which in turn 
can affect the purification process. The more hydrophobic a peptide is, the greater its 
affinity for the stationary phase, resulting in longer retention times. (D-Cit)25PYY(3-
36) eluted from the HPLC column 30 seconds later than PYY(3-36) (data not shown). 
This increase in retention time may result in the analogue co-eluting with an impurity 
that PYY(3-36) elutes earlier than. Based on the results for (D-Cit)25PYY(3-36), it 
would be expected that (Cit)25PYY(3-36) would be synthesised in similar quantities 
and at a similar purity. However, as previously mentioned, a second purification step 
was required for this analogue. The purity of the material achieved from the first 
purification step was just below the required specification. Therefore, the loss of 
material from performing the second purification step was minimal. This suggests that 
the disparity in yields between the (Cit)25 and (D-Cit)25 analogues was not simply a 
result of performing two purification steps on the (Cit)25 analogue. Rather, it appears 
that insertion of D-citrulline in position 25 has a positive stereochemical effect on the 
peptide, which helps to improve either the remaining synthesis steps and/or the 
purification. 
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The unnatural amino acid 4-guaninidino phenylalanine retains the side chain 
functionality of arginine but is a much bulkier molecule due to the presence of an 
aromatic ring in the side chain group. This could lead to steric hindrance during 
coupling and hence explain the lower yield achieved for the synthesis of (Phe-
Gu)25PYY(3-36).  
The yield achieved for (D-His)26PYY(3-36) was lower than that for the corresponding 
D-arginine analogue, suggesting that the stereochemical effects of introducing a D 
configured amino acid at position 26 are more detrimental than introducing one at 
position 25. 
Contrasting results were achieved with the methylated analogues 
((Arg(Me)2symm)25PYY(3-36), (Arg(Me)2asymm)25PYY(3-36), (His(1-
Me))26PYY(3-36) and (His(3-Me))26PYY(3-36)). For both the methyl arginine and 
methyl histidine containing analogues, relatively high yields were achieved for one 
isomer whilst low yields were achieved for the other isomer. In all cases, the presence 
of the methyl groups removed the need for side chain protecting groups in the Fmoc 
derivatised amino acid. This makes the molecules smaller and should therefore 
improve coupling efficiency. The lower yields achieved for these four analogues 
compared with PYY(3-36) are thus likely due to detrimental effects imparted on the 
peptide post-synthesis by the presence of the methyl groups. The disparity in yields 
seen between each set of isomers suggests that the orientation of the methyl groups on 
the side chains of arginine and histidine is an important factor in dictating the quality 
of the final peptide. 
Alongside production of the ten position 25 and 26 PYY(3-36) analogues, the 
analogue Biotinyl-PYY(3-36) was produced. The aim was to use this analogue as a 
label for the potential development of a fluorescence receptor binding assay. The final 
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yield achieved with this analogue was lower than for any of the other 10 analogues. 
As with (Cit)25PYY(3-36), a second purification step was required for Biotinyl-
PYY(3-36) to meet purity requirements, suggesting that addition of a biotin group to 
the N-terminal of PYY(3-36) has a negative effect on the quality of the final peptide 
produced.  
 
2.5.2 N-terminally pegylated PYY(3-36) analogues 
Of the three PYY(3-36) analogues produced with an N-terminal PEG functional 
group, the lowest final yield was obtained for AEEAc-PYY(3-36). This was 
somewhat surprising, given that the AEEAc molecule is the smallest of the PEG 
compounds used, and should therefore be the analogue closest in character to the 
native sequence. However, analysis of the weight of the crude material (data not 
shown) suggests that material may have been lost during the cleavage process. 
The yields obtained for the PEG4 and PEG6 analogues were greater than that obtained 
for PYY(3-36) during the earlier stage of the investigation. This may be due to the 
beneficial increase in solubility that PEG molecules can impart onto peptides. 
However, it may also be a result of the use of more modern HPLC and MALDI MS 
equipment during the production of this set of analogues. It could also be a reflection 
of an increase in the skill level and experience of the chemist performing the 
purification. 
 
2.5.3 Position 30, 31 and 32 PYY(3-36) analogues 
The eight PYY(3-36) analogues were all produced with final yields of between 13.4 – 
21.2%. This is a more consistent range of yields than for the previous sets of 
analogues and is almost certainly due to the similarities in the nature of the amino 
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acids that were used to create the different analogues. In the human sequence of 
PYY(3-36), the residues in positions 30, 31 and 32 are leucine, valine and threonine 
respectively. Leucine and valine are hydrophobic amino acids and similarly 
hydrophobic amino acids were substituted into positions 30 and 31. This should result 
in there being very little difference in the coupling difficulties for the position 30 and 
31 analogue amino acids compared to those used in PYY(3-36). Secondly, the overall 
hydrophobicity of the peptide is not changed across these analogue sequences, and 
thus the peptides display the same solubility properties and retention times during the 
purification process.  
The final two analogues in this set contained substitutions of the Thr32 residue. 
Threonine is an uncharged, polar amino acid containing a hydroxyl function in its side 
chain group. In one analogue, threonine was substituted for leucine which served to 
increase the overall hydrophobicity of the peptide. However, this analogue was 
produced with a final yield of 18.7%, one of the highest of all of the analogues. 
Conversely, the second analogue contained a serine for threonine substitution which 
resulted in retention of the hydroxyl function but a loss of one carbon atom. The final 
yield achieved for this peptide was 14%, the second lowest amongst the eight 
analogues. It would therefore suggest that the number of carbon atoms in the structure 
is more important than the presence of the hydroxyl function for the successful 
production of position 32 analogues of PYY(3-36). 
The highest yield achieved amongst these analogues was for (Ile)30PYY(3-36) which 
was produced in a 21.2% yield. Leucine and isoleucine contain the same number of 
atoms and differ only slightly in the structures of their side chain groups. This makes 
(Ile)30PYY(3-36) structurally the closest analogue to PYY(3-36), and may explain the 
high yield achieved compared to other analogues with more profound changes to  
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structure and/or chemical property. However, it is also worth noting that the final 
purity achieved for (Ile)30PYY(3-36) was 95%, the minimum purity requirement set 
for further studies. This was the lowest purity achieved up until this point in the 
investigation and may be a contributory factor in the increased yield. 
 
2.5.4 (Cys4, Cys29)PYY(3-36) (disulphide bridge) 
This analogue was successfully produced and proves that a PYY(3-36) analogue can 
be made containing a cross linking between amino acids in positions 4 and 29 in the 
sequence. 
This particular analogue was designed to allow the formation of a disulphide bridge 
when the peptide was in solution following cleavage from the resin. Being in solution 
enables the peptide to form its natural configuration and eliminates any steric 
hindrance that may be caused by the presence of side chain protecting groups. 
The reaction to form a disulphide bridge can be monitored by reverse phase HPLC, as 
the change in peptide confirmation upon bridge formation, will usually elicit a change 
in retention time. However, in the case of (Cys4, Cys29)PYY(3-36)(disulphide bridge), 
no change in retention time was recorded during the oxidation reaction. Taken alone, 
this could be due to one of two factors; either the formation of the disulphide bridge 
caused no significant change in peptide confirmation and so did not affect the 
retention time, or the two cysteine residues are not in close enough proximity to 
successfully form the disulphide bridge. Once the peptide had been isolated from the 
reaction solution via Flash chromatography, further tests were performed to determine 
if the disulphide bridge had been formed. The first of these was an Ellman’s test to 
determine the presence of any sulphydryl (SH) groups within the peptide. If the 
disulphide bridge had successfully formed then there would be no sulphydryl groups 
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present and the test result would be negative, as was the case. Secondly, once the 
peptide had been partially purified it was possible to obtain a more accurate 
measurement of mass through MALDI MS. In this case, the expected molecular ion 
was detected.  
The findings from the production of this analogue not only prove that amino acids 4 
and 29 within PYY(3-36) can be successfully cross linked, but also suggest that these 
two amino acids are in close proximity to each when the peptide is in solution. This 
was expected to be the case following the published 1H NMR study data that 
confirmed the hairpin-like structure of PYY(3-36) (Nygaard et al., 2006). However, 
the fact that cross linking does not seem to significantly alter the confirmation of the 
peptide suggests that it should not be detrimental to receptor binding affinity. 
The final yield achieved for this analogue was only 6%, but it must to be taken into 
consideration that the peptide underwent four separate processes following cleavage 
from the resin, each with associated losses of yield. The final purity achieved was 
only 90.5% and the purity decreased from 91.1% following the final purification step. 
It was decided that a purity of 90.5% would be sufficient to conduct further biological 
testing, and that to perform further purification steps would risk further loss in yield 
without a significant improvement in purity.   
 
2.5.5 PYY(3-36) analogues containing lactam bridges 
 As yet, it has not been possible to isolate, at sufficient purity, any of the PYY(3-36) 
analogues designed to incorporate lactam bridges. Initially, all four analogues were 
synthesised following the standard methods successfully employed for previous 
analogues, except for the presence of alternative protecting groups on the two amino 
acids to be cross linked.  
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For two of the analogues, (Cyclo(Lys4-Glu29), Glu29)-PYY(3-36) and (Cyclo(Dap4-
Glu29), Dap4, Glu29)-PYY(3-36), the decision was taken to stop the synthesis 
following automated SPPS of the linear peptides. This was based on the HPLC and 
MALDI MS analysis of cleaved samples of the resin. In the case of the analogue 
(Cyclo(Lys4-Glu29), Glu29)-PYY(3-36), the HPLC chromatogram suggested that a 
major product was present in the sample. However, the expected molecular weight 
was not detected by MALDI MS, but rather that of a number of deletion sequences. 
This peptide was synthesised on an older synthesiser which may have become 
unreliable, and hence the decision was taken not to continue with the cyclisation step. 
For the analogue (Cyclo(Dap4-Glu29), Dap4, Glu29)-PYY(3-36), the HPLC 
chromatogram showed that more than one major product was present in the sample. 
As negative results had been achieved with other analogues, the decision was made 
not to proceed with the cyclisation step. 
The first of the four analogues to be synthesised was (Cyclo(Lys4-Asp29), Asp29)-
PYY(3-36), as this was the analogue with the closest sequence homology to PYY(3-
36), differing only in an aspartic acid residue instead of asparagine at position 29. The 
quality of the linear peptide produced was sufficient to continue with the cyclisation. 
The deprotection of the two amino acids was completed successfully as assessed by 
Kaiser test. The formation of the lactam bridge was also deemed successful by Kaiser 
test following three separate overnight couplings. The HPLC chromatogram of the 
crude peptide displayed a very broad peak which suggested a large number of 
different products had been formed, and the expected molecular weight could not be 
detected by MALDI MS. Nevertheless, it was decided to purify the crude material to 
see if any of the correct peptide could be isolated. No single product could be isolated 
from this process and the results suggested that instead of forming an intramolecular 
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lactam bridge, the free amino and carboxyl groups had instead formed a number of 
different intermolecular products. 
While this analogue was being purified, work had begun on the second lactam bridge 
analogue, (Cyclo(Dap4-Asp29), Dap4, Asp29)-PYY(3-36). Again, the quality of the 
linear peptide was deemed good enough to proceed with the cyclisation step. The 
same methods were employed for this analogue as with the previous one. Results 
suggested that the lactam bridge had formed following three overnight couplings. 
However, following analysis of the subsequent crude peptide, it was clear that similar 
impurities to those formed during the synthesis of (Cyclo(Lys4-Asp29), Asp29)-PYY(3-
36) were present. 
The four analogues had all been synthesised on tricyclic amide linker resin, which had 
been successfully used in the production of all of the previous sets of analogues. The 
loading capacity of this resin was in the range 0.5 – 0.7mmol/g. Other resins are 
available that have lower loading capacities. One such resin is the TentaGel RAM 
resin from Rapp Polymere, which has a loading capacity in the range 0.15 – 
0.2mmol/g. It was thus decided to use this resin for all subsequent on-resin cyclisation 
attempts. The lower loading capacity of the TentaGel RAM resin means that the 
peptide chains are spaced further apart from each other which should hinder 
intermolecular interactions and promote intramolecular bond formation. 
At this point in the investigation it was decided to focus on developing a method for 
producing one of the analogues and then employ the successful method in the 
production of the other three analogues. The analogue chosen for this was 
(Cyclo(Lys4-Glu29), Glu29)-PYY(3-36), as the side chain functional groups of lysine 
and glutamic acid are longer than those in α,β-diaminopropionic acid and aspartic 
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acid, and it was hoped that this would further facilitate successful lactam bridge 
formation. 
The second synthesis of (Cyclo(Lys4-Glu29), Glu29)-PYY(3-36) was thus conducted 
on TentaGel RAM resin, with all other parameters kept the same as for the initial 
synthesis. Lactam bridge formation still required more than one coupling reaction, and 
the subsequent HPLC chromatogram of the resulting crude material suggested that, 
once again, a number of intermolecular products had been formed.  
The combination of the slow reaction times, and the fact that intermolecular products 
were still predominantly being formed, even on low loading resins, suggested that the 
main issue was that the two amino acids were not held in close enough proximity 
within the resin-bound peptide sequence to react with each other. 
One of the proposed advantages in the use of pseudoproline dipeptides in SPPS is that 
they can assist in the synthesis of cyclic peptides (Novabiochem, 2010). This is due to 
their ability to alter the confirmation of the resin-bound peptide. It was therefore 
decided to investigate the synthesis of (Cyclo(Lys4-Glu29), Glu29)-PYY(3-36) with a 
pseudoproline insertion. Within the sequence of PYY(3-36) are three possible sites of 
pseudoproline insertion. These are Ala12-Ser13, Ala22-Ser23 and Val31-Thr32. 
Pseudoprolines mimic the effect of proline residues and it is therefore recommended 
to not insert a pseudoproline dipeptide immediately after a proline residue, as the 
positive effect of pseudoproline insertion will have already been conferred onto the 
sequence by the proline residue preceding it (Novabiochem, 2010). Amino acid 14 in 
PYY(3-36) is proline, therefore ruling out Ala12-Ser13 as the insertion site. As the aim 
was to change the confirmation of the peptide so as to bring positions 4 and 29 closer 
together, it was decided to insert the pseudoproline between these two positions. 
Therefore position Ala22-Ser23 was chosen as the site of insertion.  
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All previous cyclisations had been attempted with the coupling reagents HOAt and 
DIC as recommended previously (Novabiochem, 2010). The advantage of using these 
reagents is that they are unlikely to react with the peptide itself and form impurities, 
which is a risk when forming on-resin cyclic peptides. However, there are more 
efficient coupling reagents available which would speed up the cyclisation reaction.     
It was thus decided to repeat the synthesis of (Cyclo(Lys4-Glu29), Glu29)-PYY(3-36) 
employing a pseudoproline insertion for one reaction vessel and standard amino acids 
in positions 22 and 23 for the other reaction vessel. Both resins would then be 
cyclised using TBTU and DIPEA activation of the carboxyl group on Glu29. 
According to the results of the Kaiser tests, the cyclisation reaction was complete in a 
few hours. However, the HPLC chromatograms of the subsequent crude peptides 
displayed similar profiles to all previous attempts at producing this set of analogues. 
There also appeared to be no significant difference in the profiles of the peptide with 
and without a pseudoproline insertion. In addition, as TBTU was used as the coupling 
reagent, there is the possibility that the guanidated form of the peptides have been 
formed alongside other impurities (Gausepohl et al., 1992). 
The analogue (Cys4, Cys29)PYY(3-36)(disulphide bridge) was successfully 
synthesised following formation of the cross linking disulphide bridge in solution 
post-cleavage. This was possible, as the peptide was able to form its natural hairpin 
like structure thus bringing the amino acids in positions 4 and 29 close together. It 
would not be possible to successfully form a single lactam bridge in solution, post-
cleavage in PYY(3-36) owing to the presence of multiple amino and carboxyl groups. 
However, it may be possible to form a lactam bridge in solution if all of the amino 
acids other than the two lactam forming residues, were still protected. It was therefore 
decided to synthesise (Cyclo(Lys4-Glu29), Glu29)-PYY(3-36) on an acid sensitive 
 156 
resin, deprotect the Lys4 and Glu29 residues and then cleave the partially protected 
peptide from the resin. The protected peptide could then be cyclised in solution as the 
peptide should be able to form the characteristic hairpin shape and bring amino acids 
4 and 29 closer together. 
The peptide was synthesised on Xanthenyl resin, which is recommended for the 
production of protected peptide amides (Mergler, 1999). It was also decided to change 
the protecting groups on both the Lys4 and Glu29 residues. Previous syntheses had 
employed the Mtt and OPip protecting groups which are acid sensitive. For this new 
synthesis, removal of these protecting groups would also cleave the peptide from the 
resin as the cleavage conditions for the two are identical. The decision was taken to 
change to the Aloc/OAll protection strategy as the deprotection conditions for these 
groups would not affect the peptide-resin linker. Another advantage of using these 
protecting groups is that, as they are TFA stable, samples of the resin can be cleaved 
with TFA and the amount of Aloc/OAll protected material present determined by 
HPLC and MALDI MS analysis. Following deprotection of the two amino acids, the 
partially protected peptide was cleaved from the resin. Unfortunately, the resultant 
material could not be characterised by either HPLC or MALDI MS. This was to be 
expected, as protecting groups impart hydrophobicity to a peptide which results in an 
increase in retention time (Mant et al., 2007). Due to the sheer number of protecting 
groups still present on the partially protected PYY(3-36) analogue, it is possible that 
the peptide bound irreversibly to the C18 column. Protected peptides more readily 
fragment than unprotected peptides during MALDI MS analysis, resulting in a greater 
range of molecular ions and making it difficult to isolate any one particular mass. 
Despite being unable to characterise the protected peptide, it was decided to continue 
with the solution cyclisation. The theory behind the process employed is that the 
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peptide is introduced in very small quantities to a concentrated solution of the 
activation reagents. As the peptide enters this solution, it is far more likely to come 
into contact with molecules of the activation reagents than it is to encounter another 
peptide molecule. This should result in a near instantaneous reaction to form the 
lactam bridge, and thus prevent the formation of intermolecular impurities. As the 
activation reagent to peptide ratio was so high, use of TBTU and similar activation 
reagents was not possible. 
To date, analysis of the crude material by HPLC and MALDI MS has failed to 
identify the presence of the target peptide. Further investigations are thus required to 
determine if the solution cyclisation method has been successful and whether any 
changes to the method can help to produce the desired lactam bridge-containing 
analogues.  
 
The work described in this chapter has demonstrated that it is possible to successfully 
produce novel analogues of PYY(3-36) utilising different solid phase peptide 
synthesis techniques. For the development of one or more of these analogues as a 
potential anti-obesity therapeutic, it would be desirable for the analogue(s) to display 
increased stability to the actions of proteolytic enzymes.      
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3 The proteolytic 
enzyme degradation 
pattern of PYY(3-
36) and its analogues 
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3.1 Introduction 
 
It is difficult to know which specific enzyme(s) would predominantly drive the 
degradation of PYY(3-36) were it to be orally administered as an anti-obesity 
therapeutic. Oral administration would expose the peptide to a number of different 
proteolytic enzymes.    
 
3.1.1 Gastro-intestinal tract proteolytic enzymes  
In the stomach, any ingested proteins and peptides are exposed to gastric juices which 
largely consist of hydrochloric acid and the protease enzyme pepsin (Schubert, 2010). 
Pepsin is released into the stomach as its precursor pepsinogen, so as to prevent 
against auto-digestion of cell proteins (Rajagopalan, 1966). Once in the stomach, 
pepsinogen is converted to pepsin which then begins to break down proteins by 
preferentially cleaving peptide bonds at positions containing aromatic and 
hydrophobic amino acids (Sigma Aldrich, 2011). The high concentration of 
hydrochloric acid in the gastric juices provides the optimal conditions for this 
enzymatic cleavage as the optimum pH for pepsin activity is 1.5 to 2.5 (Sigma 
Aldrich, 2011).     
Once a peptide has passed through the stomach it will come into contact with 
pancreatic-derived enzymes such as trypsin and chymotrypsin. Trypsin is a serine 
protease enzyme that cleaves the peptide bond at the carboxyl terminus side of 
arginine and lysine residues, unless the subsequent amino acid is a proline (Beck et 
al., 2000). It has also been found that the presence of an acidic amino acid either side 
of a lysine and arginine will slow the rate of hydrolysis (Hedstrom, 1996). Due to this 
specificity in cleavage site, trypsin is routinely used for protein sequencing (Massolini 
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and Calleri, 2005). The optimum pH for trypsin activity is pH 8, as found in the small 
intestine, its endogenous site of action.  
Chymotrypsin is co-secreted with, and similar in structure to trypsin. It cleaves the 
peptide bond at positions containing the amino acids tyrosine, phenylalanine and 
tryptophan (Hedstrom, 1996).  
In the small intestine, remaining proteins and peptides are first broken down into di- 
and tri- peptides, and then into their constituent amino acids by the actions of different 
endopeptidase enzymes located on the epithelial cells of the intestinal wall (Taylor, 
1993).  
 
3.1.2 Circulatory proteolytic enzymes 
Other proteolytic enzymes degrade circulating proteins and peptides for a number of 
different metabolic processes, including to remove blood clots and to switch off 
hormonal signalling. Two enzymes known to be involved in the degradation of gut 
derived hormones are discussed below.  
 
3.1.2.1 Dipeptidyl peptidase IV (DPP-IV) 
DPP-IV is an aminopeptidase found on the cell surface of most tissues and also in the 
circulation (Bermpohl et al., 1998). Many proteolyic enzymes are unable to cleave 
peptides at proline residues (Mentlein, 1999). However DPP-IV acts by cleaving the 
N-terminal dipeptide from a peptide where the second amino acid in the sequence is 
either proline or alanine. Studies have found that it cleaves X-Pro dipeptides more 
rapidly than X-Ala. Although DPP-IV tolerates a wide range of different amino acids 
in the X position, the identity of the third amino acid in the sequence can affect 
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activity. If this residue is proline or hyroxyproline then DPP-IV does not hydrolyse 
the sequence, as is the case with bradykinin (Mentlein, 1999).  
DPP IV has been shown to play a role in the degradation of several regulatory 
peptides. It is often found in circumventricular organs and close to physiological 
barriers such as the blood brain barrier. It is the enzyme responsible for the conversion 
of PYY(1-36)
 
to PYY(3-36) and it also inactivates GLP-1(7-36) amide through 
removal of the N-terminal His-Ala dipeptide (Mentlein, 1999). The optimum pH for it 
to operate is between 7.5 and 8.5. 
 
3.1.2.2 Neprilysin 
Neprilysin is a member of the M13 zinc metallopeptidase family of enzymes. It is 
expressed mainly in the kidneys, but has been found in lower concentrations in other 
tissues, including the brain (Turner et al., 2001).  
It has a large number of potential substrates owing to its preference for hydrolysing 
peptides at the amino terminal of single hydrophobic amino acid residues. In the 
kidneys, neprilysin constitutes 4% of the brush border membrane protein and 
facilitates the inactivation of the vasodilator, atrial natriuretic peptide (Turner et al., 
2001). 
Due to the importance of hydrophobic residues for receptor binding in bioactive 
peptides, neprilysin has been hypothesised as an important enzyme for turning off 
neuropeptide signals in the brain. The first such substrates to be identified were the 
enkephalins and substance P (Shirotani et al., 2001).  
Recently the role that neprilysin deficiency plays in the development of Alzheimer’s 
disease has been investigated (Carson and Turner, 2002). Alzheimer’s disease is 
characterised by the accumulation of amyloid β proteins in the brain. These peptides 
contain regions that are rich in hydrophobic amino acids. Neprilysin was found to be 
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the most potent amyloid β protein degrading enzyme of those tested in vivo (Shirotani 
et al., 2001). Neprilysin knockout mice displayed levels of endogenous amyloid β 
proteins comparable to those found in a mouse model of Alzheimer’s disease. Mice 
lacking neprilysin had an impaired ability to break down exogenously administered 
amyloid β proteins, though as a small proportion of degraded peptide was detected, it 
seems that neprilysin is not the sole enzyme responsible for amyloid β protein 
clearance (Carson and Turner, 2002). The pathophysiological role of neprilysin in 
Alzheimer’s, and its utility in the treatment of this disease, are currently being 
investigated.  
 
3.2 Hypothesis and aims 
 
3.2.1 Hypothesis 
Determining the degradation pattern of PYY(3-36) and analogues in the presence of 
known proteolytic enzymes, will aid the design of further PYY(3-36) analogues that 
will display greater stability to enzymatic degradation.   
 
3.2.2 Aims 
1. To determine the degradation pattern of PYY(3-36) in the presence of trypsin 
2. To determine the degradation pattern of PYY(3-36) in the presence of DPP IV 
and neprilysin. 
3. To determine the degradation patterns of ten PYY(3-36) analogues with amino 
acid substitutions in positions 25 and 26. 
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3.3 Materials and methods 
 
3.3.1 Trypsin degradation of PYY(3-36) 
3.3.1.1 Efficiency trial 
Studies were carried out in a 25mM ammonium bicarbonate (Sigma Aldrich) buffer 
solution at pH 8.0, the optimum pH for trypsin activity. A 0.123mM solution of 
human PYY(3-36) (produced as described in section 2.3.1) in buffer was prepared.
 
 
The solution was analysed by reverse-phase High Performance Liquid 
Chromatography (HPLC) (Gilson) with an analytical C-18 column (Vydac 218TP54, 
250 x 4.6mm, 5 µm particle size, and 300 Å pore size) and a linear AB gradient of 0–
100% for B over 40 min at a flow rate of 1mL/min, where eluent A was 0.1% 
TFA/water and eluent B was 0.1% TFA in 60% acetonitrile/water and Kompact Probe 
Matrix Assisted Laser Desorption/Ionisation mass spectrometer (MALDI-MS) 
(Kratos). This determined the purity, retention time and molecular weight of the 
parent peptide. Trypsin (Applied Biosystems), pre-treated with tosyl phenylalanyl 
chloromethyl ketone (TPCK) to inactivate chymotryptic activity, was prepared at a 
concentration of 12.5µg/mL in buffer.    
Reaction tubes were set up as detailed below, and each combination was run in 
duplicate (n=2); 
1. 300µL Buffer 
2. 200µL Buffer + 100µL PYY(3-36) 
3. 200µL Buffer + 100µL Trypsin 
4. 100µL Buffer + 100µL PYY(3-36) + 100µL Trypsin 
The tubes were placed in a water bath set at 37°C and left for 3 hours. The reaction 
was then stopped with the addition of 100µL of 10% TFA solution. The solutions 
were then analysed by HPLC and MALDI MS as per the stock peptide solution. 
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3.3.1.2 Time-course study I 
Due to the significant level of PYY(3-36) breakdown recorded after 3 hours 
incubation in the efficiency trial, a time-course study was set up. Reaction tubes were 
set up as above and incubated at 37°C for 30 minutes, 1 hour, 2 hours, 3 hours, 4 
hours, 5 hours or 6 hours (n=2). At the end of the allotted time period, that particular 
set of tubes were removed, and the reaction stopped and the solutions analysed as 
described in section 3.3.1.1. 
 
3.3.1.3 Time-course study II 
As significant PYY(3-36) breakdown was observed after only 30 minutes in time-
course study I,  it was repeated but the experiments terminated at 5 minutes, 10 
minutes, 15 minutes and 20 minutes (n=2). 
 
3.3.1.4 Dose response investigation 
For this stage of the investigation, digestions were set up as described above, but 
using different concentrations of trypsin; 25µg/mL, 12.5µg/mL, 6.25µg/mL and 
3.125µg/mL (n=2). All of the tubes were incubated at 37°C for 15 minutes, based on 
the results from time course study II. After this period the reaction was stopped and 
the solutions analysed as described in section 3.3.1.1. 
 
3.3.2 Dipeptidyl peptidase degradation of PYY(3-36) 
DPP IV (Sigma Aldrich) was made up in 100mM TRIS-HCl (Sigma Aldrich) pH8 
buffer to a concentration of 37.5µg/mL. A solution of human PYY(3-36) was 
prepared at a concentration of 0.123mM of buffer. Reaction tubes were set up as 
detailed below, and each combination was run in triplicate (n=3); 
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1. 200µL Buffer + 100µL PYY(3-36) 
2. 100µL Buffer + 100µL PYY(3-36) + 100µL DPP IV 
All of the tubes were incubated at 37°C for time periods of 1 hour, 2 hours, 4 hours, 8 
hours, 16 hours and 24 hours. At the end of the allotted time period, that particular set 
of tubes were removed, and the reaction stopped and the solutions analysed as 
described in section 3.3.1.1. 
 
3.3.3 Neprilysin degradation of PYY(3-36) 
Recombinant human neprilysin (R&D Systems, Minneapolis, Minnesota USA) was 
made up in 50mM TRIS HCl, 0.25M NaCl (VWR) pH 7.5 buffer solution to a 
concentration of 5µg/mL. A solution of human PYY(3-36) was made to a 
concentration of 0.123mM in buffer. Reaction tubes were prepared as detailed below, 
and each combination was run in triplicate (n=3); 
1. 200µL Buffer + 100µL PYY(3-36) 
2. 100µL Buffer + 100µL PYY(3-36) + 100µL neprilysin 
All of the tubes were incubated at 37°C for time periods of 1 hour, 2 hours, 3 hours, 4 
hours, 5 hours and 6 hours.  
At the end of the allotted time period, that particular set of tubes were removed, and 
the reaction stopped and the solutions analysed as described in section 3.3.1.1. 
 
3.3.4 Trypsin degradation of PYY(3-36) analogues 
The breakdown by trypsin of the position 25 and 26 PYY(3-36) analogues; IP1 – IP10 
was investigated. All peptide solutions were made to a concentration of 0.123mM in 
ammonium bicarbonate pH8.0 buffer and the trypsin solution was at a concentration 
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of 12.5µg/mL of buffer. Reaction tubes were prepared as detailed below and each 
combination was run in duplicate (n=2); 
1. 100µL Buffer + 100µL PYY(3-36) + 100µL Trypsin 
2. 100µL Buffer + 100µL IP1 + 100µL Trypsin 
3. 100µL Buffer + 100µL IP2 + 100µL Trypsin 
4. 100µL Buffer + 100µL IP3 + 100µL Trypsin 
5. 100µL Buffer + 100µL IP4 + 100µL Trypsin 
6. 100µL Buffer + 100µL IP5 + 100µL Trypsin 
7. 100µL Buffer + 100µL IP6 + 100µL Trypsin 
8. 100µL Buffer + 100µL IP7 + 100µL Trypsin 
9. 100µL Buffer + 100µL IP8 + 100µL Trypsin 
10. 100µL Buffer + 100µL IP9 + 100µL Trypsin 
11. 100µL Buffer + 100µL IP10 + 100µL Trypsin 
All tubes were incubated at 37°C for a period of 15 minutes. After this time, 10% 
TFA was added to stop the reaction and the solutions analysed by HPLC and MALDI 
MS as described in section 3.3.1.1. 
 
3.4 Results 
Unfortunately, due to a hardware failure and the resulting loss of the original data, the 
HPLC chromatograms for these data are presented in a format of slightly poorer 
quality than other chromatograms in this thesis.  
 
3.4.1 Trypsin degradation of PYY(3-36) 
 
3.4.1.1 Efficiency trial 
The reverse phase HPLC chromatograms for each of the four reaction combinations 
investigated are shown in Figure 3.1. Although each was run in duplicate, only one 
 167 
trace for each combination is shown. The peak in chromatogram C (ammonium 
bicarbonate pH8.0 buffer + 0.123mM PYY(3-3-6)) has a retention time of 28 minutes 
which is consistent with the retention time observed for PYY(3-36). Chromatogram D 
(ammonium bicarbonate pH8.0 buffer + 12.5µg/mL trypsin + 0.123mM PYY(3-36)) 
contains peaks with retention times of 18.5, 21.5 and 23 minutes. 
The MALDI MS facility was unavailable during this stage of the investigation. 
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Figure 3.1 Representative reverse phase HPLC absorption profiles following in 
vitro digestion of PYY(3-36) by trypsin over 3 hours at 37°C. 
A, ammonium bicarbonate pH8.0 buffer; B, ammonium bicarbonate pH8.0 buffer + 12.5µg/mL trypsin; 
C, ammonium bicarbonate pH8.0 buffer + 0.123mM PYY(3-36); D, ammonium bicarbonate pH8.0 
buffer + 12.5µg/mL trypsin + 0.123mM PYY(3-36). 
Digest solutions were analysed by reverse phase HPLC using an analytical C-18 column (Vydac 
218TP54, 250 x 4.6mm, 5 µm particle size, and 300 Å pore size) and a linear AB gradient of 0–100% 
for B over 40 min at a flow rate of 1mL/min, where eluent A was 0.1% TFA/water and eluent B was 
0.1% TFA in 60% acetonitrile/water. Peak detection was by spectrophotometry at a wavelength of 210 
nm. 
 
 168 
 
 
3.4.1.2 Time-course study I 
The HPLC chromatograms of the solutions collected at the end of this stage of the 
investigation are shown in Figure 3.2. The chromatograms are just of the solutions 
containing buffer, PYY(3-36) and trypsin. 
The three peaks present in chromatogram D (ammonium bicarbonate pH8.0 buffer + 
12.5µg/mL trypsin + 0.123mM PYY(3-36)) from Figure 3.1, are visible in all of the 
chromatograms from this time-course study. Following 30 minute incubation, the 
peak with retention time 23 minutes is still quite prominent but reduces as time 
progresses. 
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Figure 3.2 Representative reverse phase HPLC absorption profiles following in 
vitro digestion of PYY(3-36) by trypsin at 37°C, over periods of 0.5 – 6 hours 
incubation 
Incubation times; A 30 minutes, B 1 hour, C 2 hours, D 3 hours, E 4 hours, F 5 hours and G 6 hours. 
All reaction tubes contained ammonium bicarbonate ph8.0 buffer, 12.5µg/mL trypsin and 0.123mM 
PYY(3-36). Digest solutions were analysed by reverse phase HPLC using an analytical C-18 column 
(Vydac 218TP54, 250 x 4.6mm, 5 µm particle size, and 300 Å pore size) and a linear AB gradient of 
0–100% for B over 40 min at a flow rate of 1mL/min, where eluent A was 0.1% TFA/water and eluent 
B was 0.1% TFA in 60% acetonitrile/water. Peak detection was by spectrophotometry at a wavelength 
of 210 nm. 
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3.4.1.3 Time-course study II 
Figure 3.3 shows the HPLC chromatograms of solutions obtained after reaction time 
periods of 5, 10, 15 and 20 minutes. It can be seen from the chromatogram of the 5 
minute reaction (A), there is a substantial peak at 28 minutes which was not present in 
the chromatograms for the longer reaction times. Despite the presence of this peak, 
there are still earlier peaks at retention times of 23, 21 ½ and 18 minutes, though the 
latter is very small. Also present in this chromatogram is a small peak at retention 
time 24 minutes. 
As the reaction time increases up to 10 then 15 and 20 minutes, the peak with 
retention time 28 minutes diminishes until it is barely visible in trace D (20 minutes 
incubation). The peak at 24 minutes also diminishes whilst the other three increase in 
size. 
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Figure 3.3 Representative reverse phase HPLC absorption profiles following in 
vitro digestion of PYY(3-36) by trypsin at 37°C, over periods of 5 – 20 minutes 
incubation 
Incubation times; A 5 minutes, B 10 minutes, C 15 minutes and D 20 minutes. All reaction tubes 
contained ammonium bicarbonate ph8.0 buffer, 12.5µg/mL trypsin and 0.123mM PYY(3-36). Digest 
solutions were analysed by reverse phase HPLC using an analytical C-18 column (Vydac 218TP54, 
250 x 4.6mm, 5 µm particle size, and 300 Å pore size) and a linear AB gradient of 0–100% for B over 
40 min at a flow rate of 1mL/min, where eluent A was 0.1% TFA/water and eluent B was 0.1% TFA in 
60% acetonitrile/water. Peak detection was by spectrophotometry at a wavelength of 210 nm. 
 
3.4.1.4 Dose response investigation 
The HPLC chromatograms from this stage of the investigation are shown in Figure 
3.4. It can be seen that chromatograms A (25µg/mL trypsin) and B (12.5µg/mL 
trypsin) display similar peak patterns to each other, with only 3 main peaks present, at 
retention times 23, 21 ½ and 18 minutes. Chromatogram C (6.25µg/mL trypsin) 
shows a reduction in the size of the peak at 18 minutes, with peaks at 24 and 28 
minutes now present. In D (3.125µg/mL trypsin), the peak at 28 minutes is now the 
dominant one, with the other peaks all much smaller in comparison. 
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Trypsin concentrations; A 25 µg/mL, B 12.5 µg/mL, C 6.25 µg/mL and D 3.125 µg/mL. All reaction 
tubes contained ammonium bicarbonate ph8.0 buffer and 0.123mM PYY(3-36). Digest solutions were 
analysed by reverse phase HPLC using an analytical C-18 column (Vydac 218TP54, 250 x 4.6mm, 5 
µm particle size, and 300 Å pore size) and a linear AB gradient of 0–100% for B over 40 min at a flow 
rate of 1mL/min, where eluent A was 0.1% TFA/water and eluent B was 0.1% TFA in 60% 
acetonitrile/water. Peak detection was by spectrophotometry at a wavelength of 210 nm. 
 
 
3.4.1.5 MALDI MS data 
All of the solutions from the three different stages of the investigation were analysed 
by MALDI MS. If there was more than one significant peak on the HPLC 
chromatogram, the solutions were re-analysed by HPLC and the peaks collected for 
analysis by MALDI MS.  Table 3.1 details the average molecular ion mass detected 
for each of the peaks seen in the different chromatograms. 
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Figure 3.4 Representative reverse phase HPLC absorption profiles 
following in vitro digestion of PYY(3-36) at 37°C by varying concentrations 
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Table 3.1 Average molecular ion masses detected by MALDI MS during studies 
of trypsin digestion of PYY(3-36) 
 
HPLC peak retention 
time (minutes) 
Average mass by 
MALDI MS [M+H] 
Proposed PYY 
fragment 
18 1853.5 PYY(3-19) 
21.5 1015.9 PYY(26-33) 
23 2606.9 PYY(3-25) 
28 3605.1 PYY(3-33) 
 
 
3.4.2 Dipeptidyl peptidase degradation of PYY(3-36) 
The HPLC and MALDI MS data showed no degradation in reaction tubes for time 
periods up to 8 hours. After this time period, minimal degradation of PYY(3-36)
 
occurred. This was mirrored in the control tubes containing no enzyme. 
  
3.4.3 Neprilysin degradation of PYY(3-36) 
The HPLC and MALDI MS data from the solutions from this investigation showed no 
degradation of PYY(3-36) after each time interval. 
 
3.4.4 Trypsin degradation of PYY(3-36) analogues 
Figure 3.5 shows HPLC chromatograms for reaction solutions from each of the 
PYY(3-36) analogues tested. The chromatogram of the solution containing native 
PYY(3-36) is not shown as it was consistent with those produced in section 3.4.1.3. 
Only two analogues, IP7 and IP8, display similar degradation patterns, as detected by 
HPLC, to that of native PYY(3-36). The remaining analogues display a different 
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degradation pattern to native PYY(3-36) and this pattern appears to be consistent 
throughout the analogues. The average mass of the molecular ions detected in these 
solutions are shown in Table 3.2. 
 
Table 3.2 Average molecular ion masses detected by MALDI MS during studies 
of trypsin digestion of PYY(3-36) analogues 
Analogue Average mass by 
MALDI MS [M+H] 
Proposed PYY fragments 
IP1 3617.2, 1783.9 (Homoarg)25PYY(3-33), (Homoarg)25PYY(19-33) 
IP2 3603.3, 1768.8 (D-Arg)25PYY(3-33), (D-Arg)25PYY(19-33) 
IP3 3631.9, 1797.6 (Arg(Me)2symm)25PYY(3-33), 
(Arg(Me)2symm)25PYY(19-33) 
IP4 3632.4 (Arg(Me)2asymm)25PYY(3-33), 
IP5 3603.1, 1770.2 (Cit)25PYY(3-33), (Cit)25PYY(19-33) 
IP6 3603.6, 1770.1, 1851.9 (D-Cit)25PYY(3-33), (D-Cit)25PYY(19-33), PYY(3-19) 
IP7 2606.8, 1853.7, 1029.6 PYY(3-25), PYY(3-19), (His(1-Me))26PYY(3-36) 
IP8 2606.0, 1852.1, 1029.6 PYY(3-25), PYY(3-19), (His(3-Me))26PYY(3-36) 
IP9 3603.1, 1769.0 (D-His)26PYY(3-33), (D-His)26PYY(19-33) 
IP10 3650.6. 1817.9 (Phe-Gu)25PYY(3-33), (Phe-Gu)25PYY(19-33) 
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Figure 3.5 Representative reverse phase HPLC absorption profiles following in 
vitro digestion of PYY(3-36) analogues by trypsin at 37°C 
PYY(3-36) analogues; A IP2, B IP1, C IP5, D IP6, E IP10, F IP3, G IP4, H IP9, I IP7 and J IP8. All 
reaction tubes contained ammonium bicarbonate ph8.0 buffer, 12.5µg/mL trypsin and 0.123mM 
PYY(3-36) analogue. Digest solutions were analysed by reverse phase HPLC using an analytical C-18 
column (Vydac 218TP54, 250 x 4.6mm, 5 µm particle size, and 300 Å pore size) and a linear AB 
gradient of 0–100% for B over 40 min at a flow rate of 1mL/min, where eluent A was 0.1% TFA/water 
and eluent B was 0.1% TFA in 60% acetonitrile/water. Peak detection was by spectrophotometry at a 
wavelength of 210 nm. 
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Following the MALDI MS results, solutions were made containing 100µL of the 
digest solutions for analogues (IP1-6, 9 & 10), and 100µL of 0.123mM PYY(3-36) 
analogue in buffer. These solutions were analysed by HPLC. The chromatograms 
produced for analogues (IP1, 3, 4, 5 & 10) are shown in Figure 3.6. The remaining 
three chromatograms for analogues (IP2, 6 and 9) contained only one main peak and 
are not shown. 
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Figure 3.6 Representative reverse phase HPLC absorption profiles of co-injected 
solutions of PYY(3-36) analogues and the corresponding trypsin digest solution 
PYY(3-36) analogues; A IP1, B IP5, C IP10, D IP3 and E IP4. Each solution consisted of 100µL of 
digest solution and 100µL of 0.123mM PYY(3-36) analogue. Solutions were analysed by reverse phase 
HPLC using an analytical C-18 column (Vydac 218TP54, 250 x 4.6mm, 5 µm particle size, and 300 Å 
pore size) and a linear AB gradient of 0–100% for B over 40 min at a flow rate of 1mL/min, where 
eluent A was 0.1% TFA/water and eluent B was 0.1% TFA in 60% acetonitrile/water. Peak detection 
was by spectrophotometry at a wavelength of 210 nm. 
 
 177 
 
3.5 Discussion 
 
A number of interesting and surprising results have been obtained from this part of the 
investigation. The primary site for trypsin degradation of PYY(3-36) has been shown 
to be different to that which was hypothesised. Secondly, the extent to which PYY(3-
36) is degraded was higher than expected. However, it has been possible to show that 
some of the unnatural amino acid insertions in positions 25 and 26 of the molecule, 
conferred stability against trypsin activity in those positions. 
  
3.5.1 Trypsin degradation of PYY(3-36) 
From this part of the investigation it is clear that in the presence of trypsin, PYY(3-
36) is not simply cleaved at the 25-26 position into two pieces. The results of the 
initial efficiency trial show three separate peaks on the HPLC chromatogram for the 
solution containing both PYY(3-36) and trypsin. These peaks all had retention times 
different to that of the parent peptide. Hence, there must be at least three different 
peptide fragments present in this solution. If this is so, then there must be more than 
one trypsin cleavage site within PYY(3-36), or a spontaneous cleavage site that breaks 
following the initial trypsin cleavage. 
 
The time-course studies suggest that the different cleavages are time dependent. Over 
the time period 30 minutes to 6 hours, the relative sizes of the three peaks change. The 
earliest peak increases, whilst the latest peak decreases in size. This suggests that the 
peptide fragment with retention time 23 minutes is subsequently further fragmented 
producing the peptide fragment with retention time 18 minutes. 
The HPLC analysis of the reaction mixtures following shorter reaction times initially 
suggested that there is a critical time period for the onset of cleavage, as what appears 
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to be a peak representing PYY(3-36) occurs in the solutions for the 5,10 and 15 
minute reactions. However, this peak, at retention time 28 minutes, does not show the 
expected mass of the PYY(3-36) (4049.52), but rather that of a fragment (3605.1). 
This would suggest the presence of another trypsin cleavage site within the sequence 
of PYY(3-36), possibly that at position 33-34 as the molecular weight of PYY(3-33) 
is 3602.46. 
The results of the dose response investigation suggest that the cleavages occur in a 
stepwise manner. At high concentrations, the degradation pattern appears to be the 
same as those from the long reaction times. However, at lower concentrations the 
pattern mimics that of the shorter reaction times. This suggests that the cleavage site 
that creates the fragment with mass 3605 is the initial site of cleavage. 
Collection of the three peaks that were present in the majority of the HPLC 
chromatograms enabled definitive mass identification. The masses had to then be 
matched to fragments of PYY(3-36). The initial belief was that trypsin would 
preferentially cleave PYY(3-36) at the 25-26 (Arg-His) position. The mass of PYY(3-
25) is 2605.87, which suggests this is the fragment with retention time 23 minutes. 
This fragment appears to further cleaved to produce the peptide with retention time 18 
minutes. Within PYY(3-25) there is another arginine residue at position 19. The mass 
of PYY(3-19) is 1852.0 which correlates with the mass detected when the peak with 
retention time 18 minutes was collected. Initially it was thought that the fragment 
PYY(26-36) would be produced. The mass of this peptide is 1461.70, which was not 
detected by MALDI MS, suggesting that the fragment PYY(26-36) is not formed 
during trypsin degradation of PYY(3-36) ), or that if it is produced, it is only 
transiently present. 
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The sequence of PYY(26-36) contains two arginine residues at positions 33 and 35. 
The mass of PYY(26-35) is 1299.51, whilst that of PYY(26-33) is 1015.19. This 
second mass is equal to that found when the peak with retention time 21.5 minutes 
was collected and analysed by MALDI MS, further supporting the concept of position 
33-34 being the initial site of trypsin degradation. 
From these deductions, it appears that the initial site for trypsin degradation of 
PYY(3-36), is not between the pair of basic amino acids in positions 25 and 26, but 
rather between the amino acids in positions 33 and 34. The second cleavage site 
appears to be between positions 25 and 26. Finally, cleavage occurs between the 
amino acids in positions 19 and 20. 
Due to the difficulty in identifying di- and tri- peptide fragments via both reverse 
phase HPLC and MALDI MS it is not possible to determine if the PYY(34-36) 
fragment is itself cleaved between the amino acids in positions 34 and 35. The 
fragment PYY(20-25) was not detected in any of the reaction solutions. 
In conclusion, these data suggest that the degradation of PYY(3-36) by trypsin targets  
every arginine residue in the sequence. Also, it seems that this digestion proceeds in a 
particular order, with certain positions in the amino acid sequence cleaved before 
others. Importantly, the basic amino acid pair at positions 25-26 is not the initial site 
of cleavage by trypsin. 
 
3.5.2 DPP IV degradation of PYY(3-36) 
The lack of degradation found in this investigation was expected. DPP IV is known to 
cleave N-terminal dipeptides X-Ala and X-Pro and as the N-terminal dipeptide of 
PYY(3-36) is Ile-Lys, DPP IV action on this peptide would be unlikely. 
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The signs of degradation observed during the longer reaction times can not be 
attributed to the action of the enzyme as identical results were seen in the control 
reactions containing no enzyme. This degradation is therefore likely to be due to the 
prolonged exposure of the peptide to the reaction temperature and/or pH. 
 
 
3.5.3 Neprilysin degradation of PYY(3-36) 
 
The lack of degradation caused by neprilysin was unexpected, as this enzyme is 
known to cleave peptides containing hydrophobic residues (Turner et al., 2001; 
Shirotani et al., 2001). PYY(3-36) contains a number of hydrophobic amino acids, 
including a Leu-Val dipeptide at position 30 and 31. The lack of degradation observed 
may be due to the low concentration of the enzyme solution used, or perhaps due to 
the enzyme denaturing during storage at -20°C. It would be interesting to check the 
ability of the batch of enzyme used to degrade a peptide neprilysin is known to target, 
for example substance P or amyloid ß proteins, to confirm its bioactivity.  
 
3.5.4 Trypsin degradation of PYY(3-36) analogues 
It was initially thought that modifying the sequence of PYY(3-36) at positions 25 and 
26, would generate PYY(3-36) analogues that are resistant to trypsin-induced 
degradation. However, the studies with PYY(3-36) and trypsin described above 
(carried out concurrently with these analogue studies) demonstrate that this position is 
not the first site targeted by trypsin, though it is subsequently targeted. 
Each of the ten analogues produced had a different modification to the sequence in 
either the 25 or 26 positions. These data suggest that only two of these modifications 
failed to prevent trypsin cleavage at this bond. These were the substitution of His26 
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with His(1-Me) (IP7) and His(3-Me) (IP8). In both cases, fragments terminating at 
positions 25 and 26 were found, consistent with degradation of PYY(3-36).  
Of the remaining eight analogues, all of the modifications resulted in stability to 
trypsin activity at the 25-26 position. This was evident from the results which showed 
the presence of fragments containing both amino acids at positions 25 and 26. There 
was also a complete absence of fragments terminating at these positions. There 
appeared to be little difference in the stabilising qualities of the different 
modifications. This was surprising, as the modifications ranged from a subtle change 
in residue (D-Arg for Arg25) (IP2) to more extensive alterations (Phe-Gu for Arg25) 
(IP10), and suggests that the action of trypsin is highly sensitive to amino acid 
structure; even small changes in stereochemistry detrimentally affect its effects.  
Most interesting was the apparent success of the analogue IP9, in which D-His 
replaced His at the 26 position. From the investigation into the digestion of PYY(3-
36), it appeared that the identity of the amino acid residue directly following an 
arginine residue was not important for trypsin activity. This hypothesis was supported, 
first by the facts that Arg-Tyr and Arg-Gln bonds were broken in PYY(3-36), and that 
substituting His(1-Me) and His(3-Me) for His26 failed to prevent cleavage of the 25-
26 bond. However, the stability shown by analogue IP9, would suggest that changing 
the stereochemistry of the residue following an arginine, from the L to the D isomer, 
stabilises the bond against trypsin activity. 
Despite the success of these substitutions at stabilising the 25-26 bond, the masses 
detected in each of the degradation solutions demonstrated that the 33-34 bond was 
still being cleaved by trypsin at the same rate as in PYY(3-36). In all cases, the mass 
corresponding to that of the parent analogue was not detected, whilst the masses of 
PYY(3-33) analogues were evident. As a final confirmation of this, HPLC co-
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injections of the analogue solution together with the digestion solution resulted in two 
peaks in five of the eight solutions. If the PYY(3-36) analogue had been present in the 
digestion solution, these additional peaks would not have been seen on the HPLC 
chromatogram. 
The PYY(3-36) analogues were only tested over a period of 15 minutes each and it is 
possible that over longer periods of time the analogues may begin to display differing 
fragmentation patterns. 
In conclusion, it had been hoped that amino acid substitutions at the 25 and 26 
positions would lead to a PYY(3-36) analogue that was more stable than the native 
sequence to trypsin activity. This has proven not to be the case as this bond is not the 
primary site for trypsin activity. However, the majority of the substitutions were 
successful at stabilising the 25-26 bond to trypsin cleavage. There is every possibility 
that by implementing these same substitutions at other points in the molecule, in 
particular at the 33 position, the analogue would show increased stability to the action 
of trypsin.  
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4  In vitro and in vivo 
investigations with 
PYY(3-36) analogues 
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4.1 Introduction 
PYY(3-36) mediates its inhibitory effects on food intake via the Y2 receptor, a 
member of the NPY Y receptor family of G-protein coupled receptors. The Y 
receptors are distributed throughout both the central and peripheral nervous systems, 
and are also found in non-neuronal tissues (Parker and Balasubramaniam, 2008). 
 
4.1.1 The Y2 receptor 
The human Y2 receptor was first reported to have been cloned in 1986 and was found 
to have only 30% sequence homology with the Y1 and Y4 receptors (Parker and 
Balasubramaniam, 2008). The Y2 receptor is highly conserved across species, with 
greater than 90% homology between mammalian species (Berglund et al., 2003). The 
human and chicken Y2 receptors share 80% sequence homology (Parker and  
Balasubramaniam, 2008). This high degree of conservation suggests an important role 
for the Y2 receptor in, for example, developmental and metabolic mechanisms.  
The Y2 is largely located pre-synaptically where it acts to inhibit release of 
neurotransmitters (Berglund et al., 2003). 
Aside from its well reported role in the regulation of appetite, the Y2 receptor has 
been implicated in a number of other physiological and metabolic functions; Y2 
agonists increase the rate of intestinal absorption of water and sodium. Y2 knock out 
mice display slower wound healing than wild type mice, and it has also been proposed 
that the Y2 receptor has a role in angiogenesis and bone formation (Parker and  
Balasubramaniam, 2008). 
A number of human neuroblastoma cell lines express NPY Y receptors. In particular, 
the SMS KAN cell line has been found to abundantly express Y2 receptors (Shigeri 
and Fujimoto, 1994). 
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4.2 Hypothesis and aims 
 
4.2.1 Hypothesis 
In vitro and in vivo testing of PYY(3-36) analogues will determine their efficacy as 
potential anti-obesity therapeutics.  
 
4.2.2 Aims 
1. To determine the binding affinity of a series of PYY(3-36) analogues for the 
Y2 receptor,. 
2. To determine the efficacy of a series of PYY(3-36) analogues at reducing food 
intake in vivo. 
 
4.3 Materials and methods 
 
4.3.1 Membrane preparation 
For a number of the following receptor binding assays, the SMS KAN human 
neuroblastoma cell line will be used.  
Cells were grown in DMEM containing 0.11g/L Na Pyr with pyroxidone, 10% FCS 
and 100 units/L penicillin sodium pyruvate and 100µg/L streptomycin sulphate in large 
flasks (20 X T175cm2) until confluent. They were then washed with Phosphate 
Buffered Saline (PBS) and harvested from the flasks using versene alone.  Cells were 
centrifuged at 200xg for 5 minutes, the supernatants discarded and the pellets put onto 
ice.  To the pellets 20mL of ice-cold homogenisation buffer (50mM HEPES buffer pH 
7.4 containing 0.25M sucrose, and a range of protease inhibitors (10µg/mL soybean 
trypsin inhibitor, 0.5µg/mL pepstatin, 0.25µg/mL leupeptin, 0.25µg/mL antipain, 
0.1mg/mL benzamidine and 30µg/mL aprotinin)) was added and cells homogenised for 
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1 minute with an Ultra Turrax homogeniser.  Homogenates were poured into 
ultracentrifuge tubes and centrifuged for 30 minutes at 4oC, 50,000xg in a Sorvall 
OTD 55B ultra-centrifuge. Supernatants were discarded and pellets resuspended in 
homogenisation buffer without sucrose using a hand-homogeniser. 
The protein content of the membrane produced was assessed by the Biuret method as 
follows; 
A standard curve was constructed using 100, 200, 300, 400 and 500µL of 10mg/mL 
bovine serum albumin (BSA). Typically 50-200µL of membrane suspension was 
assayed. All volumes were adjusted to 500µL and 3mL Biuret reagent (1litre: 1.5g 
CuSO4.5H2O, 30g NaOH, 6g Na K tartrate, 1g KI, 15g Na deoxycholate) was added to 
all tubes. The tubes were then incubated at 100oC for 2 minutes. Samples were left at 
room temperature for 45 minutes before the absorbance at A540 nm was measured in a 
spectrophotometer (Shimadzu UV-160) and a standard curve plotted. The absorbance 
of the membrane samples was then converted to protein concentration (mg/mL) by 
comparison with the standard curve. 
 
4.3.2 Iodination of PYY(3-36)  
PYY(3-36) was iodinated by the direct iodogen method. PYY(3-36) (5nmol) in 10µl 
0.2M phosphate buffer (pH 7.2) was added to a polypropylene vial containing 10µg 
iodogen reagent together with 37MBq Na125I, and incubated for 5 minutes on ice.  
Iodinated peptide was separated by reversed-phase HPLC on a 20-50%, 90 minute 
ACN/H2O/0.05% TFA gradient.  Peak fractions containing radioactivity were tested for 
binding to membranes, freeze-dried overnight (crystalline BSA added to a final 
concentration of 0.6%) and stored in vacuo at -20oC. 
 187 
 
4.3.3 Receptor binding assays 
4.3.3.1 PYY(3-36) analogues (IP1 – IP11) 
Membranes (human SMS KAN)(100µg) were incubated for 90  minutes in silanised 
polypropylene tubes together with 125I-PYY(3-36) (500 Bq) at 30oC in binding buffer 
(HEPES pH 7.4 20mM, MgCl2 1mM, CaCl2 5mM, plus 1% BSA) in a final assay 
volume of 0.5mL. Bound and free label were separated by centrifugation at 15,600xg 
for 2 minutes followed by washing with 1mL of binding buffer and re-centrifugation. 
Radioactivity in the pellet was measured using a γ-counter. Specific binding (SB) was 
calculated as the difference between the amount of 125I-PYY(3-36) bound in the 
absence (total) and presence (non-specific) of either unlabelled PYY(3-36) (20pM – 
2nM) or PYY(3-36) analogues (IP1 – IP11) (2pM – 200nM). 
 
4.3.3.2 PYY(3-36) analogues (IP12 – IP19) 
The assays were performed according to the methods described in section 4.3.3.1. 
 
4.3.3.3 PYY(3-36) analogue (IP20) 
The assay was performed according to the methods described in section 4.3.3.1. 
Following the results of the first assay, a second assay was performed using iodinated 
PYY(1-36) (Iodinated according to methods described in section 4.3.2). 
 
4.3.3.4 PYY(3-36) analogues (4075004, 4075005 & 4075006) 
The assays were performed according to the methods described in section 4.3.3.1. The 
membranes used were HEK 293 cells manipulated to over express mouse Y2 receptors 
(a kind gift from Dr. James Gardiner, Section of Investigative Medicine, Imperial 
College). The radioactive label used was iodinated PYY(1-36) (Iodinated according to 
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methods described in section 4.3.2). The range of concentrations investigated for both 
PYY(3-36) and the analogues was 0.01pM to 200nM. 
 
 
4.3.4 Acute feeding studies 
4.3.4.1 PYY(3-36) analogues (IP1 – IP11) 
C57BL/6 mice (20-25g), purchased from Harlan UK, were singly-housed and 
maintained under controlled conditions of temperature (21-23oC) and light (lights on 
at 0700, lights off at 1900) with ad libitum access to RM1 diet (Special Diet Services, 
Witham, UK). All animal procedures undertaken were approved by the British Home 
Office Animals (Scientific Procedures) Act 1986. Animals were acclimatised to 
laboratory conditions for at least one week and handled daily prior to the first study, 
during which time they received two injections of saline in order to minimize stress 
on the study days. Stressed animals display anorectic tendencies. Exposure to minor 
stressful events, including absence of pre-study handling and exposure to a novel 
environment, inhibits the anorectic effects of PYY(3-36) in rats (Abbott et al., 2006). 
Intraperitoneal (IP) injections were administered via a 1ml syringe with a 28-gauge 
needle (maximum injection volume 0.2 ml). For each study animals were fasted from 
4pm the preceding day and randomized into groups for injection in the early light 
phase (0900-1000). Each study consisted of 48 mice randomized into five groups with 
all the members of each group receiving the same injection of either peptide or 
control. The peptides used for the studies were PYY(3-36), exendin-4 and the PYY(3-
36) analogues (IP1 – IP11). They were dissolved in 0.9% saline with 0.9% saline 
administered as the control injection. The dosage used for PYY(3-36)
 
and the 
analogues was 30nmol/kg and for exendin-4 was 3nmol/kg. Following injection, 
animals were returned to their home cages containing a pre-weighed amount of food. 
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Food remaining in the cage dispenser was re-weighed at 1, 2, 3, 4, 6, 8 and 24 hours 
post-injection. Body weight was recorded at t=0 and t=24 hours. 
 
4.3.4.2 PYY(3-36) analogues (4075004, 4075005 & 4075006) 
 
Studies were conducted as per the methods described in section 4.3.4.1. The effect of 
intraperitoneal (IP) administration of saline control, PYY(3-36), PYY(3-36) 
analogues (4075004, 4075005 & 4075006) (30nmol/kg) on food intake was 
investigated. Overnight fasted animals were injected in the early light phase 09.00-
10.00hr with the designated treatment (n=9-10). Body weight was measured at 0 and 
24 hours and food intake 1, 2, 4, 8 and 24 hours post injection. 
 
4.3.5 Statistical analysis 
All receptor binding assay and food intake data are expressed as mean ± standard 
deviation. Food intake data was also analysed by Analysis of Variance (ANOVA) 
with a post-hoc Dunnett’s test (Systat, Evanston, IL, USA). In all cases, P < 0.05 was 
considered to be statistically significant. 
 
4.4 Results 
 
4.4.1 Receptor binding assays 
4.4.1.1 PYY(3-36) analogues (IP1 – IP11) 
The specific binding curves for each of the PYY(3-36) analogues (IP1 – IP11) are 
shown in Figures 4.1 and 4.2. Two analogues were tested in each assay alongside 
human PYY(3-36), and the IC50 value for each peptide was calculated. The IC50 value 
is the concentration of unlabelled peptide required for 50% specific binding of the 
receptor. These values are summarised in Table 4.1. The IC50 value recorded for 
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human PYY(3-36)
 
is the average value from all assays (n=6). All PYY(3-36) 
analogues (IP1 – IP11) displayed less affinity for the Y2 receptor than PYY(3-36). 
 
Table 4.1 The IC50 values for the PYY(3-36) analogues (IP1 – IP11) 
Analogue Code IC50 (M) IC50 (nM) 
PYY(3-36) - 5.33E-10 0.533 ± 0.054 
(Homoarg)25 PYY(3-36) IP1 1.65E-09 1.65 
(D-Arg)25 PYY(3-36) IP2 3.78E-09 3.78 
(Arg(Me)2symm)25 PYY(3-36) IP3 2.10E-09 2.10 
(Arg(Me)2asymm)25 PYY(3-36) IP4 1.45E-09 1.45 
(Cit)25 PYY(3-36) IP5 3.08E-09 3.08 
(D-Cit)25 PYY(3-36) IP6 1.30E-08 13.0 
(D-His)26 PYY(3-36) IP7 9.65E-09 9.65 
(His(1-Me))26 PYY(3-36) IP8 1.49E-09 1.49 
(His(3-Me))26 PYY(3-36) IP9 1.77E-09 1.77 
(Phe-Gu)25 PYY(3-36) IP10 4.38E-09 4.38 
Btn-PYY(3-36) IP11 1.04E-09 1.04 
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Figure 4.1 Representative competition binding affinity curves of PYY(3-36) 
analogues IP1 – IP6 to the human Y2 receptor 
A, IP1; B, IP2; C, IP3; D, IP4; E, IP5; F, IP6. Abbreviations: % SB, specific binding of, unlabelled 
peptide relative to labelled peptide, to the receptor. Radiolabelled I125-PYY(3-36) was used to compete 
with unlabelled peptide for human Y2 receptor binding sites. Cell membranes of SMS KAN cells were 
the source of receptors. 
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Figure 4.2 Representative competition binding affinity curves of PYY(3-36) 
analogues IP7 – IP11 to the human Y2 receptor 
G, IP7; H, IP8; I, IP9; J, IP10; K, IP11. Abbreviations: % SB, specific binding of, unlabelled peptide 
relative to labelled peptide, to the receptor. Radiolabelled I125-PYY(3-36) was used to compete with 
unlabelled peptide for human Y2 receptor binding sites. Cell membranes of SMS KAN cells were the 
source of receptors. 
 
 
 193 
4.4.1.2 PYY(3-36) analogues (IP12 – IP19) 
The specific binding curves for each of the PYY(3-36) analogues (IP12 – IP19) are 
shown in Figures 4.3 and 4.4. Two analogues were tested in each assay alongside 
human PYY(3-36) and the IC50 value for each peptide was calculated. These values 
are summarised in Table 4.2. For all analogues except IP13 and IP18, repeat assays 
were performed (n=2). The IC50 value recorded for human PYY(3-36) is the average 
value from all assays (n=7). (Leu)31PYY(3-36) (IP17) was the only analogue to 
display greater affinity for the Y2 receptor than PYY(3-36).   
 
Table 4.2 The IC50 values for the PYY(3-36) analogues (IP12 – IP19) 
Analogue Code IC50 (M) IC50 (nM) 
PYY(3-36) - 9.67E-10 0.967 ± 0.47 
(Ala)30PYY(3-36)  IP12 3.90E-09 3.90 
(Ile)30PYY(3-36) IP13 2.45E-09 2.45 
(Val)30PYY(3-36) IP14 9.97E-09 9.97 
(Ala)31PYY(3-36) IP15 1.36E-08 13.6 
(Ile)31PYY(3-36) IP16 1.06E-09 1.06 
(Leu)31PYY(3-36) IP17 4.01E-10 0.401 
(Leu)32PYY(3-36) IP18 3.15E-09 3.15 
(Ser)32PYY(3-36) IP19 1.23E-09 1.23 
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Figure 4.3 Representative competition binding affinity curves of PYY(3-36) 
analogues IP12 – IP15 to the human Y2 receptor 
A, IP12; B, IP13; C, IP14; D, IP15. Abbreviations: % SB, specific binding of, unlabelled peptide 
relative to labelled peptide, to the receptor. Radiolabelled I125-PYY(3-36) was used to compete with 
unlabelled peptide for human Y2 receptor binding sites. Cell membranes of SMS KAN cells were the 
source of receptors. 
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Figure 4.4 Representative competition binding affinity curves of PYY(3-36) 
analogues IP16 – IP19 to the human Y2 receptor 
E, IP16; F, IP17; G, IP18; H, IP19. Abbreviations: % SB, specific binding of, unlabelled peptide 
relative to labelled peptide, to the receptor. Radiolabelled I125-PYY(3-36) was used to compete with 
unlabelled peptide for human Y2 receptor binding sites. Cell membranes of SMS KAN cells were the 
source of receptors. 
 
 
4.4.1.3 PYY(3-36) analogues (4075004, 4075005 & 4075006) 
The specific binding curves for the three PYY(3-36) analogues (4075004, 4075005 & 
4075006) are shown in Figure 4.5. The analogue 4075006 was tested twice (n=2), as 
was human PYY(3-36) and the IC50 values for each peptide calculated. These values 
are summarised in Table 4.3, (where n=2 the average IC50 value has been calculated).  
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Table 4.3 The IC50 values for the PYY(3-36) analogues (4075004, 4075005 & 
4075006) 
Analogue Code IC50 (M) IC50 (nM) 
PYY(3-36)   9.64E-11 0.0964 
AEEAc-PYY(3-36)  4075004 4.95E-11 0.0495 
Aminoethyl-PEG4-carbonyl-PYY(3-36)  4075005 8.45E-11 0.0845 
Aminoethyl-PEG6-carbonyl-PYY(3-36)  4075006 1.92E-10 0.1920 
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Figure 4.5 Representative competition binding affinity curves of PYY(3-36) 
analogues 4075004, 4075005 and 4075006 to the mouse Y2 receptor 
A, 4075004; B, 4075005; C, 4075006. Abbreviations: % SB, specific binding of, unlabelled peptide 
relative to labelled peptide, to the receptor. Radiolabelled I125-PYY(1-36) was used to compete with 
unlabelled peptide for mouse Y2 receptor binding sites. Cell membranes of HEK 293 cells over 
expressing mouse Y2 receptors were the source of receptors. 
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4.4.1.4 PYY(3-36) analogue (IP20) 
The results from two separate Y2 receptor binding assays with analogue (Cys4, 
Cys29)PYY(3-36)(disulphide bridge) (IP20), were such that a specific binding curve 
could not be plotted due to an indiscriminate spread of low and negative specific 
binding values. In both assays, human PYY(3-36) was run alongside IP20. In the first 
assay, the results for PYY(3-36) were such that a specific binding curve could also not 
be plotted, due to minimal variation in the specific binding values over the 
concentrations investigated. However, in the second assay, it was possible to plot a 
curve for PYY(3-36) and the IC50 value was 0.238nM.  
 
4.4.2 Acute feeding studies 
 
4.4.2.1 PYY(3-36) analogues (IP1 – IP11) 
4.4.2.1.1 Study 1 – IP1 and IP2 (Figure 4.6)  
 
PYY(3-36) analogue IP2 significantly reduced food intake compared with saline 
control at 0-1 hour (Saline, 0.96g ± 0.13; IP2, 0.806 ± 0.13; (p≤0.05)) and reduced 
food intake over remaining time periods compared with saline, but these effects did 
not reach statistical significance. Analogue IP1 failed to reduce food intake compared 
with saline over time periods 0-1 and 0-2 hours and produced a small reduction 
compared with saline over the time periods 0-8 and 0-24 hours.  
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Figure 4.6 The effect of intraperitoneal administration of Exendin-4, PYY(3-36) 
and PYY(3-36) analogues IP1 and IP2 on cumulative food intake in overnight 
fasted C57BL/6 mice  
A, 0-1 hour; B, 0-2 hours; C, 0-4 hours; D, 0-24 hours post-injection. Doses: Exendin-4, 3nnmol/kg, 
PYY(3-36) and analogues, 30nmol/kg. (* p≤0.05, **p≤0.01compared to saline using one way ANOVA 
with post hoc Dunnett’s test (n=10)) 
 
 
4.4.2.1.2 Study 2 – IP3 and IP4 (Figure 4.7) 
 
PYY(3-36) analogue IP4 significantly reduced food intake compared with saline 
control at 0-1 hour (Saline, 1.06g ± 0.14; IP4, 0.807 ± 0.15; (p≤0.05)) and reduced 
food intake over remaining time periods compared with saline, but these effects did 
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not reach statistical significance. Analogue IP3 reduced food intake compared with 
saline over time periods 0-1, 0-2 and 0-4 hours but theses effects did not reach 
statistical significance.  
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Figure 4.7. The effect of intraperitoneal administration of Exendin-4, PYY(3-36) 
and PYY(3-36) analogues IP3 and IP4 on cumulative food intake in overnight 
fasted C57BL/6 mice  
A, 0-1 hour; B, 0-2 hours; C, 0-4 hours; D, 0-24 hours post-injection. Doses: Exendin-4, 3nnmol/kg, 
PYY(3-36) and analogues, 30nmol/kg. (* p≤0.05, **p≤0.01compared to saline using one way ANOVA 
with post hoc Dunnett’s test (n=9/10)) 
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4.4.2.1.3  Study 3 – IP5, IP6 and IP7 (Figure 4.8) 
 
All three PYY(3-36) analogues reduced food intake compared with saline control at 
0-1 hour, 0-2 hours and 0-4 hours but these effects did not reach statistical 
significance. Analogue IP5 further reduced food intake compared with saline over 
time periods 0-8 and 0-24 hours but theses effects also did not reach statistical 
significance.
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Figure 4.8 The effect of intraperitoneal administration of PYY(3-36) and PYY(3-
36) analogues IP5, IP6 and IP7 on cumulative food intake in overnight fasted 
C57BL/6 mice 
A, 0-1 hour; B, 0-2 hours; C, 0-4 hours; D, 0-24 hours post-injection. Dose: PYY(3-36) and analogues, 
30nmol/kg. (* p≤0.05, **p≤0.01compared to saline using one way ANOVA with post hoc Dunnett’s 
test (n=9/10)) 
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4.4.2.1.4  Study 4 – IP8, IP9 and IP10 (Figure 4.9) 
 
All three PYY(3-36) analogues reduced food intake compared with saline control at 
0-1 hour, 0-2 hours and 0-4 hours but these effects did not reach statistical 
significance. Analogue IP10 further reduced food intake compared with saline over 
time periods 0-8 and 0-24 hours but theses effects also did not reach statistical 
significance. 
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Figure 4.9 The effect of intraperitoneal administration of PYY(3-36) and PYY(3-
36) analogues IP8, IP9 and IP10 on cumulative food intake in overnight fasted 
C57BL/6 mice 
A, 0-1 hour; B, 0-2 hours; C, 0-4 hours; D, 0-24 hours post-injection. Dose: PYY(3-36) and analogues, 
30nmol/kg. (* p≤0.05, **p≤0.01compared to saline using one way ANOVA with post hoc Dunnett’s 
test (n=9/10)) 
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4.4.2.1.5  Study 5 – IP11 (Figure 4.10) 
 
PYY(3-36) analogue IP11 significantly reduced food intake compared with saline 
control at 0-1 hour (Saline, 0.83g ± 0.2; IP11, 0.46g ± 0.07; p≤0.01), 0-2 hours 
(Saline, 1.13g ± 0.27; IP11, 0.52g ± 0.07; p≤0.01), 0-4 hours (Saline, 1.67 ± 0.34; 
IP11, 0.5g ± 0.01; p≤0.01) and 0-24 hours (Saline, 6.41 ± 0.65; IP11, 5.62g ± 0.26; 
p≤0.01). 
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Figure 4.10 The effect of intraperitoneal administration of PYY(3-36) and 
PYY(3-36) analogue IP11 on cumulative food intake in overnight fasted C57BL/6 
mice 
A, 0-1 hour; B, 0-2 hours; C, 0-4 hours; D, 0-24 hours post-injection. Dose: PYY(3-36) and analogues, 
30nmol/kg. (* p≤0.05, **p≤0.01 compared to saline using one way ANOVA with post hoc Dunnett’s 
test (n=10)) 
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4.4.2.2 PYY(3-36) analogues (4075004, 4075005 & 4075006) (Figure 4.11) 
 
PYY(3-36) analogue 4075004 reduced food intake compared with saline control in 
the time period 0-1 hour but this effect did not reach statistical significance. It 
significantly reduced food intake compared to saline over the period 0-2 hours 
(Saline, 0.65g ± 0.25; 4075004, 0.37g ± 0.1; p≤0.01). Over the time period 0-4 hours, 
the analogue reduced food intake compared with saline but this effect did not reach 
statistical significance. Finally, over the time period 0-24 hours, 4075004 slightly 
increased food intake compared to saline. 
PYY(3-36) analogue 4075005 significantly reduced food intake compared with saline 
over the time period 0-1 hour (Saline, 0.42g ± 0.16; 4075005, 0.28g ± 0.11; p≤0.05). 
Over the time period 0-2 hours, the analogue significantly reduced food intake 
compared to saline control (Saline, 0.65g ± 0.25; 4075005, 0.37g ± 0.12; p≤0.01). The 
analogue significantly reduced food intake over the time period 0-4 hours compared 
with saline (Saline, 1.04g ± 0.33; 4075005, 0.71g ± 0.16; p≤0.05). Over the total 
study time period 0-24 hours, the analogue slightly reduced food intake compared 
with saline but this effect was not statistically significant. 
PYY(3-36) analogue 4075006 significantly reduced food intake compared with saline 
over the time period 0-1 hour (Saline, 0.42g ± 0.16; 4075006, 0.23g ± 0.09; p≤0.01). 
Over the time period 0-2 hours, the analogue significantly reduced food intake 
compared to saline control (Saline, 0.65g ± 0.25; 4075006, 0.32g ± 0.16; p≤0.01). The 
analogue significantly reduced food intake over the time period 0-4 hours compared 
with saline (Saline, 1.04g ± 0.33; 4075006, 0.69g ± 0.27; p≤0.05). Over the total 
study time period 0-24 hours, the analogue slightly increased food intake compared 
with saline.  
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Figure 4.11 The effect of intraperitoneal administration of PYY(3-36) and 
PYY(3-36) analogues 4075004, 4075005 and 4075006 on cumulative food intake 
in overnight fasted C57BL/6 mice 
A, 0-1 hour; B, 0-2 hours; C, 0-4 hours; D, 0-24 hours post-injection. Dose: PYY(3-36) and analogues, 
30nmol/kg. (* p≤0.05, **p≤0.01 compared to saline using one way ANOVA with post hoc Dunnett’s 
test (n=9/10)) 
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4.5 Discussion 
The series of in vitro and in vivo tests conducted on a number of PYY(3-36) 
analogues, have provided some interesting results. The majority of the analogues 
displayed less affinity for the Y2 receptor compared with PYY(3-36) but three 
analogues did record IC50 values lower than those recorded for PYY(3-36) in the same 
series of assays. 
Likewise, the majority of the analogues subjected to in vivo studies failed to elicit 
significant inhibition of food intake. However, a number of the N-terminal modified 
PYY(3-36) analogues did significantly reduce food intake in fasted mice. 
 
4.5.1 Receptor binding studies 
Amino acid substitutions at the 25 or 26 position do not eliminate the ability of these 
peptides to bind to the Y2 receptor. However, they do reduce the affinity of the 
peptides for the receptor compared to PYY(3-36). This is clearly seen by comparing 
the IC50 values of the analogues with that of the parent peptide. The IC50 for PYY(3-
36) was 0.533nM, whilst the analogue with the IC50 closest to this was IP11 
(1.04nM). This analogue only had an N-terminal modification and so had the closest 
sequence homology with the native peptide. All the other analogues had IC50 values in 
excess of this, ranging from 1.45 to 13.0nM. This suggests that substituting amino 
acids in the positions 25 and 26 has a detrimental effect on the ability of the molecule 
to bind to the Y2 receptor. It is known that the C-terminal segment amino acids Thr32, 
Arg33, Arg35 and Tyr36 are the most important for receptor binding (Beck-Sickinger et 
al., 1994; Pedersen et al., 2009). It is possible that changes to the amino acids in the 
25 and 26 positions elicited a change in the orientation of these important amino acids 
further along the sequence, thus reducing the binding affinity. 
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The lowest IC50 values were seen for the analogues containing methyl group additions 
to the standard amino acids arginine and histidine, (IP1, IP3, IP4, IP7 and IP8). Where 
a more drastic amino acid substitution occurred, this was reflected in the loss of 
binding affinity. For example, the substitution of guanidino-phenylalanine for arginine 
(IP10), for this analogue the IC50 value increased tenfold compared to PYY(3-36). 
The IC50 values for the analogues with a D for L amino acid substitution (IP2 and 
IP9), were also high compared to other analogues. This suggests that a change in 
stereochemistry in these positions has a profound effect on receptor affinity. Finally, 
the substitution of citrulline for arginine also had a detrimental effect. There is little 
difference in structure between these amino acids, though crucially the replacement of 
the amino function NH with oxygen results in a loss of charge. The high IC50 value 
for the (Cit)25 substituted analogue suggests that the presence of the base pair in the 
25-26 position is also important for receptor binding. This loss of basicity together 
with the change in stereochemistry is a probable reason why analogue IP6, with a D-
citrulline for arginine substitution at position 25, gave the highest IC50 value. 
In conclusion, amino acid substitutions made at positions 25 and 26 in the PYY(3-36) 
molecule resulted in decreased affinity for the Y2 receptor. However, it should be 
noted that whilst the IC50 value calculated for PYY(3-36) was the average from six 
different assays, the values for the analogues came from one single assay each. It 
would therefore be desirable to repeat these assays to verify binding affinity. It is also 
worth considering that peptides with lower receptor affinities can have increased 
bioactivity compared to the native peptide if they have, for example, longer half-lives 
or increased tissue permeability. It is therefore important to test the ability of these 
analogues to reduce food intake in vivo.  
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In the case of the analogues IP12 – IP19, the substitution of amino acids in the 30, 31 
and 32 positions did not eliminate the ability of the peptides to bind to the Y2 receptor. 
However, for all but one of the analogues, the binding affinity was lower than that 
displayed by PYY(3-36) across the same assays. The analogue (Leu)31PYY(3-36) 
(IP17) was the only PYY(3-36) analogue produced in this investigation displaying 
greater affinity for the Y2 receptor than native PYY(3-36). Position 31 is adjacent to 
the C-terminal pentapeptide region that is known to be key for receptor binding 
(Beck-Sickinger et al., 1994; Pedersen et al., 2009). It is therefore likely that position 
31 is also important in the binding affinity of the peptide to the receptor, and that 
changing the structure of the amino acid in this position will change this affinity. The 
amino acid in position 31 of PYY(3-36) is valine. Leucine and valine differ in 
chemical composition by just one methyl group and both side chains terminate in a 
branched structure. (Ile)31PYY(3-36) (IP16) had an IC50 value only slightly higher 
than that of PYY(3-36), but over twice as high as that of (Leu)31PYY(3-36). 
Isoleucine has the same chemical composition as leucine but has a different 
configuration of its side chain group. These results therefore suggest that it is the 
combination of an extra carbon atom in the side chain together with retention of the 
terminal branched structure in the side chain, that facilitates the improved binding of 
(Leu)31PYY(3-36) to the Y2 receptor.  To further support this hypothesis, the IC50 
value for (Ala)31PYY(3-36) (IP15) was 13.6nM, over ten times higher than for 
analogues IP16 and IP17, and PYY(3-36). Alanine contains two fewer carbon atoms 
than valine in its side chain group, and has no branching in its structure. 
Surprisingly, given that it lies within the C-terminal pentapeptide region of PYY(3-
36), substitutions at the 32 position were relatively well tolerated. The IC50 values for 
both analogues with changes as this position were greater than that recorded for 
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PYY(3-36), but not as high as for some other analogues. Substitution of serine in this 
position resulted in an IC50 value only marginally higher than that of PYY(3-36), 
whilst substitution with leucine resulted in an IC50 value approximately three times 
that of PYY(3-36). This would suggest that the hydroxyl function in threonine is 
important for receptor binding at position 32. 
For the three position 30 analogues, the IC50 values were all higher than that of 
PYY(3-36). This suggests that position 30 is also important for receptor binding. As 
previously mentioned, there is only a slight change in structure between leucine and 
isoleucine, yet inserting an isoleucine residue in position 30 decreased receptor 
binding affinity by a factor of 2.5. The high IC50 value of 9.97 for analogue IP14, 
(Val)30PYY(3-36) was surprising given that a valine/leucine substitution at position 
31 had been shown to beneficial to binding affinity, but supports the concept that 
position 30 is sensitive to changes in the amino acid composition. 
Once again, the IC50 value for PYY(3-36) is more reliable than that for the analogues, 
as it represents the mean of seven separate assays. It would therefore be desirable to 
run repeat assays with analogues IP12 – IP19, to verify that the same patterns of 
binding affinity are observed.    
Two of the N-terminally pegylated PYY(3-36) analogues showed greater affinity for 
the Y2 receptor than PYY(3-36). These were analogues 4075004 and 4075005, 
containing N-terminal AEEAc and PEG4 respectively. The analogue containing the 
larger PEG6 group had twofold lower affinity for the receptor than PYY(3-36). These 
findings suggest that addition of PEG molecules to the N-terminal of PYY(3-36) can 
have a beneficial effect on the binding affinity of the peptide to the Y2 receptor, but 
that the size of the PEG molecule is important. These results are somewhat surprising, 
given that that the N-terminal region of PYY(3-36) is believed to be located outside of 
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the binding site and thus is not thought to play a role in binding to the Y2 receptor. It 
is possible that extending the peptide with the addition of a PEG molecule brings the 
N-terminal region into closer proximity to the binding site and facilitates additional 
interactions between peptide and receptor that enhance binding. The effects on 
receptor binding of the PEG6 addition, suggest that there a size constraint to this 
enhancing effect, and that addition of larger PEG molecules compromises binding 
affinity. 
All of the PEG molecules used in this investigation contained α-amino functional 
groups (Figure 2.3), but it is possible to obtain PEG molecules with different terminal 
functional groups, for example, a methyl group. It would therefore be interesting to 
investigate the effects on receptor binding of attaching methyl-PEG molecules to the 
N-terminal of PYY(3-36). This would help to determine whether the α-amino group is 
important in enhancing receptor binding of N-terminally pegylated PYY(3-36) 
analogues. 
It is worth noting that the IC50 values for both the analogues and PYY(3-36) are 
significantly lower in this set of RBA’s than those obtained in the previous RBA 
studies. This is because a different cell line and a different competing radioactive 
label were used. Previous studies used the SMS KAN cell line, which express the 
human Y2 receptor, whilst the latest study used HEK 293 cells that were manipulated 
to over express mouse Y2 receptors. Although there is a high degree of homology 
between the mouse and human Y2 receptors (Berglund et al., 2003), it is possible that 
N-terminal pegylated PYY(3-36) analogues have greater affinity for the mouse Y2 
receptor over the human Y2 receptor. It might therefore be useful to repeat these 
assays with a human Y2 receptor expressing cell line to see if the same patterns of 
binding affinity are observed. However, to date, in all PYY analogue studies carried 
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out in the Section of Investigative Medicine, the relative affinity of the analogue for 
the mouse Y2 receptor compared to PYY(3-36) has reflected the relative affinity at 
the human Y2 receptor. This latest set of assays also used iodinated PYY(1-36) as the 
competing ligand with the analogues, rather than PYY(3-36). PYY(1-36) has a lower 
affinity for the Y2 receptor than PYY(3-36), and would therefore be expected to result 
in lower IC50 values than assays using radiolabelled PYY(3-36). To enable direct 
comparison between all analogues, it would be beneficial to repeat this set of assays 
using radioactive PYY(3-36) as the competing ligand. 
The results obtained from the two receptor binding assays conducted with the 
analogue (Cys4, Cys29)-PYY(3-36)(disulphide bridge) suggest that cross linking 
amino acids 4 and 29 in PYY(3-36) severely impairs binding affinity to the Y2 
receptor. This was a somewhat surprising result, as the synthesis and purification of 
this analogue suggested that forming the cross linkage did not drastically change the 
confirmation of the peptide. However, the results from these receptor binding assays 
would suggest that the confirmation has been sufficiently altered so as to completely 
prevent the peptide binding to the receptor.  It is possible that this inhibitory effect is 
not due to the cross linkage itself, but rather due to the presence of two cysteine 
residues in the sequence. The endogenous residues in positions 4 and 29 are lysine 
and asparagine, and there are significant structural and functional differences between 
these two amino acids and cysteine. It would therefore be interesting to investigate the 
receptor binding properties of both (Cys4, Cys29)-PYY(3-36) without a disulphide 
bridge and a PYY(3-36) analogue containing a cross linkage between amino acids 
more homologous to lysine and asparagine.       
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4.5.2 Acute feeding studies 
Of all of the first eleven PYY(3-36)
 
analogues synthesised (IP1 – IP11), only one, 
Biotinyl-PYY(3-36) (IP11), was shown to have a statistically significant effect in 
reducing food intake compared with saline over the entire 24 hour time period. The 
receptor binding studies suggest that this increased effect is not due to improved 
binding affinity to the Y2 receptor; the IC50 value for this analogue was higher than 
that of natural PYY(3-36). The improved bioactivity may be due to the biotin 
molecule increasing the half life of the peptide in the circulation. Biotin is a large 
bulky molecule and it may be that its presence at the N-terminal of the peptide hinders 
the action of enzymes which naturally degrade PYY(3-36). To test this hypothesis it 
would be interesting to determine the effects on food intake of administration of both 
Biotin and Biotin in combination with PYY(3-36), and to assess the ability of this 
peptide to resist different types of enzymatic degradation. 
Of the remaining analogues synthesised and tested in vivo, two had statistically 
significant effects in reducing food intake compared with saline over the first hour of 
the study. These were the analogues IP2 and IP4 which contain D-Arg and 
Arg(Me)2asymmetrical in position 25 respectively. These analogues both had 
relatively low IC50 values compared to others and are structurally similar to the 
endogenous PYY(3-36). Therefore, the positive effect they had in relation to reducing 
food intake is more likely due to effective binding of the Y2 receptor, than an increase 
in stability to enzymatic degradation. This hypothesis is further supported by the 
observation that the significant effect in reducing food intake was not long lasting.  
In conclusion, the analogues (IP1 – IP11), produced with the aim of stabilising the 25-
26 position to enzymatic degradation in PYY(3-36), did not demonstrate significantly 
increased bioactivity in vivo. However, following on from the investigation into 
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trypsin digestion of PYY(3-36), it may worth investigating what effect stabilising 
position 33-34 in the molecule has both in vitro and in vivo. The strong inhibitory 
effect on food intake of Biotinyl-PYY(3-36) (IP11) was an interesting and unexpected 
result, and suggests further investigation into the effects of N-terminal modifications 
of PYY(3-36) may yield useful results. 
Due to concerns over solubility and regulatory issues, of developing therapeutics 
containing a biotin group, it was decided to instead develop analogues with N-
terminal PEG modifications. Such modifications are already FDA approved for use in 
pharmaceuticals (Harris and Chess, 2003). The three N-terminal pegylated PYY(3-36) 
analogues developed significantly reduced food intake in mice compared to saline at 
specific time points, though there was no significant difference in cumulative food 
intake between the PEG-PYY(3-36) administered mice and the saline control mice 
over the total 24 hour time period. During the first hour, the PEG-PYY(3-36) groups 
all consumed less food than both the saline and PYY(3-36) groups. The analogues 
containing the largest PEG molecules had the greatest inhibitory effect. The three 
PEG-PYY(3-36) treated groups continued to consume less food during the second 
hour of the study. It appears that the inhibitory effects of the PEG-PYY(3-36) 
analogues wear off after this point.; between 4 and 8 hours post-injection, the three 
PEG-PYY(3-36) groups consumed more food than either the PYY(3-36) and the 
saline groups. The mice are likely compensating for the earlier reduction in food 
intake by consuming more food following cessation of the inhibitory effect. Thus 
using these molecules for weight control would likely require a frequent dosing 
regimen or the administration of high doses.  
The results from the receptor binding studies with the pegylated analogues suggest 
that both 4075004 and 4075005 bind to the Y2 receptor with greater affinity than 
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PYY(3-36). This would help to explain the greater inhibitory effect on food intake 
these two analogues show when compared with PYY(3-36). However, the analogue 
4075006 had lower affinity for the Y2 receptor than PYY(3-36) yet had the greatest 
effect on inhibiting food intake. Thus whilst the presence of the PEG molecules may 
enhance receptor binding to some degree, it is more likely that an increase in the 
circulating half life is more of a contributory factor. The PEG molecules are large and 
therefore could inhibit the action of proteolytic enzymes by blocking some or all of 
the active site. The analogue 4075006 contained the largest PEG molecule and so by 
this rationale, would resist enzymatic degradation relatively well. This might explain 
why of the three pegylated analogues produced, this analogue had the greatest effect 
on reducing short term cumulative food intake. However, the results in this particular 
study for the PYY(3-36) group were unexpected. At no stage in the study did the 
PYY(3-36) mice display a significant reduction in food intake when compared with 
the saline group as has been widely reported in previous studies. Therefore, the effects 
of the PEG-PYY(3-36) analogues on cumulative food intake cannot be accurately 
compared with PYY(3-36) without further investigations. 
In conclusion, these studies have provided useful insights into the structure function 
relationships of the PYY(3-36) molecule, and suggest that PYY(3-36) analogues may 
be useful tools to reduce food intake. Further work is required to assess their utility in 
the regulation of body weight.  
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discussion 
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5.1 Introduction 
 
 
The aim of this programme of work was to successfully develop novel analogues of 
the anorectic gut derived hormone PYY(3-36) that displayed greater inhibitory effects 
on food intake than the endogenous molecule. Should such an analogue have been 
developed, there would then be scope to investigate its potential for use in humans an 
anti-obesity therapeutic. At this stage, no single analogue has been produced that 
displays a consistent increase in reducing food intake in mice compared to PYY(3-
36). However, a number of interesting results have been obtained throughout the 
various stages of this investigation which will hopefully be useful to those looking to 
conduct further investigations in this field. 
   
5.2 The use of SPPS techniques to produce PYY(3-36) analogues 
 
My investigations have shown that a number of PYY(3-36) analogues, embodying 
varied design strategies, can be successfully produced utilising specific solid phase 
peptide synthesis techniques. A number of unnatural amino acids were successfully 
incorporated into the peptide sequence at positions 25 and 26. Following this, further 
analogues were synthesised with natural amino acid substitutions in positions 30, 31 
and 32. Whilst the incorporation of some of these amino acids was less successful 
than others, all nineteen analogues designed were produced in sufficient yields and of 
suitable purity to enable them to be used for biological testing. The addition of PEG 
molecules to peptides, particularly those being developed as therapeutics, is an 
attractive option. This is because the hydrophilic nature of the PEG molecules can 
increase the solubility of the peptide to which they are attached. However, the 
hydrophilic nature of PEG can also hinder the work of a peptide chemist. Depending 
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upon the size of the PEG unit, the starting material can often be in the form of an oil, 
which makes the handling and accurate weighing of the material difficult. The 
resulting PEG-peptide can be so hydrophilic that it will resist lyophilisation to a dry 
powder. This makes the final purification and characterisation processes challenging. 
Despite these concerns, I was able to successfully produce three novel N-terminal 
pegylated PYY(3-36) analogues in sufficient yields and of suitable purity to enable 
biological testing of the compounds. 
The concept behind the final set of analogues utilised the natural hairpin shape of 
PYY(3-36) (Nygaard et al., 2006). The aim was to successfully cross link amino acids 
in the N and C-terminal regions of the peptide, at positions 4 and 29. Were this 
approach to prove successful, and the subsequent analogues found to retain biological 
activity, further manipulations of the peptide sequence were planned. These 
manipulations would have included the removal of amino acids from non-critical 
positions within the 5 – 28 loop, with the ultimate goal of producing a small molecule 
mimetic of PYY(3-36).  
The analogue (Cys4, Cys29)-PYY(3-36)(disulphide bridge) was successfully produced 
in sufficient yield and of suitable purity to enable biological testing to be performed. 
The synthesis of this analogue proved that the amino acid positions 4 and 29 could be 
successfully cross linked. The HPLC data obtained during the reaction to form the 
disulphide bridge suggested that the formation of the cross linkage did not 
significantly change the confirmation of the peptide. This result was promising, as it 
suggested that the presence of the cross linkage would not be detrimental to receptor 
binding. 
Unfortunately, attempts to synthesise further cross linked analogues of PYY(3-36) 
were unsuccessful. The aim was to synthesise analogues containing lactam bridges 
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between the amino acids in positions 4 and 29, as the amino acids used to form the 
bridges would be more homologous to the endogenous residues in these positions. 
Lactam bridges are formed between the amino side chain group of one amino acid and 
the carboxyl side chain group of a second amino acid. PYY(3-36) contains a number 
of basic and acidic residues, and thus these other amino acids would need to be 
protected during the formation of the lactam bridge between the two designated amino 
acids to avoid the formation of multiple bridges.. The most straightforward way of 
doing this is to perform the reaction on the resin bound peptide and selectively 
deprotect the two designated amino acid side chains. In total, six attempts were made 
at synthesising PYY(3-36) analogues containing a lactam bridge between amino acids 
4 and 29. A number of different synthesis techniques were utilised to try to improve 
the process but ultimately without success. The crux of the problem behind the 
unsuccessful formation of the proposed lactam bridge may be that amino acid 
positions 4 and 29 are insufficiently close to one another when the peptide is bound to 
the resin to enable the reaction to proceed.  
I thus attempted to form the lactam bridge in solution, on a partially protected peptide. 
This was based on the successful formation in solution of the disulphide bridge in the 
analogue (Cys4, Cys29)-PYY(3-36)(disulphide bridge), and was based on the idea that 
the protected peptide would still be able to form the hairpin like shape in solution. 
Difficulties in producing the analogue in this manner were predicted, mainly linked to 
the solubility and characterisation of a protected peptide containing 34 amino acids. 
These expected problems did occur, but it was still surprising that the initial analysis 
of the resultant crude peptide suggested that the synthesis had failed. It may be that 
the amino and carboxyl groups of the lysine and glutamic acid residues were 
sufficiently hindered by the presence of adjacent amino acid protecting groups, to 
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successfully form the lactam bridge. However, were this to be the case, I would 
expect to have observed the linear material in the subsequent analysis of the crude 
material, which was not the case. Therefore, it would be desirable to attempt a repeat 
synthesis of this analogue, following the same methods, to see if identical results were 
obtained.      
 
5.3 The effects of PYY(3-36) analogues in vitro and in vivo  
 
Due to the considerable effort and resources spent working on developing novel 
synthesis protocols, it was not possible to conduct the extensive in vitro and in vivo 
testing of various analogues originally planned. Following the work into trypsin 
degradation of PYY(3-36) and the analogues IP1 – IP10, it was discovered that 
position 33-34 within PYY(3-36) is likely the primary site of cleavage by trypsin. I 
subsequently demonstrated that insertion of specific unnatural amino acids in the 25 
and 26 positions succeeded in stabilising the bond between them to trypsin-induced 
degradation.  
The series of receptor binding assays that were conducted showed that, in general, 
making amino acid substitutions in either the 25 and 26 positions or in the 30, 31 and 
32 positions decreased the resulting analogues binding affinity for the Y2 receptor 
compared to PYY(3-36). The exception to this was the analogue (Leu)31PYY(3-36), 
which displayed greater affinity for the Y2 receptor than PYY(3-36). Promising 
results were also obtained from the receptor binding studies with the PEG-PYY(3-36) 
analogues. Both AEEAc-PYY(3-36) and PEG4-PYY(3-36) had greater affinity for the 
Y2 receptor than PYY(3-36), whilst PEG6-PYY(3-36) displayed a small decrease in 
binding affinity. It is interesting to speculate whether this increased affinity represents 
improved binding of the molecule or, for example, increased stability of the receptor-
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ligand complex. It would also be helpful to repeat these RBAs in order to confirm 
some of the conclusions reached in this thesis. 
 
Perhaps the most surprising result was obtained from the receptor binding assays 
conducted with the analogue (Cys4, Cys29)-PYY(3-36)(disulphide bridge). This 
suggested that formation of the cross linkage completely eliminated the affinity of the 
analogue for the Y2 receptor. This deleterious effect may be due to the nature of the 
cysteine residues as opposed to the presence of a cross linkage per se. However, due 
to the failure to successfully synthesise analogues incorporating a lactam bridge, it is 
not currently possible to test this hypothesis. 
In vivo studies with mice, were conducted using the IP1 – IP11 and PEG-PYY(3-36) 
analogues. From these analogues, only the N-terminally modified peptides; Biotinyl-
PYY(3-36), AEEAc-PYY(3-36), PEG4-PYY(3-36) and PEG6-PYY(3-36) were found 
to significantly reduce cumulative food intake in fasted mice. In the case of the three 
PEG-PYY(3-36) analogues, the promising results obtained need to be tempered by the 
fact that PYY(3-36) did not behave as expected in this particular study. Further 
studies are now required to assess the utility of pegylated PYY(3-36) analogues in the 
treatment of obesity.  
 
5.4 Further work 
 
The results of the investigations described in this thesis leave scope for further 
development work with PYY(3-36) analogues.  In particular, following the positive 
biological results that were obtained for the analogues (Leu)31PYY(3-36) and the 
various PEG-PYY(3-36) peptides, it would interesting to synthesise an analogue 
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incorporating (Leu)31 and pegylation to test whether the observed effects on receptor 
binding and inhibition of food intake are additive. It would also be interesting to study 
the effects of stabilising the amino acid position 33 in PYY(3-36) following the 
results obtained from the trypsin degradation studies.      
In conclusion, further work is required to determine the utility of PYY(3-36) 
analogues in the treatment of obesity.  
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Appendices 
 
Appendix I – List of suppliers 
 
Alfa Aesar, Lancaster, UK 
Applied Biosystems, Warrington, UK 
Apollo Scientific, Stockport, UK 
Avantor, Deventer, Netherlands 
Bachem AG, Bubendorf, Switzerland UK 
BDH, Poole, UK 
Gilson, Middleton, Wisconsin, USA 
GraphPad, La Jolla, CA, USA 
Iris Biotech, Marktredwitz, Germany 
Kratos, Manchester, UK 
M56 Chemicals, Runcorn, UK 
Novabiochem, Nottingham, UK 
Perkin Elmer, Massachusetts, USA 
P&R Labpack, St. Helens, UK 
Protein Technologies, Tucson, Arizona, USA 
Rapp Polymere, Tübingen, Germany 
R&D Systems, Minneapolis, Minnesota USA 
Romil, Cambridge, UK 
SDS UK, Witham, UK 
Severn Biotech, Kidderminster, UK 
Sigma-Aldrich Company Ltd., Poole, UK. 
VWR, Poole, UK 
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